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ABSTRACT 
 
 
Ex vivo gene transfer has been used to improve the outcome of islet transplantation for 
treating type I diabetes. RNA interference is an effective approach for reducing gene 
expressions at the mRNA level. The application of RNA interference to improve the 
outcome of islet transplantation was reviewed in Chapter 2, where I summarized 
biological obstacles to islet transplantation, various types of RNAi techniques, 
combinatorial RNAi in islet transplantation, and different delivery strategies. 
 
Upregulation of inducible nitric oxide synthase (iNOS) and subsequent product of radical 
nitric oxide (NO) impair islet β cell function.  Therefore, we hypothesized that iNOS 
gene silencing could prevent β cell death. In Chapter 3, we designed and used siRNA to 
silence iNOS gene in a rat β cell line and human islets.  We found that siRNA inhibited 
rat iNOS gene expression and NO production in rat β cells in a dose and sequence 
dependent manner. iNOS gene silencing also protected these β cells from inflammatory 
cytokine-induced apoptosis and increased their capacity to secret insulin. Although there 
was also dose and sequence dependent iNOS gene silencing and NO production in human 
islets, the effect of iNOS gene on apoptosis of islets was only moderate, as evidenced by 
25-30% reduction in caspase 3 activity and in the percentage of apoptotic cells. Since an 
islet is a cluster of 20-1000 cells, the transfection efficiency of lipid/siRNA complexes 
into human islets was only 21-28%, compared to effective transfection efficiency 
(> 90%) in β cells. 
 
Gene delivery vectors which can express a growth factor gene to promote 
revascularization and silence of proapoptotic genes might be good for ex vivo genetic 
modification of islet prior to transplantation. Thus, in Chapter 4, we constructed bipartite 
plasmid vectors to co-express a vascular endothelial growth factor (VEGF) cDNA and 
shRNA targeting iNOS gene. Firstly, shRNA sequences against human iNOS gene were 
screened. Then, we determined the effect of different promoters and shRNA backbones 
on gene silencing. The shRNA with H1, U6 and CMV promoters showed similar 
efficiency in iNOS gene silencing. In addition, a conventional shRNA showed better 
silencing of iNOS gene, compared to shRNA containing mir375 and mir30 backbones. A 
bipartite plasmid was also constructed with mir30-shRNA and a VEGF cDNA controlled 
by a single CMV promoter. This plasmid showed a better silencing effect compared with 
plasmid without VEGF cDNA. In conclusion, we have successfully constructed bipartite 
vectors co-expressing a VEGF cDNA and a shRNA against iNOS gene. These vectors 
could be an attractive candidate to improve the survival of transplanted islets. 
 
The second part of research was focused on the study of polymeric micelle formulations 
for treating cancers. Two key elements were integrated in my research projects: 
development of polymeric micelle delivery systems; discovery of new therapeutics for 
better treatment of cancers. 
 
The project described in Chapter 5 was carried out in collaboration with Dr. Miller’s 
group at The University of Tennessee Health Science Center. In this study, we showed 
 v 
 
that SMART-100 effectively inhibited HepG2 cell proliferation and was able to 
circumvent multiple drug resistance (MDR) in cancer cells. SMART-100 inhibited P-gp 
activity, which may be responsible for its ability to overcome MDR. Since SMART-100 
is poorly soluble in water, it was formulated in poly(ethylene glycol)-b-poly(D, L-lactide) 
(PEG-PLA) micelles. The solubility of SMART-100 was increased by more than 1.1x105 
folds. SMART-100 loaded PEG-PLA micelles could effectively inhibit HepG2 cell 
growth and arrest cell cycle progression at G2/M phase, followed by cell apoptosis. 
Increased caspase 3 activity was also observed when HepG2 cells were treated with 
SMART-100. The anticancer activity of SMART-100 loaded PEG-PLA micelles was 
also evaluated on luciferase expressing C4-2-Luc cell lines by IVIS imaging. Our results 
suggest that SMART-100 has the potential to treat resistant cancers and PEG-PLA 
micelles can be used to formulate SMART-100. 
 
We are not only interested in using commercial polymers but also interested in designing 
new polymers for micellar drug delivery. Therefore, the objective of study described in 
Chapter 6 was to design lipopolymers for hydrophobic drug delivery. In this study, 
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodeca
nol) (PEG-PCD) lipopolymers were synthesized and characterized by 1H NMR, FTIR, 
GPC, and DSC. The critical micelle concentration (CMC) of PEG-PCD micelles was 
around 10-8 M and decreased with increasing length of hydrophobic block. PEG-PCD 
micelles could efficiently load a model drug embelin into its hydrophobic core and 
significantly improve its solubility. The drug loading capacity was dependent on the 
polymer core structure, but the length of hydrophobic core had little effect. PEG-PCD 
formed both spherical and cylindrical micelles, which were dependent on the copolymer 
structure and composition. Lipopolymers PEG-PCD with various hydrophobic core 
lengths showed similar drug release profiles, which were slower than that of 
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) 
(PEG-PBC) micelles. Embelin loaded PEG-PCD micelles showed significant inhibition 
of C4-2 prostate cancer cell proliferation, while no obvious cellular toxicity was observed 
for blank micelles. 
 
In Chapter 7, we studied the use of paclitaxel and lapatinib loaded lipopolymer micelles 
for treating MDR prostate cancers. Although paclitaxel remains effective in treating 
prostate cancer, its prolonged treatment develops MDR due to the over-expression of 
P-gp. Our hypothesis is that combination of paclitaxel and lapatinib, which is a potent 
P-gp inhibitor, can overcome MDR in prostate cancers. Paclitaxel and lapatinib loaded 
lipopolymer micelle formulations were developed and evaluated in vitro with cell-based 
assay. The paclitaxel and lapatinib combination effectively inhibited in vitro MDR cancer 
cell proliferation, induced cell cycle perturbation and cell apoptosis. In contrast, 
monotherapy with paclitaxel or lapatinib alone showed minimal anticancer effect. The 
combination therapy was further investigated in vivo with athymic nude mice xenograft 
MDR tumor model. Similar to in vitro study, paclitaxel (5 mg/kg) and lapatinib 
(5 mg/Kg) combination therapy significantly inhibited tumor growth in vivo when 
compared to high dose paclitaxel (10 mg/kg) monothearpy. These studies indicate that 
the paclitaxel and lapatinib loaded PEG-PCD lipopolymer micelle formulation could be 
used to treat MDR prostate cancers.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
 
1.1. RNA Interference and Islet Transplantation 
 
Islet transplantation is a potential cure for type 1 diabetes mellitus. Despite recent 
therapeutic success, it is still not common because a large number of transplanted islets 
are damaged by multiple challenges: including instant blood mediated inflammatory 
reaction, hypoxia/reperfusion injury, inflammatory cytokines, and immune rejections. As 
a potent approach to selectively degrade target mRNA, RNA interference (RNAi) was 
developed rapidly as a novel therapeutic strategy. The use of RNAi technologies to 
down-regulate the expression of harmful genes has the potential to improve the outcome 
of islet transplantation. 
 
In the first part of this dissertation, I reviewed how to use RNAi technique to improve the 
outcome of islet transplantation. And the following specific topics were discussed: 
 
 Develop potential RNAi targets based on biological obstacles for islet transplantation. 
 Design effective RNAi strategies: chemically synthesized small interfering RNA 
(siRNA), vector-based short hairpin RNA (shRNA), and their critical design elements 
(such as sequences, promoters, backbones). 
 Use combinatorial RNAi in islet transplantation. 
 Enhance gene silencing with various delivery strategies: chemical modification of 
siRNA, complex formation, bioconjugation, and viral vectors. 
 
Inducible nitric oxide synthase (iNOS) are up-regulated after islet transplantation, which 
will increase the production of radical nitric oxide (NO), and impair islet β cell viability 
and function. This is one of the major reasons lead to the failure of islet transplantation. 
In the first project, we hypothesized that iNOS gene silencing will prevent β cell death 
and improve the survival and function of islets. Following specific aims were studied in 
this project: 
 
 Optimize the siRNA sequence, dose, and transfection conditions to effectively silence 
iNOS gene expression in a rat β cell line and human islets. 
 Determine the effect of iNOS gene silencing on NO production, inflammatory 
cytokine-induced cell apoptosis, and insulin production. 
 
It is also known that multiple reasons are responsible for the damage of transplanted 
islets, including inflammation and cell apoptosis, poor revascularization and hypoxia. In 
the following project, we are interested in developing bipartite vectors for co-expression 
of a growth factor cDNA, which can promote the revascularization of islets, and shRNA 
against an apoptotic gene to improve the viability of islets. Therefore, we have the 
following specific aims: 
 
 Screen shRNA sequences for silencing human iNOS.  
 Study the effect of different promoters (such as H1, U6 and CMV) and miRNA 
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backbone (mir375 and mir30) on gene silencing.  
 Develop bipartite plasmid vectors co-expressing mir30-based shRNA and VEGF 
cDNA with a single CMV promoter. 
 Develop bipartite plasmid vectors co-expressing shRNA and cDNA under separated 
expression cassettes. 
 
 
1.2. Polymeric Micelle-based Nanomedicine for Prostate Cancer Therapy 
 
Polymeric micelles can solubilize hydrophobic drugs and effectively deliver drugs into 
tumors by the enhanced permeability and retention (EPR) effect. Several polymeric 
micelle formulations are currently under clinical trials or approved for treating cancers [1, 
2]. For an example, PEG-PLA micelles (Genexol-PM) have been successfully used as a 
Cremophor EL-free formulation for paclitaxel. It was approved and marketed at Korean 
in February 2007 and currently under clinical trial in USA (http://www.clinicaltrials.gov). 
In this section, our research was focused on the development of polymeric micelle-based 
nanomedicines for treating cancers. 
 
The first project in polymeric micelles formulation development was carried out in 
collaboration with Dr. Miller’s research group. They have discovered a potent anticancer 
compound, substituted methoxybenzoyl-ary-thiazole-100 (SMART-100). SMART-100 
showed excellent anticancer activity in many cancer cells and even in MDR prostate 
cancers. However, the application of SMART-100 for chemotherapy was limited by its 
low aqueous solubility (less than 2 ng/mL ). We are interested in developing a polymeric 
micelle formulation for SMART-100, and have the following specific aims: 
 
 Determine in vitro anticancer effect of SMART-100 on HepG2 Cells and MDR 
prostate cancer cells (DU145-TXR). 
 Prepare and characterize SMART-100 loaded PEG-PLA micelle formulations. 
 Determine drug solubility and loading efficiency of SMART-100 in polymeric 
micelles. 
 Determine in vitro anticancer effect of SMART-100 loaded PEG-PLA micelles: cell 
cycle perturbation and apoptosis, caspase 3 activity assay, IVIS imaging.  
 
In the following study, we designed and synthesized a lipopolymer for micellular 
delivery of embelin, which is an XIAP inhibitor and showed good anticancer activity on 
prostate cells in combination with bicalutamide. We have following specific aims: 
 
 Design and optimize the synthesis procedure of lipopolymers poly(ethylene glycol)-
block-poly(2-methyl-2-carboxyl-propylene carbonate–graft-dodecanol). 
 Characterize lipopolymers with 1H NMR, FTIR, GPC, and DSC. 
 Determine the effect of hydrophobic core length and structure on the CMC value of 
polymers. 
 Determine the effect of core structure and length on drug loading, micelle 
morphology, and in vitro drug release. 
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 Evaluate the anticancer effect of embelin loaded lipopolymer micelle in vitro with 
prostate cancer cells. 
 
In the last project, we developed paclitaxel and lapatinib combination therapy to 
overcome MDR in prostate cancers. Lipopolymer PEG-PCD was used to prepare 
paclitaxel and lapatinib loaded micelles. Thus, the following specific aims were tested in 
this project: 
 
 Synthesize and characterize PEG-PCD lipopolymers. 
 Develop a HPLC method to simultaneously determine paclitaxel and lapatinib in 
lipopolymer micelles. 
 Optimized and characterize paclitaxel and lapatinib loaded lipopolymer PEG-PCD 
micelle. 
 Determine the effect of paclitaxel and lapatinib combination on MDR prostate cancer 
cells in vitro: MTT assay, TUNEL assay, cell cycle analysis. 
 Determine the effect of paclitaxel and lapatinib combination in vivo with athymic 
nude mice xenograft MDR tumor model. 
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CHAPTER 2. RNA INTERFERENCE FOR IMPROVING THE OUTCOME OF 
ISLET TRANSPLANTATION* 
 
 
2.1. Introduction 
 
The first attempt to transplant pancreatic tissue was performed 29 years before the 
clinical introduction of insulin, when a young boy dying of diabetic ketoacidosis had 
three small pieces of sheep’s pancreas implanted beneath his skin [3]. But the patient died 
after 3 days. In 1966, the first pancreatic allotransplantation was performed at the 
University of Minnesota [4]. Since then, more than 30,000 pancreas transplantations were 
carried out worldwide. In 2008, approximately 1300 patients were transplanted with 
pancreas in the United States with the majority of them being simultaneous pancreas-
kidney transplantations [5]. Although there are some beneficial effects, pancreas 
transplantation remains an invasive procedure with significant mortality and morbidity 
[6]. Pancreas transplantation is also limited by the death of organs, and the need for non-
specific immune suppression.  
 
Insulin-producing β cells in the islets of Langerhans are the target of autoimmune 
aggression in type I diabetes, and non-β cells and the exocrine pancreas is unaffected. 
The islets constitute only a tiny fraction (1%) of the whole pancreas and it is functionally 
unnecessary to transplant the whole pancreas when only its endocrine tissue is required. 
Islet transplantation provides a less invasive alternative approach for the treatment of type 
1 diabetes with reduced antigen load, relative simplicity, and low morbidity. However, 
since the initiation of clinical islet transplantation from early 1970s, most of these trials 
were failed, until the breakthrough at the University of Alberta in Edmonton, Canada. 
The “Edmonton protocol” was published in 2000, reporting that seven patients with type 
I diabetes became insulin independent after receiving islet transplantation with a 
prednisone-free protocol [7]. 
 
The Edmonton protocol has been replicated and further modified worldwide with many 
successes. In 2001, the National Center for Research Resources (NCRR) of the National 
Institutes of Health (NIH) established ten islet resource centers with the mission of (1) 
providing high quality human islets for both clinical and basic research use; (2) 
optimizing processes for islet isolation, purification, and storage; and (3) developing the 
methods for characterization of islets (http://icr.coh.org). In the same year, the Immune 
Tolerance Network (ITN) with the joint help from the Juvenile Diabetes Research 
Foundation (JDRF) and NIH began a trial at nine centers worldwide to perform 
transplants in 40 subjects to determine if the Edmonton results could be reproduced on a 
broad scale. The ITN aims at developing a core group of excellent clinical islet transplant 
centers for future testing of tolerance-based trials (http://www.immunetolerance.org). 
From 1999 to 2008, around 400 patients received allogeneic islet transplantation [8, 9]. 
 
 
* Adapted with permission. F. Li, R.I. Mahato, RNA interference for improving the 
outcome of islet transplantation, Adv Drug Deliv Rev, 63 (2011) 47-68. 
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Despite these successes, only less than 10% of the recipients remain insulin independent 
for up to 5 years, and most recipients return to insulin because the islet function 
decreased over time [10]. After transplantation, Islet grafts face multiple challenges 
including innate and adaptive immune rejection, toxicity associated with immune 
suppressive agents, and insufficient islet revascularization [11, 12]. Therefore, islets 
isolated from two to four donors are needed for single patient islet transplantation [13]. 
At present, even with expansion in the currently available organ donor pool, islet 
transplantation will only benefit about 0.5% of potential recipients [14].  
 
Ex vivo genetic modification of islets before transplantation has the potential to 
overcome several problems associated with islet transplantation [12, 13, 15-19]. Growth 
factor gene expression has the potential to promote islet revascularization; while anti-
apoptotic gene expression can reduce inflammation and immune rejection; and prevent 
islet cell apoptosis. This strategy can help to reduce the number of islets needed for each 
recipient and prolong the time that a recipient can maintain insulin independence after 
transplantation. The genetic modification of islets could be the over-expression of 
protective genes or inhibition of harmful gene expression [20]. Antisense 
oligonucleotides (ODNs), ribozymes, DNAzymes, and RNA interference (RNAi) are 
major approaches which are currently being used to sequence specifically reduce or 
inhibit gene expression. Among these approaches, RNA interference (RNAi) is relatively 
new and evolutionally conserved biologic process that regulates gene expression using 
small interfering RNA (siRNA) mediated sequence specific, post-transcriptional gene 
silencing [21, 22]. Since the discovery of RNAi by Fire and Milo in 1998, it has been 
widely used as a tool for basic research as well as a potential therapeutics [23-26]. The 
application of RNAi and other approaches have been extensively reviewed [27]. siRNA 
molecules can recycle between different copies of mRNA, while antisense ODN can only 
block the translation of one mRNA before its degradation [28]. Therefore, siRNA is more 
effective than antisense ODN in reducing target gene expression [29]. Miyagishi et al. 
has demonstrated that the IC50 for siRNA was about 100-fold lower that of the antisense 
[30]. Similarly, Bertrand et al. has reported that siRNAs are more efficient in silencing 
target gene and its effect is lasting longer. In addition, RNAi could also be achieved 
though the delivery of shRNA, which is expressed endogenously and has longer gene 
silencing effect [29]. 
 
In this review, we will discuss the biological obstacles to islet transplantation and 
potential RNAi targets; principles and design element for RNAi; and delivery 
approaches. 
 
 
2.2. Obstacles to Islet Transplantation 
 
Since the success of Edmonton protocol, significant progress has been made in human 
islet transplantation. However, this protocol is still not widely used mainly due to the fact 
that islets from several donors are needed for a single recipient, since majority of the 
islets are damaged prior and post transplantation. The destruction of transplanted islets is 
a complex problem with many facets including enzyme and mechanical damages induced 
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by the isolation process, hypoxia, inflammatory reaction, and immune rejection. Since 
many of these factors are inter-related, a thorough understanding of these molecular 
processes will help us to develop more effective therapeutic interventions. 
 
 
2.2.1. Instant blood-mediated inflammatory reaction 
 
Due to non-immunological and innate immunological factors, 50%-70% islets lose their 
viability immediately after transplantation by instant blood-mediated inflammatory 
reaction [31-33]. This phenomenon is also called “early graft loss” or “primary non-
function.” The pathophysiology of blood-mediated inflammatory reaction involves 
platelet binding and activation, coagulation, complement activation, and infiltration of 
neutrophils, monocytes, and macrophages (Figure 2.1) [31]. Activation of coagulation 
could be triggered through both the intrinsic pathway by islet surface collagen residues 
and the extrinsic pathway by tissue factors or monocyte chemoattractive protein-1 (MCP-
1) [34, 35]. Complement is possibly activated through the alternative pathway [36, 37]. 
Infiltration of these immune cells could be observed within 1 h after coagulation and 
complement activation [38]. There are multiple interactions between coagulation, 
complement, and inflammatory cells, which are responsible for the infiltration of 
inflammatory cells. Neutrophils and monocytes interact with activated platelets through 
P-selectin over-expressed on platelets [39]. Macrophages could directly be activated by 
tissue factor, fibrin, or fibrinogen [40]. Soluble C3a and C5a produced through 
complement activation are potent chemoattractants for neutrophils and macrophages [36]. 
The effects of blood-mediated inflammatory reaction are multiple. Firstly, both 
monocytes and macrophages are major phagocytes leading to the destruction of islet 
cells. Secondly, proinflammatory cytokines lead to islet cell apoptosis and necrosis. Last 
but not the least, the infiltrating neutrophils and macrophages will eventually induce 
subsequent adaptive immune response [41].  
 
 
2.2.2. Inflammatory cytokine-induced islet cell death  
 
Mechanical and enzymatic stresses during the islet isolation, purification and transfection 
process result in the activation of resident islet macrophages, which release several 
proinflammatory cytokines including  interleukin-1ß (IL-1ß), tumor necrosis factor-α 
(TNF-α), and interferon- (IFN-). In addition, infiltrating host immune cells (monocytes, 
neutrophils) also produce inflammatory cytokines [42]. These proinflammatory cytokines 
are responsible for the non-specific inflammation and the damage to transplanted islets 
during the early stage of transplantation. The exact source and timing of proinflammatory 
cytokine production still remains elusive and greatly depends on the islet isolation, 
purification and transplantation protocols. For an example, Kupffer cells produce 
inflammatory cytokines, NO, and reactive oxygen species (ROS), which are toxic to 
intraportally transplanted Islets [43-45]. The release of cytokines by islet resident 
macrophages is known to occur during in vitro culture prior to transplantation [46]. The 
levels of IL-1β and TNF-α increase soon after transplantation, and maximum level was 
reached at 3 h for IL-1β and at 6 h for TNF-α. Depletion of kupffer cells significantly 
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Figure 2.1 Instant blood-mediated inflammatory reaction. 
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reduced the levels of IL-1β and TNF-α, indicating the role of macrophage in producing 
inflammatory cytokines [47]. Another study also showed that IL-1β mRNA was 
detectable in islet immediately after isolation and was increased after transplantation. IL-
1β mRNA increased by 9 fold on day 1, by 7 fold on day 3 after transplantation, and 
decreased to baseline level on day 7 [48]. It has also been reported that the expression of 
proinflammatory cytokines (including IL-1β and TNF-α) were observed at 8 h after 
transplantation and declined after 24 h. In the same study, however, IFN- was not 
observed until 48 h post transplantation [49]. Ozasa et al. reported that IFN- mRNA was 
observed in allogeneic transplantation at 1, 3, 5, and 7 days after transplantation with a 
peak at day 5, however, it was almost absent in syngeneic transplantation [50]. Although 
the exact source and level of proinflammatory cytokines production varies among 
different transplantation protocols used, some common intracellular signal pathways are 
activated. These cytokines activate JNK/p38, NF-β, STAT-1, up-regulate the expression 
of several significant genes, and finally result in β cell death (Figure 2.2) [36-37]. 
 
The binding of IL-1β to its receptor IL-1R1 leads to the docking of the IL-1 receptor 
accessory protein (IL-1AcP) and followed by the recruitment of IL-1R1 activated kinase 
(IRAK) through an adaptor protein named myeloid differentiation factor 88 (MyD88). 
Recruitment of IRAK leads to the activation of TNF-receptor-associated factor-6 
(TRAF6), resulting in the phosphorylation and degradation of IκB. NF-κB is then 
released from inhibitory IκB, translocates into the nucleus, and induces the expression of 
multiple genes, including IL-1, IL-6, TNF-α, and iNOS [51, 52].  
 
IFN- binds to IFN receptor 1 (IFNR1), which recruits IFN receptor 2 (IFNR2). 
IFNR1and IFNR2 are associated with Janus tyrosine kinase 1 and 2 (JAK1/2) and 
results in the activation of JAK1 and JAK2. Then signal transducers and activators of 
transcription 1 (STAT1) is activated by JAK2 and then translocates to the nucleus, where 
it binds to the regulatory regions of different genes [53]. In addition, the ischemia-
induced STAT1 also regulates caspase gene expression through the activation of 
transcription factor IRF-1 [54]. 
 
Upon binding of TNF-α, TNF receptors form trimers and undergo conformational 
change, leading to the exposure of intracellular death domain. The death domain interacts 
with TNF-α associated death domain (TRADD), which serves as an adaptor to initiate 
three signal pathways, including the activation of NF-κB, activation of MAPK pathway, 
and induction of apoptosis [55-57]. TNF receptor-associated factor 2 (TRAF2) and 
receptor-interacting protein (RIP) are associated with TRADD to recruit and activate 
kinase IKK, which in turn releases NF-κB by degradation of IκB [55]. TRAF2 also 
activates MAPK pathways and leads to the protein kinases such as c-jun N-terminal 
kinase (JNK) and p38 [58]. Apoptosis are activated through both MAPK pathway (direct 
activation of caspase 3) or FADD mediated activation of caspase 8, which in turn leads to 
the activation of effector caspase, such as caspase 3 [57].  
 
Under in vitro conditions, IL-1β induces functional impairment in the mouse and rat β 
cells, and prolonged exposure (6-9 days) to IL-1β in combination with IFN- and TNF-α 
leads to human, mouse, and rat β cell death [52]. The fate of β cells after exposure to 
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Figure 2.2 Extrinsic and intrinsic pathways for islet cell apoptosis. 
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inflammatory cytokines depends on the type of cytokines, time course and severity of 
perturbation to the key β cell gene networks [52, 59]. Inflammatory cytokines upregulate 
or downregulate around 200 genes, which are either protective or deleterious to β cell 
survival and function [59, 60]. These genes are related to metabolism, signal 
transduction, and transcription factors, suggesting that β cells are making attempt to adapt 
to the effect of cytokine exposure [59]. Several of these genes are putative targets of 
transcription factor NF-B [61]. Transcriptional activity of NF-B is related to the 
expression of proapoptotic genes in β cells [62]. The activation of NF-B is a necessary 
step for inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) 
production [61]. The cytotoxic effect of cytokines is mediated through the production of 
radical NO as well as other free radicals, such as peroxynitrite and superoxide [48, 63]. 
Increased iNOS gene expression leads to an early inflammatory process in islet 
transplantation, suggesting iNOS is an important mediator of graft inflammation and islet 
damage in the early stage of islet transplantation. Inflammatory cytokines initiate β cell 
apoptosis mainly though the extrinsic pathway and function through several molecules in 
the death receptor pathway, such as Fas (CD95), Fas-associated death domain (FADD), 
and the death-inducing signaling complex (DISC), leading to the activation and release of 
caspase 8, which in turn activate caspase 3 [64-66]. 
 
 
2.2.3. Hypoxia and ischemic reperfusion injury  
 
In an intact pancreas more than 15% of the total blood flow goes to islets, which accounts 
for only 1% of the pancreatic tissue [67]. During isolation and purification process, the 
capillary network for blood supply is destroyed; therefore, oxygen and nutrients are 
solely supplied through diffusion. The oxygen tension in portal vein (where the islets are 
transplanted) is 8-10 mmHg, which is much lower than that in the intact pancreas (PO2 = 
40 mmHg) [68, 69]. Although the angiogenesis initiates soon after transplantation, 
revascularization of islets may take up to 10-24 days [70]. Therefore, newly transplanted 
islets are under persistent hypoxic conditions prior to and post transplantation, until 
revascularization process is completed. The reperfusion following prolonged ischemia 
causes injury, commonly known as ischemia/reperfusion (IR) injury. For an example, IR 
injury in the liver activates Kupffer cells, which will produce inflammatory cytokines, 
ROS and NO, resulting in islet cell apoptosis [71]. Hypoxia induces the intrinsic pathway 
of apoptosis though the disruption of the mitochondrial integrity, induction of 
cytochrome C release, and the activation of caspase 9 and 3 [64-66]. Nutrient deprivation 
can also induce islet apoptosis through the intrinsic pathway [64]. 
 
 
2.2.4. Autoimmune recurrence and allogeneic immune rejection 
 
In addition to hyperacute rejection, acute rejection, and chronic rejection experienced 
during the transplantation of other organs such as heart, lung, liver, and kidney, 
transplanted islets are under additional attacks due to autoimmune rejection against β 
cells in type I diabetic patients. In the following paragraph, we will briefly summarize the 
immunology of islet transplantation (Figure 2.3).   
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Figure 2.3 Autoimmune recurrence in type 1 diabetes and activation of T cells in 
host immune rejection against transplanted islets. 
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2.2.4.1. Autoimmune recurrence 
 
Type I diabetes is caused by autoimmune mediated damage of islet β cells. It is 
characterized by the presence of β cell reactive T cells, proinflammatory cytokines, and 
other molecules. Transplanted islets are also attacked by the same stresses that destroy 
host β cells. Among them, CD8+ T cells are one of the major players in destroying β 
cells. The infiltration of CD8+ T cells is observed in the pancreas of type 1 diabetic 
patients as well as transplanted pancreas [72, 73]. In addition, activated CD4+ T cells are 
also involved in the killing of β cells. Reduced insulitis is observed in the absence of 
CD4+ T cells [74]. The activation of CD8+ T cells is dependent on CD4+ T cells. CD8+ 
T cells kill target cells through direct contact and mediated by perforin and granzyme B. 
Perforin can disturb target cell membrane integrity and facilitate the release of granzyme 
B into the cytoplasm of target cells, whereas granzyme B cleaves proapoptotic molecule 
Bid. Activated Bid sequesters anti-apoptotic Bcl-2 molecules and triggers β cell apoptosis 
through the intrinsic apoptotic pathway [75-77]. Fas is also upregulated in pancreatic β 
cells of type 1 diabetic patients and causes β cell apoptosis through FasL-Fas interaction 
[78, 79]. 
 
2.2.4.2. Allogeneic immune rejection 
 
Successful transplantation of allogeneic islets is difficult, because transplanted islets are 
recognized not only by the host immune system, but the adaptive immune rejections are 
also activated [80]. Failure of allogeneic islet transplantation is correlated with increased 
T cell reactivity or alloantibody titers [81, 82]. Antigen presenting cells (APCs) process 
and present peptide fragments of various surface, secreted and shed protein from the 
donor. APCs from both donor and host (including dendritic cells, macrophages, 
passenger leukocytes, and mononuclear cells) are involved in the antigen presentation. 
After maturation, APCs provide three signals to fully activate T cells: signal 1, 
recognition of major histocompatibility complex (MHC) and the bound peptide by the T 
cell receptor on the host T cells; signal 2, interaction of co-stimulation signals (such as 
CD40, CD80/86) with their corresponding receptors on host T cells; signal 3, soluble 
cytokines (IL-12, IL-10, IL-2) further stimulate the proliferation and differentiation of T 
cells [83, 84]. All of these three signals are required; otherwise, it will result in the 
apoptosis, anergy, and differentiation of T cells. In addition, anti-donor antibodies are 
also developed in most allograft recipients after immunosuppressive medication is 
discontinued. The presence of alloantibodies usually lead to the graft failure of islets from 
donors with the recognized human leukocyte antigen (HLA) allodeterminants [81]. 
 
 
2.3. Potential Targets for Gene Silencing 
 
As a potent approach for inhibiting aberrant protein expression, RNAi can theoretically 
be used to silence any gene involved in the biological processes that lead to the damage 
of islets. However, due to the complexity of pathophysiology of islet transplantation, only 
some key mediators are potential targets for RNAi-based intervention. A wide variety of 
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potential therapeutic targets are investigated in the past, which are discussed in the 
following paragraphs. 
 
 
2.3.1. Modulation of immune rejection 
 
Immunosuppressive agents mediated non-specific immunosuppression is commonly used 
to reduce the immune rejection in islet transplantation, however, even the most islet-
friendly immunosuppressive regimen are toxic to islets. For example, the treatment of 
islets with sirolimus (also known as rapamycin) or  tacrolimus (also known as FK-506 or 
Fujimycin) causes islet apoptosis [85]. Immune modulation with other biological 
approaches could also provide alternative ways to reduce immune rejection [12].  
 
2.3.1.1. Genetic modification of dendritic cells 
 
Dendritic cells are one of the most important APCs, which play a critical role in the 
regulation of immune responses. The activation and maturation of T cells relies on the 
signals from APCs. T cells will undergo apoptosis, if any one of these signals is blocked.  
DCs are genetically modified to act as a suppressor of immune responses. These DCs are 
called tolerogenic DC (Tol-DC).  Clinically, we could isolate DCs from the host and then 
administer them back to the host after making them tolerogenic. Inhibition of the genes 
associated with DC maturation is one of the promising approaches to generate Tol-DC. 
NF-B is an essential transcription factor for DC differentiation and maturation. It 
includes a group of proteins with similar structures. Inhibition of NF-B pathway has 
been shown to produce tolerogenic DC [86, 87]. Silencing of RelB, which is a primary 
NF-B protein, reduces the expression of MHC-II, CD80, CD86, and finally prevents DC 
maturation. RelB silenced DCs were able to inhibit antigen-specific alloreactive immune 
rejection, and decrease antigen specific T cell proliferation [88]. Significantly reduced 
allograft rejection was achieved after administration of RelB silenced donor DC [88]. 
Inhibition of the expression of p35, which is a subunit of IL-12, was an effective 
approach for antigen-specific immune modulation [89, 90]. DCs treated with siRNA 
against p35 were able to induce potent Th2 deviation of antigen-specific response; reduce 
alloreactivity by effective inhibition of T cell proliferation; shift allogeneic T cell 
polarization from Th1 to Th2.  In another study, Tol-DC was generated through the 
treatment of antisense ODN to inhibit the expression of CD80 or CD86.  Allograft 
survival was prolonged by administration of modified DCs, which could induce T cell 
hyporesponsiveness and apoptosis of T cells [91]. In addition, silencing of CD80 or 
CD86 with siRNA inhibited T cell responses in mixed lymphocyte reaction (MLR), 
generated T regulatory cells [92], and improved cardiac allograft survival [93]. Tol-DC 
could also be generated through the silencing of CD40, which is another critical co-
stimulatory molecules [94]. Silencing of CD40 gene expression in DCs resulted in 
increased IL-4 production, and decreased IL-12 production and allostimulation activity. 
The Th2 cytokine production from allogenic T cells was stimulated [95]. MyD88 is a key 
adaptor of toll-like receptor signaling [83]. It is critical for DC function and 
proinflammatory cytokine production. The silencing of MyD88 significantly improved 
the allograft survival [96]. Suppressor of cytokine signaling (SOCS) molecule is an 
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intracellular inhibitor of Janus kinase. Silencing of SOCS gene in DC resulted in reduced 
allogeneic mixed leukocyte reactions. In addition, systemic administration of SOCS 
silenced DCs improved the survival of allograft in rat [97]. 
 
2.3.1.2.  Reducing immunogenicity of donor islets 
 
HLA is one of the primary causes of Th1/HLA class II antigen rejections in solid organ 
transplantation. Human islet also has an immunogenic potential, which depends on their 
HLA incompatibility with the recipient. The alloreactivity is correlated with acute 
rejection and graft failure. In HLA matching human islet transplantation, the 
alloreactivity is significantly reduced [98]. However, because of the limited sources of 
islet donor and extensive HLA polymorphisms, the availability of HLA-match donors is 
extremely limited. In addition, the fact that multiple donors being required to obtain a 
sufficient number of islets for transplantation makes the donor selection based on HLA 
more difficult. Therefore, HLA-unmatched islets are used to meet the clinical needs. 
These transplanted islets undergo aggressive immune rejections. Silencing of HLA 
expression provides a promising method to reduce the immunogenicity of HLA-
unmatched donor islets [99]. Enhanced resistance to allo-reactive T cell toxicity was 
observed in human cells treated with lentivirus expressing shRNA against pan class I and 
allele-specific HLA [100]. Silencing of HLA in solid organ transplantation was also 
reported [101, 102]. 
 
 
2.3.2. Preventing ischemic reperfusion injury and apoptosis 
 
There are multiple challenges including ischemia/reperfusion, mechanical and enzymatic 
stresses during islet isolation and preservation processes. These factors can activate 
inflammation and intracellular stress signal pathways, and lead to the over-expression of 
proinflammatory mediators, such as proinflammatory cytokines, ROS, caspases, and 
transcription factors. The consequence is the loss of islet function and viability. In 
addition, further adaptive immune response against transplanted islets will also be 
triggered [103].  
 
2.3.2.1.  Block the apoptosis 
 
During the isolation and preservation processes, islets are challenged with various 
stresses. After transplantation, there are multiple factors that could induce the islet cell 
death. The survival of transplanted islets could be improved by preventing islet β cells 
apoptosis [64]. Caspases are the most important mediators of apoptosis, which include 
initiator caspases (caspase 8 and 9), and effector caspases (caspase 3, 7). Inhibition of 
caspase activity with caspase inhibitors, or anti-apoptotic genes, has been reported to 
prevent apoptosis of islets and improve their function [64]. The silencing of caspase 3 
and/or caspase 8 was able to reduce renal and liver ischemia/reperfusion injury, which is 
a significant problem in organ transplantation [104-106]. Silencing of caspase 8, which is 
a mediator of extrinsic apoptosis pathway, could minimize Fas or proinflammatory 
cytokines-induced cell apoptosis. Silencing of caspase 3 (which is the converging point 
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for both extrinsic and intrinsic apoptotic pathways) prevented β cell apoptosis triggered 
by both extrinsic and intrinsic stimulations. We have demonstrated that the silencing of 
caspase 3 protects islets from inflammatory cytokine-induced apoptosis [107]. Delivery 
of caspase 3 siRNA to rat insulinoma (INS-1E) cells significantly reduced the number of 
apoptotic cells. Ex vivo transduction of human islets with adenoviral shRNA prior to 
transplantationreduced caspase 3 activity in islets and significantly improved islet 
function. All of the mice transplanted with adv-caspase 3 shRNA transduced islets 
achieved normoglycemia one day posttransplantation and maintained up to 17 days. In 
contrast, for mice transplanted with untreated islets, where normoglycemia was achieved 
in only 60% at day 1, and 80% at day 4 post transplantation. Fas: Fas/FasL interaction is 
another important mechanism for triggering β cell apoptosis [78]. Treating β cells with 
siRNA-Fas significantly reduced caspase 3 activity and inhibited Fas-mediated β cell 
apoptosis [108]. In other studies, Fas siRNA has been successfully used to reduce 
apoptosis in the liver [109, 110] and heart transplantation [111]. Burkhardt et al. used 
siRNA to silence Fas expression in murine insulinoma cells. Their results showed that 
siRNA against Fas inhibited cytokine-induced Fas mRNA expression and reduced cell 
surface Fas protein. However, due to the slow turn-over of Fas protein, a complete 
inhibition was not observed until prolonged incubation with siRNA. In addition, Fas 
siRNA effectively reduced cytokine-induced β cell apoptosis as determined by caspase 3 
activity and TUNEL assay [108]. 
 
2.3.2.2. Prevent complement activation 
 
Downregulation of complement 3 or complement C5a receptor with siRNA has the 
potential to prevent renal ischemia-reperfusion injury [104, 112]. In another study, UW 
solution containing siRNA against complement 3 also showed the ability to protect donor 
organs in heart transplantation [111]. For islet transplantation, the complement pathway 
is activated during the ischemia-reperfusion injury and blood-mediated inflammatory 
reaction. siRNA targeting C3 and C5a receptors might be a potential target for improving 
the viability of transplanted islets. 
 
2.3.2.3. Inhibit inflammatory pathway 
 
As discussed in the previous section, proinflammatory cytokines activate several 
inflammatory signal pathways, upregulate multiple key genes, and finally results in islet 
cell death. The major mediators in this process are potential targets for preventing islet 
cell death. iNOS gene: iNOS gene expression on islets increased significantly after 
transplantation. The maximal iNOS gene expression was observed one day after islet 
transplantation and then declined progressively [48]. Increased iNOS gene expression led 
to an early inflammatory process in transplanted islets. Nearly, 50% of the cytokine-
induced genes are NO dependent, emphasizing the role of this radical in the late effects of 
cytokines on insulin producing β cells [59]. Therefore, silencing of iNOS gene might 
reduce iNOS mediated inflammatory response and prevent islet cell death. McCabe et al. 
used lentiviral vector expressing shRNA to suppress IL-1β-mediated induction of iNOS 
expression, resulting in significant protection against the cytotoxic effects of IL-1β 
exposure [113, 114]. We designed siRNA to inhibit rat and human iNOS gene expression 
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[115, 116]. Due to the difference between human and rat iNOS mRNA sequences, 
different iNOS siRNA were designed for efficient gene silencing.  A dose and sequence 
dependent inhibition of iNOS gene expression and NO production was observed in rat β 
cell line (INS-1E cell) and human islets. iNOS gene silencing protected β cells from 
inflammatory cytokine-induced apoptosis and preserved their insulin secretion ability. 
However, the effect of iNOS gene silencing on the apoptosis of islet was only moderate, 
as evidenced by 25–30% reduction in caspase 3 activity and in the percentage of 
apoptotic cells. Since an islet is a cluster of 200–1000 cells, the transfection efficiency of 
lipid/siRNA complexes on human islets was only 21–28%, in contrast to the high 
transfection efficiency ( > 90%) in β cell lines. Therefore, to achieve satisfactory 
protective effects on human islets, we need to improve the transfection efficiency, which 
could be achieved by the rationale design of vectors [107, 117] or modifying the delivery 
approaches. This will be discussed in the later sections. 
 
Transcription factor NF-B plays an important role in the inflammation and ischemia-
reperfusion injury. For example, several genes are putative targets of NF-B and their 
expression levels are changed after cytokine exposure [61]. Transcriptional activity of 
NF-B is related to the expression of proapoptotic genes in cytokine stimulated β cells 
[62]. Recombinant adeno-associated virus (AAV) encoding shRNA against NF-B RelA 
(p65) subunit was evaluated to reduce NF-B mediated inflammation [118]. The 
expressed shRNA against RelA significantly reduced p65 protein expression and 
suppressed IL-8 secretion in a cellular TNF-α-induced inflammation model. In another 
study, siRNA against NF-B RelB significantly attenuated ischemia-reperfusion injury-
induced renal dysfunction and protected mice against lethal kidney ischemia [119].  
 
 
2.4. Method of Gene Silencing 
 
 
2.4.1. Types of RNAi methods 
 
The applications of RNAi generally utilize two types of molecules: chemically 
synthesized short interfering RNA (siRNA) or vector-based short hairpin RNA (shRNA). 
Although siRNA and shRNA can be applied to achieve similar functional outcomes, they 
are intrinsically different molecules as discussed below. 
 
2.4.1.1.  Chemically synthesized siRNA  
 
siRNA of 19-23 bp can be synthesized chemically in vitro. Advances in solid phase 
synthesis technique make it possible to produce siRNA with high purity and precise-
controlled sequence. Both sense and antisense strands are synthesized separately and 
annealed to form double stranded siRNA duplex. After being delivered into cytoplasm, 
siRNA is directly incorporated into RNA-induced Silencing Complex (RISC) to have its 
function. Several rate-limiting steps for vector-based shRNA are avoided in siRNA 
mediated gene silencing. Therefore, the gene silencing effect of siRNA is potent and can 
appear in a short time after transfection. This feature also makes the design of siRNA 
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relatively simple, since the factors regarding short hairpin expression and process are not 
involved. However, the 2’-OH group in siRNA molecules makes them extremely 
unstable and susceptible to enzymatic degradation. Only transient gene silencing can be 
achieved with siRNA and it disappears within several days post transfection. 
 
2.4.1.2.  Vector-based shRNA  
 
shRNA is an RNA sequence that makes a tight hairpin turn that can be used to silence 
gene expression via RNAi. Vector-based shRNA utilizes endogenous cellular machinery 
to function. After entering the cell nucleus, vector-based shRNA with stem loop structure 
is expressed to produce pri-shRNA in the nuclei, which is then processed into pre-shRNA 
by an enzyme named Drosha. Pre-shRNA is exported to the cytoplasm by exportin-5, 
where it is further processed by Dicer (an RNAse III enzyme) to produce functional 
siRNA [120]. siRNA is then incorporated into RISC. Activated RISC with antisense 
strand is formed by cleavage of sense strand. Activated RISC recognizes target mRNA 
with a complementary sequence, and result in the cleavage of target mRNA (perfect 
complementarities) or translation inhibition (not prefect complementarities) [24]. 
 
 
2.4.2. Design elements of siRNA and shRNA 
 
2.4.2.1. siRNA and shRNA sequences  
 
siRNA sequence is the most important factor that determines the level and duration of 
gene silencing. Because of high sequence specificity, gene silencing efficiency changes 
dramatically with minor alteration in siRNA sequence. Mutation in the antisense strand 
usually makes the activated RISC unable to recognize target mRNA. There are several 
web-based tools available for predicting effective siRNA sequences and empirical rules 
are incorporated in the siRNA design software to optimize siRNA sequence [121-124]. 
These rules includes: thermodynamic property [125], length of siRNA sequence [126], 
GC contents, RNA secondary structure, sequence region, single nucleotide polymorphism 
sites, avoiding repeats and low complex sequence, avoiding off-target effects on other 
genes or sequences [127, 128]. siRNA sequences predicted by software, however, are not 
always very effective in silencing a target gene, and sometime the most potent siRNA 
sequence is missed. Practically, a potent siRNA can be selected through testing of several 
candidate siRNA sequences designed with bioinformatics tools.  
 
Since shRNA works through the production of siRNA within the cells, there are plenty of 
common rules applicable to both siRNA and shRNA sequence design. Actually, people 
have used the siRNA designing software to predict shRNA sequence with success. Due to 
the similarity between siRNAs algorithm and that of shRNAs, it is not surprising to keep 
the gene silencing efficiency after converting siRNAs into shRNAs. However, some 
features are not required for siRNA but are essential for shRNA expression. For an 
example, strong GC preference at position 11 and the preference for AU but not GC at 
position 9 might be the different properties for shRNA sequences [125]. The 
incompatibility of siRNA design algorithm for shRNA design has also been reported 
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[129]. It would be a good idea to design shRNA sequences using shRNA design 
algorithm. Similar to siRNA design, several shRNA sequences should be experimentally 
screened to find potent shRNA sequences. An obvious disadvantage of this approach is 
that the cloning of shRNA into plasmid is a time consuming process. Fortunately, pre-
designed shRNA plasmids for most genes are now commercially available. In most cases, 
potent shRNA sequences for a particular gene could be found by screening several pre-
designed shRNAs. 
 
2.4.2.2. Expression cassette for shRNA  
 
Although shRNA sequence design is critical for efficient gene silencing, it is equally 
important to have a proper shRNA expression cassette, which determines the magnitude, 
duration and specificity of shRNA expression. In addition, the structure of shRNA 
backbone also plays an important role in shRNA transcription, processing, and nuclear 
export. The effect of different promoters and shRNA structures has been extensively 
investigated to improve the level and duration of gene silencing. 
 
Promoters refer to DNA sequences that provide a binding site for RNA polymerase and 
transcription factors. DNA transcription starts after transcription factor binding to 
promoter sequences and recruitment of polymerase. The level and duration of shRNA 
expression depends on the properties of promoters used. Three types of promoters, such 
as constitutive promoter, inducible promoters, and islet specific promoter will be 
discussed here. 
 
The first type of promoters is constitutive promoters. There are three types of constitutive 
promoters used for shRNA expression, including polymerase III, polymerase II, and 
polymerase I promoters. U6 and H1 are the two most commonly used polymerase III (Pol 
III) promoters for shRNA expression.  This is because Pol III promoters transcribe small, 
highly structured RNAs without poly (A) and 5’-cap in mammalian cells [130]. However, 
Pol II promoters such as CMV [131, 132], U1 promoter [133], and E1b promoter [134] 
are also used for shRNA expression. Particularly, CMV promoter can be used for co-
expression of a cDNA and a shRNA with a single promoter or to drive the expression of 
a shRNA embedded in a miRNA structure [132]. Usually, a poly (A) signal is needed for 
the termination of CMV promoter expression. A modified CMV promoter can also be 
terminated by poly(T) termination signal [131]. To increase the activity of U6 or H1 
promoter, hybrid promoters composed of CMV enhancer and U6 or H1 promoter were 
constructed for shRNA expression [135-137]. Polymerase I promoter has also been 
reported for shRNA expression [138], however, the use of pol I promoter is still not well 
investigated.  
 
The second type of promoters is inducible promoter. High level constitutive expression of 
shRNA may saturate cellular machinery and cause cell toxicity. In addition, it is 
undesirable to constitutively silence genes that are essential for cell viability. Therefore, 
inducible promoters that can silence genes in a tunable pattern were developed. Different 
conditional RNAi strategies have been reviewed elsewhere [139].  Here, we list some 
examples to discuss the concept of using inducible promoters for gene silencing. 
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Czauderna and coworkers [140] constructed tetracycline-inducible U6 or 7SK promoters 
by introducing a tetracycline operator (tet O) sequence between TATA box and 
transcription start site. shRNA expression was induced by adding tetracycline which 
could dissociate the repressors from the tet O. Similarly, tetracycline inducible H1 
promoter was also constructed to silence β-catenin [141]. An IPTG-H1 promoter has 
been developed by placing a lac operator between TATA box and transcription start site 
[142]. Reversible gene silencing was achieved with above expression systems and the 
gene silencing effect will disappear within 3-4 day after removing the inducers. An 
alternative way for inducible gene silencing is Cre-LoxP recombination system, which 
usually results in an irreversible gene silencing. In this system, a Lox-flanked stuffer 
sequence with termination sequence (five thymidines) is inserted between H1 promoter 
and transcription start site. After expression of Cre protein, the stuffer sequence is 
removed due to the recombination of two loxP sites and thus activate the promoter [143]. 
Hypoxia inducible promoter may have additional advantages for its application in islets, 
which are usually under the hypoxic condition after isolation. The use of hypoxia 
inducible promoter could restrict the gene or shRNA expression within hypoxic islets. 
Therefore, it could avoid unwanted gene expression and silencing on normoxic tissue or 
organs and prevent potential toxic side effects. Lee et al. constructed pRTP801-Luc or 
pRTP801-VEGF plasmids bearing a hypoxia inducible promoter. After transfection into 
rat islets, transgene expression was higher in hypoxic islets than those in normoxic 
condition [144, 145]. Although there is still little report about the use of hypoxia 
inducible expression cassette for gene silencing in islets, we believe that its application in 
islet gene silencing will increase in the future. 
 
The third type of promoters is islet-specific promoter. Several islet-specific promoters 
have been tested to drive the specific transgene expression in islets. Among them, rat 
insulin promoters are being extensively investigated [108, 146, 147]. To improve the 
performance of rat insulin 2 gene promoter in isolated pancreatic islets, an expression 
cassette including 1.5 kb of the porcine INS 5’ UTR and the 3’ UTR of the bovine growth 
hormone gene  was constructed, which showed robust and specific gene expression on 
islet β cells [148]. Chai et al. have compared a series of rat insulin promoter sequences 
with various lengths. The highest promoter activities was observed in a modified RIP3.1 
promoter including the non-coding regions in exon1, intron1, and part of exon2 of the rat 
insulin gene 1 as well as the insulin gene promoter region. This promoter showed 5-fold 
higher activity in INS-1E cells than a full-length RIP promoter or a CMV promoter. In 
addition, RIP3.1 promoter demonstrated β cell specific gene expression and glucose 
responsive gene expression [146]. Recently, the promoter for pri-mir375 has been 
indentified, which could selectively express pri-mir375 in pancreatic islets [149]. Since 
miRNA-based shRNAs have been successfully used for shRNA expression, the finding 
of this promoter provided an option for islet specific shRNA expression. 
 
shRNA backbone structure is also critical for effective gene silencing. High level of 
shRNA expression does not necessarily lead to efficient gene silencing, because nuclear 
export, dicer enzyme processing and other rate limiting steps are also critical for efficient 
gene silencing. These processes are greatly influenced by the shRNA structure, which 
includes the stem length, loop sequence, the sequence of flanking regions. A typical 
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shRNA is composed of a 19-21bp sense sequence and a 19-21bp antisense sequence 
linked with 6-9bp loop sequence. A termination sequence of 5-6 thymidines is usually 
included at the end of stem-loop structure, except for shRNA driven by a pol II promoter. 
Various shRNA structures have been studied to improve gene silencing efficiency. Siolas 
et al. found that synthetic 29-mer shRNAs were more potent than 19-mer shRNAs, while 
the loops sequence did not have any effect [150]. In contrast, Jeanson-Leh et al. reported 
that increase in the stem length from 19-mer to 29-mer did not show any improvement in 
gene silencing [151]. It was also reported [125] that gene silencing of shRNAs with 19-
mer stem was better than those of shRNA with  29-mer stem in the context of a 9-bp 
loop.  
 
An emerging trend in shRNA design is to incorporate siRNA into a miRNA precursor 
backbone so that it can be processed efficiently by intracellular miRNA machinery. 
mir30-based shRNA has been reported to be more efficient than conventional shRNA 
[152-154]. Boden et al. designed a shRNA against HIV-1 transactivator protein TAT with 
a mir30 backbone, which showed 80% more potency in silencing target gene than a 
conventional shRNA [152]. In another study, Li et al. compared 14 pairs of conventional 
shRNA and mir30-based shRNA against luciferase gene, and 10 pairs of conventional 
shRNA and mir30-based shRNA against the mouse tyrosine gene. Results indicated that 
in 11 out of 14 pairs of shRNA against luciferase and all of those for mouse tyrosine 
gene, a better gene silencing was observed in conventional shRNA rather than in mir30-
based shRNA [125]. Boudreau et al. have also demonstrated that optimized shRNA are 
more efficient than mir30-based shRNA in silencing of several genes, including green 
fluorescent protein (GFP), spinocerebellar ataxias, and Huntington disease [155]. In our 
own studies, we also found that mir30-based shRNA against human iNOS genes was less 
potent compared with conventional shRNA [117]. These discrepancies indicate that 
current understanding of shRNA design is still limited and further exploration is 
necessary to develop a satisfactory rule for shRNA design. The use of miRNA backbone 
for shRNA expression also has the potential to reduce toxicity [156] and to have tissue or 
cell type specific gene silencing [157].In addition, we could also construct  pri-miRNA 
cluster, in which multiple miRNA-based shRNA is driven by a single promoter to form a 
single transcript [158, 159]. 
 
Recently, several other shRNA structures have been investigated for different 
applications. In one study, a tRNA-shRNAs chimeric expression cassette was 
constructed, in which a tRNA promoter was used to drive the expression of shRNA 
linked to the 3’ acceptor stem of tRNA [160]. This system could achieve similar or even 
high gene silencing than shRNAs expressed from U6 or H1 promoters [160-162]. Since 
exportin-t, but not exportin-5, was used for the nuclear export of tRNA-shRNAs, it could 
reduce toxicity related to exprortin-5 saturation [161, 163]. Tandem siRNAs: Zheng et al. 
designed a dual promoter system (pDual) by inserting siRNA sequence between two 
promoters (including mouse U6 and human H1 promoters) with opposing directions 
[164]. 
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2.4.2.3. Off-target effects 
 
Since the first report by Jackson et al. in 2003 [165], many studies have shown that both 
siRNA and shRNA could cause off-target effects. From a therapeutic standpoint, the off-
target effects should be avoided to prevent unintended effects. Therefore, understanding 
the mechanisms of off-target effects and developing strategies to enhance RNAi 
specificity is critical for the application of RNAi. There are two types of off-target 
effects: specific off-target effects, which are caused by the partial sequence 
complementarity between mRNA and siRNA, and non-specific off-target effects, which 
are the outcome of overall translation inhibition due to the activation of immune system 
and cellular toxicity. The mechanism of off-target effects was reviewed extensively 
elsewhere [166, 167]. 
 
One type of off-target effecs is specific off-target effects. Silencing of non-target genes is 
possible if there is as little as 8-nt homology at the seed region sequence [168]. The off-
target effects may also be observed when mRNA shared 7-nt homology with the guide 
siRNA sequence [169]. However, not all the mRNA with this level of homology will be 
silenced and it depends on the location of complementary region within siRNA and the 
mRNA. Seed region is the nucleotides 2–7 at the 5′ end of siRNA. Complementarity 
between the siRNA seed region and the 3’ UTR of mRNA is an important predictor for 
off-target effects [168]. Several approaches have been developed to avoid the specific 
off-target effects. It could be prevented by designing siRNA sequences to minimize the 
complementarity between seed region of siRNA and the 3’ UTR of mRNA [170]. One or 
two base mismatch between siRNA and target mRNA are usually tolerated without losing 
gene silencing efficiency [171]. This allows us to modify the siRNA sequence to 
minimize the complementarity with 3′UTRs of the untargeted mRNAs. However, the 
modification of siRNA sequence is associated with the risk of losing gene silencing 
efficiency. Since the passenger strand is not involved in the recognition with target 
mRNA, modifications of passenger stand is preferred and more tolerant. For example, 
breaking a passenger strand into two segments significantly reduced off-target effects 
[172]. RNA-DNA chimeras [173] have also been developed to avoid off-target effects.  
 
Another type of off-target effects is nonspecific. The innate immune systems could be 
activated by several elements including dsRNA, plasmid or viral vectors, cationic 
delivery carriers. The activation of immune system causes the inhibition of global gene 
expression and false positive gene silencing effect. There are multiple receptors involved 
in the activation of immune system. They are cytoplasmic receptors, including dsRNA-
dependent protein kinase R (PKR), retinoic acid-inducible gene-1 (RIG-1), and 
melanoma differentiation-associated gene-5 (MDA-5) [174-176] and endosomal toll-like 
receptors (TLRs) [177, 178]. For an example, introduction of long dsRNA into cells leads 
to the activation of PKR , and results in the activation of innate immune system and type-
I IFN production [176]. Although the use of shorter siRNAs could minimize the 
activation of immune response, sequence dependent activation of TLR7 and 8 could not 
be eliminated [179]. For vector-based shRNA, siRNA expressed inside the nucleus and 
exported into the cytoplasm. The use of vectors-based shRNA could thus avoid the 
activation of TLR3, which recognize dsRNA. However, the plasmid vectors will activate 
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TLR9, unless the unmethylated CpG motifs were removed from the vectors [180, 181]. 
High levels of siRNA and shRNA could also compete for intracellular miRNA/shRNA 
process machinery. The saturation of epxortin-5 and RISC component, Argonaute-2 will 
cause cell toxicity [182]. This can be minimized by designing of proper expression 
cassettes to carefully control shRNA expression levels and avoid the saturation of 
miRNA machinery. 
 
 
2.5. Combinatorial RNAi 
 
Due to the complexity of molecular mechanism of islet cell death, it is almost impossible 
to effectively prevent islet cell apoptosis by silencing the expression of a single gene or 
over-expression of a single protective gene. Therefore, combinatorial RNAi strategies 
which could synergistically work on multiple targets are required to achieve satisfactory 
outcomes. This could be realized by simultaneous knockdown of different genes involved 
in multiple biological processes or signal pathways. Alternatively, we could also 
simultaneously silence certain harmful genes and at the same time over-express 
protective genes. Different strategies for combinatorial RNAi will be discussed (Figure 
2.4).  
 
 
2.5.1. siRNA pool 
 
The use of several siRNAs target different regions of a single gene is more efficient than 
the use of a single siRNA sequence in reducing gene silencing. Cheng et al. tested a pool 
of two siRNA sequences against TGF-β1 gene in HSC-T6 cells [183]. In that study, the 
siRNA pool showed better inhibition of TGF- β1 protein expression as determined by 
western blot analysis. In addition, an enhanced inhibition of the expression of 
downstream genes including type α1 (I) collagen and α-smooth muscle actin (α-SMA) 
were also observed. In another study, Chen et al. used siRNA pool targeting different 
regions of human hepatitis B surface antigen. The treatment of this siRNA pool showed 
efficient inhibition of hepatitis B surface antigens production at HBV-producing 
HepG2.2.15 cells [184]. Alternatively, co-silencing of multiple genes with siRNAs has 
also been used to achieve synergistic effect. For an example, siRNA against three 
different genes including TNF-α, complement 3 (C3) and Fas were tested to reduce 
ischemia/reperfusion injury to donor organs. The siRNAs used in this study, were 
supposed to silence several different genes involved in apoptosis, complement activation, 
and inflammations [111]. In other studies, combination of siRNAs targeting complement 
3 and caspase 3 [104] or siRNAs targeting caspase 3 and caspase 8 [105] have been used 
to prevent renal ischemic injury. siRNA pool targeting mRNAs of multiple genes will be 
suitable for improving the islet viability because of  the involvement of  multiple 
processes in islet damage. 
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Figure 2.4 Combinatorial RNAi strategies for islet genetic modification. 
 
(A) siRNA pool  targeting different sites of a single gene or targeting multiple genes. (B) 
Co-expression of multiple shRNAs, (I) multiple shRNAs under separate promoters, (II) 
miRNA cluster mimics, (III) long hairpin RNA. (C) Co-expression of shRNAs and 
cDNAs, (I) from a single miRNA backbone, (II) from separate promoters. 
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2.5.2. Co-expression of multiple shRNAs 
 
There are several scenarios for co-expression of multiple shRNAs from a single vector: 
(1) multiple shRNAs with the same sequence, (2) multiple shRNAs against different 
regions of the same gene, or (3) multiple shRNAs against different genes. For the first 
one, the purpose is to increase the intracellular shRNA levels. However, it is rarely used 
because the shRNAs levels could be controlled more conveniently by selecting proper 
promoters. The use of multiple shRNAs against different regions of a single gene is 
believed to be more efficient in reducing target gene expression levels, possibly due to 
the synergistic effect. The advantage of using multiple shRNAs against different genes is 
the possibility to block multiple mediators in the signal pathways. Co-expression of 
multiple shRNAs were widely studied as an antiviral treatment modality [185]. Although 
the disease targets are different, the shRNAs expression strategies could be applied to 
genetic modification of islets. Here, some strategies for co-expression shRNAs will be 
reviewed. 
 
Gonzalez et al. constructed a vector where multiple shRNAs against HLA class genes 
were under the control of a common U6 promoter. A dose dependent increase in RNAi 
efficiency was achieved though raising shRNA copy numbers up to six [186]. Several 
other studies demonstrated the feasibility of co-expressing multiple shRNAs by utilizing 
miRNA backbone. In these studies, strong promoters (such as a CMV promoter or a 
unbiquitin C promoter) were used to control the expression concatemerized multiple 
miRNA (miR30 or miR155)-based shRNAs [158, 187-189]. However, the increase in 
shRNA copy number does not necessary improve gene silencing efficiency. Further 
investigation will help us to understand the optimal hairpin numbers, positions, backbone 
sequences required for efficient RNAi.  
 
Long hairpin RNA (lhRNA) [190, 191] or extended hairpin RNAs (e-shRNAs) [192, 
193], also showed the potential to co-express several siRNAs. For an example, Liu et al. 
constructed a vector with e-shRNAs containing two siRNAs and found that a stem length 
of 43 bp is the minimal requirement. The 66 bp was the minimal length needed to 
produce three siRNAs [193]. Instead of expressing multiple shRNAs, a single hairpin 
with multiple siRNAs was expressed in this type of construct. Different levels of gene 
silencing were observed among these siRNAs and were dependent on their position to the 
stem loop. The siRNA most close to the loop showed comparable gene silencing to single 
shRNA, however, other siRNAs usually showed less gene silencing efficiency [191, 
193]. In addition, three siRNA units is the upper limit for one construct and the gene 
silencing efficiency was significantly reduced when four siRNA units were included 
within one construct [193]. 
 
Alternatively, it is also possible to express shRNAs from two or more independent 
promoters. For example, two shRNAs against different isoforms of glycogen synthase 
kinase 3 gene were under the control of separate U6 promoters and achieved efficient 
inhibition of target gene with additive effect [194]. A similar study showed the use of 
separate U6 promoters to control the expression of shRNAs targeting different Smads 
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[195]. Co-expression of multiple miRNA-based shRNAs against different gene has also 
been reported [196].  
 
 
2.5.3. Co-expression of shRNAs and cDNAs 
 
We have recently demonstrated the beneficial effects of co-expressing multiple genes 
from a single vector for improving the outcome of islet transplantation. The combination 
of growth factor and anti-apoptotic genes showed synergistic effect in protecting 
transplanted islets [18, 19]. A vector could co-express both siRNA and cDNA will be 
particularly interesting [197]. Not only is the inhibition of harmful genes but also over-
expression of protective genes is needed to protect islets. We constructed vectors for co-
expression of shRNAs against iNOS genes and a VEGF cDNA. In this vector, VEGF was 
designed to promote the revascularization of transplanted islets. The shRNA against 
iNOS were designed to reduce the expression of iNOS genes and minimize iNOS 
mediated islet cell death. In this study, we also investigated the use different expression 
cassettes for co-expression of shRNA and cDNA from a single vector. The plasmid 
vector contained two expression cassettes, where VEGF was under the control of a strong 
CMV promoter and shRNA was driven by U6, H1, or CMV promoters. Alternatively, it 
was also possible to express cDNA and shRNA from a single expression cassette. In this 
case, we used CMV promoter to drive the expression of miRNA-based shRNA and 
VEGF cDNA was inserted between the CMV promoter and shRNA. This strategy was 
reported previously by Qiu et al. , where a miRNA-based shRNA was placed in the 3’-
UTR of a red fluorescent protein (RFP) for co-expression of both shRNA and RFP [198]. 
Similar study was also reported by Shin et al., where a GFP gene was inserted between 
the Tet response element promoter and miR30-based shRNA. This construct allows the 
co-expression of both GFP and shRNA [196]. In our study, both monocistronic and 
bicistronic systems showed high VEGF expression and efficient reduction of iNOS gene 
expression. These vectors could be further modified by replacing VEGF cDNA with 
another cDNA such as hepatocyte growth factor (HGF), which will enhance angiogenesis 
and promote β cell proliferation. The shRNA against iNOS genes could be replaced 
various other shRNA targeting proapoptotic and inflammatory genes. 
 
 
2.6. Delivery Strategies for Enhanced Gene Silencing  
 
Although good progress has been made since the discovery of RNAi technique, the 
application of RNAi for therapeutic purposes is still limited, because of several  
biological barriers for siRNA delivery [199]. Systemic delivery of siRNA is required to 
block host against islet graft immune rejection. However, siRNA face several biological 
barriers after systemic administration [199], which usually result in the degradation of 
siRNA. Another potential issue for systemic siRNA delivery is the lack of its targeting 
ability, which requires the use of targeted delivery system to avoid gene silencing on 
other tissues or organs. In addition, the systemic administration will possibly induce the 
immune reaction not only by the siRNA but also by the delivery system, especially, when 
a viral vector is used. Alternatively, ex vivo delivery is an ideal approach for genetic 
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modification of islets prior to transplantation. Since after isolation, islets are usually 
preserved in storage solutions before transplantation, we can transfer siRNA into islets 
prior to transplantation. This ex vivo siRNA delivery approach can also be used to 
generate immune tolerant dendritic cell (Tol-DC). 
 
The design of proper delivery systems is critical for the clinical application of RNAi 
technology. Both non-viral and viral vectors have been widely used. The main advantage 
of viral vectors is their high transduction efficiency. However, the use of viral vectors is 
undermined due to safety issues and also the construction of individual viral vector is a 
time consuming process. Alternatively, non-viral approaches, which could avoid the 
problems for viral vectors, have become a promising approach for gene silencing. In this 
section, we will discuss siRNA delivery systems applicable to islet transplantation 
(Figure 2.5). Firstly, we will discuss the possibility of using free siRNA and chemically 
modified siRNA. Secondly, we will visit the cationic lipids or polymers for siRNA 
delivery. Thirdly, the use of bioconjugation will be discussed, which could enhance 
siRNA delivery into the cells and increase siRNA stability. Finally, we will summarize 
some viral vectors used for gene silencing including adenovirus and lentivirus. 
 
 
2.6.1. Free siRNA 
 
Free siRNAs are difficult to be transfected into the cells mainly because of their poor cell 
membrane permeability and sensitive to nuclease mediated degradation. However, it is 
still possible to deliver free siRNAs to islets with some physical approaches, such as 
hydrodynamic injection [200], in situ perfusion [201], and microporation [202]. Zheng et 
al. protected donor organs for heart transplantation with siRNA-containing solution 
[111]. In that study, heart graft from BALB/C mice were preserved in solution containing 
siRNAs against several genes involved in ischemia/reperfusion injury. This treatment 
resulted in efficient silencing of target genes in the grafts and lead to improved graft 
function. Due to the similarity among different organ transplantations, this approach 
should be equally applicable for islet transplantation. 
 
However, native siRNA is degraded rapidly due to nuclease attack, therefore, chemical 
modification of siRNA has been extensively studied to (1) minimize nuclease 
degradation; (2) avoid innate immune system activation; and (3) reduce off-target effects 
[203, 204]. Since most siRNAs were produced through chemical synthesis, it is 
technically possible to incorporate various modifications into siRNA backbones (Figure 
2.6). These modifications could be applied to phosphodiester or ribose. Non-bridging 
oxygen in the phosphodiester could be replaced with sulfur (phosphorothioate), boron 
(boranophosphate), or methyl (methylphosphonate) groups. The 2’-position of the ribose 
could also be modified to improve the stability of siRNA. The modification of ribose 
includes 2’-O-methyl (2’OMe), 2’-fluoro(2’-F), 2’-O-fluoro-β-D-arabinonucleotide 
(FANA), 2’-O-(2-methoxyethyl) (MOE), and locked nucleic acid (LNA), which contains 
a methylene bridge connecting the 2’-O with the 4’-C of the ribose ring. Single or 
combination of various types of modifications could be used depending on the aim of 
modification, which will be briefly discussed below.  
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Figure 2.5 Delivery strategies for gene silencing. 
 
Cationic liposomes and polymers are commonly used as transfection reagents for siRNA 
and shRNA. To avoid the use of cationic carriers, siRNA can also be conjugated to 
polymers such as poly(ethylene glycol) carrying targeting ligand(s). For enhanced and/or 
prolonged gene silencing, shRNA is often cloned into a viral (adenovirus, lentivirus, or 
adeno associate virus) vector. After administration, these delivery systems enter the cells 
mainly through endocytosis. Vector-based shRNA is further translocated into cell 
nucleus, where shRNA is expressed to produce pri-shRNA, which is further processed 
into pre-shRNA by an enzyme named Drosha. Pre-shRNA is exported to the cytoplasm 
by exportin-5, where it is processed by Dicer (an RNAse III enzyme) to produce 
functional siRNA. For siRNA bioconjugation or siRNA complex, the escape and release 
of free siRNA from endosome into cytoplasm is an essential step. Finally, siRNAs will be 
incorporated into RNA-induced silencing complex (RISC) and guide the recognition and 
degradation of target mRNA. 
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Figure 2.6 Common modification introduced to siRNAs. 
 
(A) Modification of non-bridging oxygen internucleotide linkage. (B) Modification of the 
sugar unit. 
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2.6.1.1. Enhancing serum stability 
 
Unmodified naked siRNAs are extremely unstable with a serum half-life of less than 5 
min [205, 206], which restricts their clinical application. Thus, chemical modification of 
siRNAs has been extensively studied to improve the resistance of siRNAs to nuclease 
degradation. Theoretically, all above mentioned modifications can be applied to increase 
the serum stability of siRNA. The modification strategies should be carefully designed, 
since extensive modification of siRNAs usually leads to decreased potency [207-209]. 
Alternatively, selective modification of siRNAs at minimal position has been 
demonstrated to significantly improve the serum stability, while keeping the gene 
silencing potency. The 2’-O-Me or 2’F-RNA modification have been applied to the 
termini of the strands or a pyrimidine nucleotide which are vulnerable position for 
nuclease cleavage [24, 207, 210].  
 
2.6.1.2. Reducing innate immune system activation 
 
As we discussed previously, siRNAs will activate the innate immune system and result in 
non-specific off-target effects. Chemical modifications can also be used to avoid or 
minimize siRNA-mediated activation of immune system. For an example, 2’-O -Me 
modification of siRNA was able to minimize the immune system activation [211]. Since 
the 2’-O-Me group is a competitive inhibitor of TLR7,  minimal number of 2’-
modification is sufficient to inhibit the TLR-7 mediated immune stimulation [212].  
 
2.6.1.3. Reducing off-target effects 
 
Chemical modification could be applied to reduce specific off-target effects through 
minimizing the unwanted participation of siRNA in miRNA pathways. For an example, 
modification of the +2 position with 2’-O-Me on the antisense strand effectively reduced 
seed region mediated off-target effects [168]. The seed region could also be replaced 
entirely with DNA residues to reduce off-target effects while preserving the gene 
silencing potency [173]. 
 
 
2.6.2. Complex formation 
 
Both cationic liposomes and polymers are widely used to form complexes with siRNA or 
plasmid shRNA through electrostatic interaction between positive charged carriers and 
negatively charged nucleic acids. Complex formation helps to condense siRNA or 
plasmid DNA and thus facilitate their cellular uptake.   
 
Cationic lipids: Since the introduction of lipofectin at late 1980s [213], many cationic 
liposomes have been tested for delivery of plasmids, and recently for the delivery of 
siRNA. There are several commercial cationic lipid formulations for siRNA delivery, 
including lipofectamine 2000, oligofectamine, lipofectamine, RNAifect, and Fugene HD. 
We have tested lipofectamine to transfect a plasmid encoding an enhanced green 
fluorescent protein gene, pCMS-eGFP into intact human islets. However, only low 
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transfection efficiency was observed, this is due to the fact that human islets are a cluster 
of around 1000 non-dividing cells [16]. In our further studies, a novel lipid with 
methylsulfonic acid in the cationic head group region to enhance lipid/DNA interaction 
was synthesized, which showed higher transfection efficiency than those of lipofectamine 
in intact human islets [214]. In contrast to plasmids, siRNA is efficiently transfected into 
human islets as well as INS-1E rat β cell line. In this study, we used lipofectamine 2000 
to transfect fluorescein-labeled siRNA. The transfection efficiency was determined by 
flow cytometry analysis. There was increase in transfection efficiency with increase in 
siRNA concentration, with maximum transfection efficiency of 95.9% and 28.3% on rat 
β cell line and intact human islets, respectively [115]. This demonstrated the feasibility of 
in vitro genetically modifying human islets with siRNA/lipid complex.  
 
Cationic polymers: In addition to cationic lipids, cationic polymers are also being used 
for plasmid or siRNA delivery. Although we could achieve decent in vitro transfection 
efficiency by optimizing transfection conditions, the cellular toxicity of cationic carrier is 
a major concern for its therapeutic applications. Furthermore, the poor intracellular 
dissociation of siRNA/polycation complex may reduce the intracellular bioavailability of 
siRNA. Recently, several biodegradable carriers have been developed to reduce toxicity 
and improve transfection efficiency. Here, we focus on the some recent progresses, rather 
than a comprehensive review of the use of cationic polymer for siRNA delivery which 
was extensively discussed elsewhere [215]. 
 
Reducible biodegradable carriers are designed based on the different redox potential 
between intra and extra cellular environment. The disulfide bonds in these carriers are 
usually stable enough to keep the integrity of the carrier and protect siRNA before 
cellular uptake. After cellular uptake, the disulfide bonds are cleaved, in response to the 
reducing intracellular environment. This will result in the degradation of carriers and 
release of siRNA. Reducible polymers with disulfide bonds have been investigated for 
delivery of both plasmid and siRNA [216-222]. The advantage of using reducible 
polymers is obvious, which not only reduced carriers associated toxicity, but also 
enhanced dissociation of siRNA from polycation/siRNA complex and thus improved 
gene silencing efficiency. The performance of these carriers could be further improved by 
incorporation of endosomal escaping moieties, such as histidine [220], and protonatable 
pendants [221]. Since the endosomal release of siRNA is a significant barrier for siRNA 
and gene delivery, those components which could facilitate “endosomal escape” will 
greatly enhance the gene silencing efficiency. 
 
Poly (amino ester) (PAE) is another type of biodegradable polymers which has been 
extensively studied for gene delivery. Green et al. generated a library of PAE and 
determined parameters such as polymer type, polymer weight, DNA loading, and other 
biophysical properties. The leading PAE carrier found in their studies were better than 
jetPEI and lipofectamine2000 [223]. PAE has also been successfully used for siRNA 
delivery into lung cancer cells [224], hepatoma cells and primary hepatocytes [225], and 
fibroblasts [226]. Besides, several other biodegradable polymers can also be used for 
siRNA delivery, including polyphosphoesters [227-229], poly(2-aminoethyl ethylene 
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phosphate) [230], poly(ethylene glycol)-peptide copolymers [231] and ketalized 
polyethylenimine [232]. 
 
 
2.6.3. siRNA bioconjugation 
 
Bioconjugation of siRNA with lipids, polymers or other molecules will help to enhance 
its  cellular uptake,  systemic stability, and targeted delivery to specific cells. Technically, 
siRNA could be modified at the 5’ or 3’ terminus of sense strand or antisense strand. 
Because of the pivotal role of antisense strand in gene silencing, the modification of 
sense strand is preferred. Both cleavable and non-cleavable bonds can be used for siRNA 
conjugation. Acid-sensitive or reducible disulfide bonds are the most commonly used, 
because of the enhanced release of siRNA from conjugation inside the cell. It could avoid 
potential negative effects of bioconjugation and provide more amount of free siRNA 
available for gene silencing.  
 
The molecules used for conjugation with siRNA determine the properties of siRNA 
conjugate. Attachment of lipids usually increases the hydrophobicity of siRNA, which 
are highly hydrophilic macromolecules. Lipophilic molecules such as cholesterol [233], 
bile acid and long chain fatty acid [234, 235], and vitamin E [236] could be conjugated to 
siRNA. After systemic injection, siRNA-lipid conjugate binds with lipoproteins 
depending on the degree of hydrophobicity. The interaction between siRNA-lipid 
conjugate and lipoproteins, lipoprotein receptors and transmembrane proteins has a great 
influence on the biodistribution and cellular uptake of siRNA after intravenous injection 
[234]. For an example, siRNA bound to low density lipoprotein (LDL) is mainly 
delivered to the liver, while a broader distribution was observed for siRNA binding to 
high density lipoprotein (HDL).  
 
Conjugation of siRNA with cell-penetrating peptides (CPPs) such as TAT [237, 238], 
penetratin [238] and Transportan [239], has also been studied for siRNA delivery. 
siRNA-peptide conjugates show a cellular uptake as efficient as that achieved by cationic 
lipids and resulted in efficient silencing of target genes. However, conjugation of siRNA 
with peptides does not improve the in vivo stability of siRNA [238]. In addition, innate 
immune response could be activated after intratracheal administration of pentratin-siRNA 
conjugate [238], may be due to the immunogenicity of peptide.  
 
To increase the systemic stability of siRNA, poly(ethylene glycol) (PEG) has been 
conjugated to siRNA by several research groups. In this type of conjugation, siRNA can 
be linked with PEG through disulfide bond or ß-thio-propionate linkage. Polyelectrolyte 
complex micelles (PEC micelles) were formed between PEG-siRNA and cationic peptide 
(KALA) [240] or cationic polymers, such as polyethylenimine (PEI) and poly(L-lysine) 
(PLL) during the application of siRNA-PEG conjugate. A core was formed between 
negatively charged siRNA and polycation through condensation, while PEGs are 
surrounding the core to form a hydrophilic shell. This special core-shell structure can 
effectively protect siRNA against enzymatic degradation; prevent self-aggregation 
between PEC micelles, and increase the circulation time after systemic administration. 
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This delivery system can efficiently silence VEGF gene expression in PC-3 cells in vitro 
[240, 241]. After intravenous injection, enhanced distribution of PEC micelles in tumor 
was observed, which resulted in significant reduction in VEGF expression in tumor and 
suppressed tumor growth [242]. siRNA-PEG PEC can be further improved by 
conjugation of lactose moiety at the distal end of PEG (siRNA-PEG-Lac). This will 
confer targeting ability to this carrier. The cellular uptake of siRNA in hepatoma cells 
was enhanced via receptor mediated endocytosis [243, 244]. Delivery of siRNA against 
RecQL1 gene with lac-PECs inhibited muticellular HuH-7 spheroids growth for up to 21 
days, while almost no effect was observed with oligofectAMINE/siRNA lipoplexes. It is 
probably due to the facilitated cellular uptake of Lac-PECs into the spheroids cells [244]. 
 
In addition to the enhanced delivery, siRNA are also conjugated with probes or dyes for 
bioimaging [245]. Multiple component siRNA conjugate was prepared which includs 
iron oxide core coated with crosslinked dextran coat, cy5.5 dye, as well as siRNA. After 
in vitro incubation, this conjugate was efficiently taken up by murine islets. The celluar 
uptake of siRNA was observed by magnetic imaging of iron core and near-infrared 
imaging. This study showed the posibility to integrate gene silencing and imaging 
components into a single conjugate to create a multiple function siRNA conjugtes. 
 
 
2.6.4. Viral vectors  
 
As naturally evolved vehicles, viral vectors utilize the virus infection mechanism for 
efficient gene transfer into host cells. Although safety concerns retarded the clinical use 
of viral vectors, their application in genetic modification of islets has the potential to 
improve the outcome of islet transplantation. This is mainly because of their high 
transduction efficiency compared with non-viral vectors. Here, we will discuss the 
properties of some commonly used viral vectors and their application in islet 
transplantation. 
 
2.6.4.1. Adenovirus 
 
Adenovirus is non-enveloped DNA virus, which could infect both dividing and non-
dividing cells. Recombinant adenovirus derived from adenovirus serotype 5 is commonly 
used for gene delivery. E1 region, which is essential for virus replication, is usually 
deleted to make replication-deficient adenovirus. In addition, adenoviral genome will not 
integrate to the targeting cells; therefore, a transient gene expression is achieved by 
adenoviral vector. The advantages of adenovirus include capacities to carry large DNA 
insert, easy to produce high titer virus, and its ability to infect non-dividing cells with 
high efficiency and high gene expression level.  
 
We and others have used replication deficient adenoviral (Adv) vectors for ex vivo 
transduction of genes to islets to reduce the immune attack, prevent apoptosis, and 
promote the revascularization of transplanted islets [15, 18, 19, 64, 107, 117, 246]. Bain 
et al. first reported the feasibility of using Adv vector for gene silencing in islets and β 
cell lines [247]. Adv vectors expressing siRNA against GLUT2 gene was used in their 
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study to transduce rat islets. Maximum reduction in GLUT2 gene expression was 
achieved 3 days post transduction with > 90% at both mRNA and protein levels. After 
then, Adv vectors have been used to silencing different genes in islets to study the 
function of genes, such as synaptotagmin 9 [248], pyruvate carboxylase [249], tissue 
factor [250], and proislet amyloid polypeptide [251]. The maximum silencing efficiency 
was varied from 35% to 75% and achieved 3-4 days post-transduction. Gene silencing 
efficiency is determined by several factors: (1) the properties (turnover time, abundance) 
of target gene mRNA and protein; (2) the design of siRNA targeting sequence as well as 
expression cassette.  
 
Since caspase 3 played an important role in islet β cell apoptosis induced by different 
factors, the inhibition of caspase activities was a potential approach to improve the graft 
survival [64]. Recently, we determined the level and duration of caspase 3 gene silencing 
after transfection of caspase 3 siRNA into INS-1E cells and demonstrated transient gene 
silencing which did not last beyond 3 days. In an attempt to enhance the level and 
duration of caspase 3 gene silencing, we then constructed Adv vectors expressing shRNA 
against caspase 3 (Adv-caspase-3-shRNA) and determined their gene silencing efficiency 
in human islets. This adenoviral vector showed efficient caspase 3 gene silencing, which 
became more significant on day 5. Further, Adv-caspase 3-shRNA mediated caspase 3 
gene silencing was able to counteract inflammatory cytokine-induced islet cell apoptosis 
in vitro. Taking care of these encouraging in vitro results, we then transduced human 
islets with this advenoviral vector prior to transplantation under the kidney capsules of 
diabetic NOD-SCID mice. There was some improvement in islet survival and function 
after transplantation [107]. 
 
Adv vectors have several particular advantages for gene silencing in human islets. (1) 
Thorough understanding of the structure of Adv DNA may provide much flexibility in 
genetically engineer Adv vectors to make them more proper for shRNA delivery and 
expression. For example, it is convenient to construct shRNA expression vectors with 
different promoters and backbones with commercially available Adv shuttle vectors for 
optimal gene silencing; (2) high expression levels achieved by Adv vectors will help to 
increase gene silencing efficiency and help to get more beneficial effect. (3) Adv vectors 
has the capacity to carry a large insert, which will make it possible to express multiple 
shRNAs; or to co-express an shRNA to silence harmful genes and a cDNA to protect 
islets [117]. The disadvantage of Adv vector is the transient expression profile, which is 
not suitable for long-term gene silencing. Since the majority of islet cell death occurs 
within several days after transplantation, the use of Adv to silence genes involved in this 
process is appropriate. 
 
2.6.4.2. Lentivirus 
 
Lentivirus is a type of retroviral vector, which reverse transcribes into DNA, be actively 
transported into the nucleus, and integrate into the genome of target cells. Therefore, 
stable gene expression or silencing could be achieved by using lentiviral vector [252]. 
Unlike other retrovirus such as moloney murine leukemia virus, which could only 
transduce dividing cells, lentivirus can transduce both dividing and non-dividing cells. 
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Vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped lentiviral vectors is the 
most commonly used vector, which could transduce a broad range of cell types [253]. 
Lymphocytic choriomeningitis virus (LCMV)-pseudotyped is more efficient in 
transducing human islet insulin-secreting ß cells and shows less toxicity compared with 
VSV-G pseudotyped lentivirus [254]. Lentivirus were successfully used for genetic 
modification of islets with various genes, including reporter genes (GFP, Luciferase) 
[255, 256], antioxidative genes [257], antiapoptotic genes (cFLIP) [255], anti-
inflammatory and immunoregulatory genes (CTLA4, TGF-β, interleukin-1 receptor 
antagonist, and IL-4) [258-260]. Unlike Adv vectors which give high level transient gene 
expression, a prolonged gene expression is usually achieved after transduction islets of 
lentiviral vectors. For example, after transduction of islets with lentiviral vectors 
encoding a luciferase gene, bioluminescence is persistent for above 140 days post 
transplantation. However, the bioluminescence of islets transduced with Adv vector 
encoding a luciferase gene decrease from thousand fold at the beginning to ten fold over 
background at 60 days posttransplantation [256]. An optimized ex vivo transduction 
procedure should neither induce significant toxicity nor affect the insulin release function 
of islets [257]. In addition, lentiviral vectors-induced immune system activation was also 
minimal [260]. Under optimized conditions, lentivirus could transduce around 10% to 
30% of islet cells in an intact islet, which are mainly the cells at the periphery [255, 261, 
262]. This is still enough to have significant effect on the viability, probably due to the 
“barrier” effect, that is shield the core of islets by protecting the periphery of islets [255]. 
 
Several other approaches have also been investigated to improve the transduction 
efficiency. Callewaert et al. demonstrated increased transduction efficiency from around 
11.2% to 80.0% by dissociation of islets to single cells prior to transduction and re-
aggregation of islets before transplantation [262]. However, improvement in the 
transfection efficiency did not translate into the improved function of islets. More cells 
are needed to achieve normoglycemia compared with intact islets. Barbu et al. tested the 
possibility to transduce islets by whole pancreas perfusion. This transduction procedure 
could transduce 30% of the cells, while keeping the structural integrity of islets. 
However, the cells within the core of islets still cannot be effectively transduced [263].  
 
Lentiviral vector has also been used for shRNA delivery for gene silencing [264]. 
Because of the long term expression achieved by lentiviral vectors, it has been used to 
stably silence harmful genes to prevent the death of islet β cells. For example, 
transduction of lentiviral vectors carrying shRNA against iNOS gene, significantly 
reduced IL-1β-induced iNOS expression in islet β cells and protect β cells from IL-1β-
induced cell death [113]. Since the silencing effect achieved by lentiviral vector is long 
term, it is suitable for delivery of shRNA against genes that need to be continuously 
silenced. Otherwise, an inducible or switchable expression cassette should be used to 
control the timing of gene silencing and thus avoid potential side effects. 
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2.7. Concluding Remarks 
 
Theoretically, any gene of interest could be silenced or effectively inhibited, which is 
unachievable by conventional small molecule chemicals. In the past few years, RNAi 
technology has moved rapidly from bench to bedside at unprecedented speed. Currently, 
there are more than ten ongoing and completed clinical trials using siRNA as therapeutics 
(http://clinicaltrials.gov). It is interesting to note that one of these trials sponsored by 
Quark Pharmaceuticals was related to kidney transplantation, where a siRNA named 
I5NP was tested for the prophylaxis of delayed graft function in kidney transplantation 
patients. Although recent progresses have already demonstrated its great potential, the 
application of RNAi technology for improving the outcome of islet transplantation is still 
a fledgling area. Further understanding of the biological perspective of the islets 
transplantation is essential, as it may help to discover effective RNAi target genes. A 
combination of multiple gene silencing or simultaneously gene silencing and gene over-
expression is likely to have improved beneficial effects through synergistic effects. 
Meanwhile, the advances in RNAi technology will enable us to design more potent 
siRNA or shRNAs, while minimizing the side effects caused by off-target effects and 
immune simulation. Last but not the least, the development of safe and efficient delivery 
systems is the key for successful gene silencing. 
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CHAPTER 3. INOS GENE SILENCING PREVENTS INFLAMMATORY 
CYTOKINE-INDUCED β CELL APOPTOSIS* 
 
 
3.1. Introduction 
 
Human islet transplantation is a promising therapeutic strategy for treating type I diabetes 
mellitus. Despite recent success, islet transplantation still lags behind primarily because a 
large number of transplanted islets do not function. This results in the need for multiple 
islet infusions for each patient. Most islet grafts are destroyed due to immune and 
inflammatory reaction mediated by proinflammatory cytokines, such as interleukin-1ß 
(IL-1β), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). These 
proinflammatory cytokines induce a series of intracellular inflammatory signal cascades, 
leading to β-cell death, probably due to apoptosis, necrosis, and other processes [52]. The 
stimulation of inducible nitric oxide synthase (iNOS) expression and consequent 
production of radical nitric oxide (NO) as well as of the other radicals, such as 
peroxynitrite (OONO-) and superoxide (O2-) represent a pivotal step in these processes 
[48, 63, 265, 266]. The inhibition of iNOS has shown significant protection of β cells 
from proinflammatory cytokine-induced damage [113, 267, 268]. Therefore, it is 
reasonable to suggest that iNOS might be a potential target for improving the outcome of 
human islet transplantation. 
 
RNA interference (RNAi) is a promising therapeutic strategy which utilizes an 
evolutionary conserved biologic process to induce sequence-specific, post-transcriptional 
gene silencing by small interference RNA (siRNA) [269]. siRNA-mediated gene 
silencing in rodent β-cells and pancreatic islets has been shown to inhibit a target gene 
[270, 271]. In mouse insulinoma cells, Burkhardt et al. [108] demonstrated that siRNA 
targeting Fas, another important mediator of β-cell death, was able to silence Fas gene 
expression and inhibit Fas-mediated β-cell damage in response to inflammatory 
cytokines. Keeping these promising findings in mind, we recently tested the effect of 
chemically synthesized siRNAs against iNOS and NF-κB on gene expression, NO 
production, and apoptosis in insulin producing β-cell line (INS-1E) and  demonstrated 
that silencing of iNOS gene to be more effective than that of NF-κB [116]. There are also 
conflicting reports on the role of NF-κB on pancreatic β-cell death [62, 272, 273]. 
McCabe and O’Brien used lentiviral vector-based shRNA delivery to suppress IL-1-
mediated induction of iNOS expression, resulting in significant protection against the 
cytotoxic effects of IL-1 exposure [113, 114]. However, these authors used rat 
insulinoma (RIN-r) cell lines and not human islets. Moreover, they did not determine the 
functional viability of RIN-r cells by measuring glucose-stimulated insulin release. 
Taking care of the usefulness of iNOS gene silencing in islet transplantation, in this 
study, we compared transfection efficiency and effect of iNOS gene silencing on  
 
 
* Adapted with permission. F. Li, R.I. Mahato, iNOS gene silencing prevents 
inflammatory cytokine-induced ß cell apoptosis, Mol Pharm, 5 (2008) 407-417. 
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apoptosis in INS-1E cells and intact human islet, which is a cluster of 200-1000 cells and 
hard to transfect. 
 
This report implicated the pivotal role of iNOS in cytokine-induced β cell death. We 
demonstrate the possibility of using iNOS gene silencing as a strategy to improve the 
outcome of human islet transplantation. 
 
 
3.2. Materials and Methods 
 
 
3.2.1. Materials 
 
Fetal bovine serum (FBS), sodium pyruvate, and CMRL 1066 medium were purchased 
from Mediatech, Inc (Herndon, VA). Penicillin/streptomycin, phosphate-buffered saline 
(PBS), 0.25% (w/v) trypsin-EDTA and RPMI-1640 medium and OptiMEM-I reduced 
serum medium were purchased from GIBCO-BRL (Gaithersburg, MD). 2-
Mercaptoethanol was obtained from Sigma Aldrich (St. Louis, MO). Recombinant IL-1β, 
TNF-α and IFN- were purchased from R&D Systems (Minneapolis, MN). siRNA 
against rat iNOS (Gene Bank # NM_012611, Table 3.1) and human iNOS (Gene Bank # 
NM_000625, Table 3.2), control siRNA, fluorescein-labeled siRNA, and Lipofectamine 
2000 were purchased from Invitrogen (Carlsbad, CA). All primers used for real time RT-
PCR were obtained from Integrated DNA Technology (Coralville, IA). TUNEL assay kit 
was from BD Pharmingen (Franklin Lakes, NJ). Caspase 3 cellular activity assay kit was 
purchased from EMD Biosciences, Inc.  (San Diego, CA). RNeasy Mini kit and RNase-
Free DNase Set were purchased from Qiagen (Valencia, CA). Multiscribe reverse 
transcription kit was from Applied Biosystems (Foster City, CA). SYBR Green-I dye 
universal PCR master mix and other reagents for real time RT PCR were from Roche 
(Indianapolis, IN). Griess assay kit was from Promega (Madison, WI). BCA protein assay 
kit was from Pierce Chemical Company (Rockford, IL). 
 
 
3.2.2. Cell culture and transfection 
 
Rat insulin producing β-cells (INS-1E cells), a kind gift from Professor Claes B. 
Wolheim (University Medical Center, Geneva, Switzerland), were cultured at 37ºC in a 
humidified atmosphere containing 5% CO2 in complete medium composed of RPMI 
1640 supplemented with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 50 M 
2-mercaptoethanol, 100 U/mL penicillin, and 100 g/mL streptomycin. 
 
INS-1E cells were seeded 24 h before transfection in a 24-well plate (5 x 105 cells/well) 
for all the experiments except for TUNEL assay, for which we used 12-well plates (106 
cells/well). siRNAs were transfected into INS-1E cells after complex formation with 
Lipofectamine 2000 according to the manufacturer’s instructions. Briefly, siRNA 
molecules and Lipofectamine 2000 were mixed together in OPTMEM I reduced serum 
medium at a ratio of 30 nmol/1 mg (siRNA/ Lipofectamine 2000), and complex 
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Table 3.1 Small interfering RNA (siRNA) sequences of rat iNOS (NM_012611).  
 
Start site siRNA sequence Coding region* 
224 
S†: 5’-CUACCAAGGUGACCUGAAAGA[dT][dT]-3’ 
AS‡: 5’-UCUUUCAGGUCACCUUGGUAG[dT][dT]-3’ 224-244 
675 
S: 5’-GAAGCCGUAACAAAGGAAAUA[dT][dT]-3’ 
AS: 5’-UAUUUCCUUUGUUACGGCUUC[dT][dT]-3’ 675-695 
898 
S: 5’-CCUCGGAUAUCUCUUGCAA[dT][dT] -3’ 
AS: 5’-UUGCAAGAGAUAUCCGAGG[dT][dT] -3’ 898-916 
2225 
S:5’-GUUCGAUGUUCGAAGCAAACA[dT][dT] -3’ 
AS: 5’-UGUUUGCUUCGAACAUCGAAC[dT][dT] -3’ 2225-2245 
 
*ORF region; † S, sense; ‡ AS, antisense. 
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Table 3.2 Small interfering RNA (siRNA) sequences of human iNOS (NM_000625). 
 
Start site siRNA sequence Coding region* 
511 
S†: 5’-CGGCAUGUGAGGAUCAAAA[dT][dT] -3’ 
AS‡: 5’-UUUUGAUCCUCACAUGCCG[dT][dG] -3’ 511-529 
539 
S: 5’-GCGGGAUGACUUUCCAAGA [dT][dT] -3’ 
AS: 5’-UCUUGGAAAGUCAUCCCGC[dT][dG] -3’ 539-557 
691 
S:5’-GCUAUCGAAUUUGUCAACC[dT][dT] -3’ 
AS: 5’-GGUUGACAAAUUCGAUAG [dT][dT] -3’ 691-709 
 
*ORF region; † S, sense; ‡ AS, antisense. 
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formation was allowed to proceed for 30 min at room temperature before adding into 
INS-1E cells. At 12 h post transfection, medium containing lipid/siRNA complexes were 
replaced with fresh medium.  
 
To determine the transfection efficiency and effect of iNOS gene silencing on protection 
of human islets from proinflammatory cytokines, we re-designed three siRNA sequences 
targeting different regions of human iNOS mRNA (Table 3.2), and used for transfection 
into human islets. These islets were received from one of the several Islet Cell Resource 
(ICR) Centers through ICR Services for Basic Science Applications. On arrival at our 
facility, islets were cultured at 37 ºC in CMRL 1066 medium supplemented with 10% 
FBS. Human islets were seeded at 24-well plate (2000 IE/well) 2 hours before 
transfection and were transfected with siRNA after complex formation with 
Lipofectamine 2000 as described above. 
 
 
3.2.3. Fluorescence microscopy and flow cytometry 
 
To determine the transfection efficiency, INS-1E cells and human islets were transfected 
with fluorescein-labeled siRNA after complex formation with Lipofectamine 2000. At 12 
h post transfection, cells were visualized under fluorescence microscopy. To determine 
the percentage of transfected cells, INS-1E cells were washed with 1 x PBS, trypsinized, 
and suspended in 1 x PBS. Since human islets are a cluster of cells, they were treated 
with trypsin-EDTA for 10 min at 37 °C followed by vigorous pipeting to create a single-
cell suspension. Then the cell suspension were directly introduced to a FACSCaliburTM 
Flow Cytometer (Becton Dickinson, NJ) equipped with a 488 nm argon ion laser. The 
FL-1 emission channel was used to monitor the fluorescein and results from 10,000 
fluorescent events were obtained for analysis. Cells without transfection were served as 
negative controls.  
 
 
3.2.4. Real time RT-PCR 
 
Expression of rat iNOS gene in INS-1E cells and that of human iNOS in human islets 
was determined at mRNA level by real time RT-PCR. Following treatment, total RNA 
was extracted with RNeasy Mini KIT and treated with DNase by on-column digestion 
(RNase-Free DNase Set). RNA concentration was determined by spectrophotometer 
(NanoDrop). One hundred and seventy nanograms total RNA was converted into cDNA 
using multiscribe reverse transcriptase reagents and random hexamers at a 10 µl reaction 
system. Two microliters of cDNA were used as a template and analyzed by SYBR 
Green-I dye universal PCR master mix on LightCycler 480 Instrument. The primers used 
for real-time PCR were as follows: rat iNOS [116] Forward: 5’-
ACCAGAGGACCCAGAGACAAGC-3’;  Reverse: 5’-
TCCAGGCCATCTTGGTGGCAAA-3’ (amplicon size 208 bp); rat 18S rRNA 
[274]:Forward: 5’-CGG CTA CCA CAT CCA AGG AA-3’ ; Reverse :  5’-GCT GGA 
ATT ACC GCG GCT-3’(amplicon size 186 bp); human iNOS [275]: Forward  5’-
ACGTGCGTTACTCCACCAACA-3’; Reverse  5’-CATAGCGGATGAGCTGAGCA-
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3’(amplicon size 102 bp); human ribosomal protein S19 (human S19); Forward  5’ 
GCTTGCTCCCTACCGATGAGA-3; Reverse 5’-ACCCCGGAGGTACAGGTG-
3’(amplicon size 73 bp). To assess the specificity of the amplified PCR product, the 
Melting Curve Analysis was performed on the LightCycler 480 Instrument. The results 
iNOS mRNA level were compared by calculating the CP value and normalized by the 
reference genes (rat 18S or human S19). Four independent experiments were performed 
and the results were expressed as a percentage of control. 
 
 
3.2.5. Griess assay 
 
Nitric oxide (NO) is rapidly oxidized in culture medium into nitrite, which accumulate in 
the sample and can be easily correlated with NO production. Therefore, nitrite 
concentration was determined using the Griess assay (Promega, Madison, MI). Fifty 
microliters of cell culture supernatant was added to a 96 well-plate and mixed with 50 µL 
of 1% sulfanilamide in 5% phosphoric acid solution and incubated for 5 min at room 
temperature in dark. Then, 50 µL of 0.1% N-1-napthylethylenediamine dihydrochloride 
(NED) aqueous solution was added to each well. The plate was incubated for additional 
10 min, and absorbance was measured at 560 nm using a microplate reader. To determine 
the nitrite concentration in each sample, a standard curve was prepared using nitrite 
standard solution and culture medium as matrix. 
 
 
3.2.6. Effect of iNOS gene silencing on apoptotic cell death 
 
3.2.6.1. Microscopy 
 
To determine whether iNOS gene silencing inhibits apoptosis of  cells due to 
inflammatory cytokines, INS-1E cells (106 cells/well in a 12 well plate) were transfected 
with siRNA against iNOS as well as with control siRNA. The cells were incubated with a 
cocktail of TNF- (50 pg/mL), IL-1 (5 ng/mL) and IFN- (50 ng/mL) for 48h, then 
visualized under microscopy.   
 
3.2.6.2. Caspase 3 activity assay 
 
The cellular caspase 3 activity of INS-1E cells or human islets was measured with 
Caspase 3 Cellular Activity Assay Kit. INS-1E cells were seeded at a density of 5 x 105 
cells/well in 24-well plate; human islets were seeded at a density of 2000 IE/well in 24-
well plate. After treatment, cells were collected and lysed with lysis buffer. Ten 
microliters of the cell lysate solution was added in 40 µL assay buffer and mixed with 50 
µL caspase 3 substrate (Ac-DEVD-pNA) at a  half volume 96-well plate. The mixture 
was kept at 37°C and absorbance at 405 nm was read continuously using a 
spectrophotometer every 5 min for one hour. The absorbance versus time for each sample 
was plotted and the activity was calculated from the slope of the linear curve. To 
normalize the activity, total protein concentration of each sample was also measured with 
BCA protein assay kit. 
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3.2.6.3. TUNEL assay 
 
To gain insights on the mechanism of  cell death, a terminal 
deoxynucleotidyltransferase dUTP nick end labeling (TUNEL) assay with the APO-
DIRECTTM kit was used to detect apoptotic cells. Following transfection and incubation 
with a cytokine cocktail, INS-1E cells and human islets were made to single cell 
suspension as described above. The cells were fixed in 1% paraformaldehyde in PBS (pH 
7.4) and then treated with ice-cold 70% ethanol, stained with FITC-dUTP, and then with 
propidium iodide. The intensity of fluorescence was measured by a flow cytometer and 
analyzed using CELLQUEST software (BD Bioscience). Non-transfected cells without 
cytokine treatment were served as a negative control. Three sets of independent 
transduction experiments were carried out for each assay. 
 
 
3.2.7. Assessment of human islet function post-transfection 
 
The ability of human islets to respond to glucose stimuli was used to determine the effect 
of transfection of Lipofectamine 2000/siRNA complexes on human islet function. 
Following transfection, islets were incubated with a cocktail of inflammatory cytokines 
including TNF- (50 pg/mL), IL-1 (5 ng/mL) and IFN- (50 ng/mL) for 48 h. Then, 
islets were challenged with two different concentration of glucose (60 mg/dL and 300 
mg/dL) for 1 h at 37 C. Supernatants were then collected for measuring insulin secretion 
by human insulin ELISA Kit (Alpco Diagnostics, Windham, NH). Results were 
normalized by measuring the total protein using a BCA assay kit. Stimulation index was 
calculated by measuring insulin release by islets 1h after incubation with media 
containing basal (60 mg/dL) and stimulated (360 mg/dL) levels of glucose.  
 
 
3.2.8. Statistical analysis  
 
The difference between groups was determined by unpaired t-test and a P < 0.05 was 
considered statistically significant. Results are expressed as the means ± standard 
deviation (SD). 
 
 
3.3. Results 
 
 
3.3.1. Transfection efficiency of lipid/siRNA complexes in rat β cells 
 
We used fluorescein labeled siRNA at a concentration of 50,100, and 150 nM to 
quantitatively asses the incorporation of siRNA into rat β cells. After 12 h of incubation 
with Lipofectamine 2000/fluorescein-labelled siRNA complexes, cells were observed 
under fluorescence microscopy. Figure 3.1A demonstrates that these cells were 
effectively transfected with fluorescein-labeled siRNA. The photographs show green 
cells with distinct spots speckled their surface and in the nucleus, suggesting enhanced 
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Figure 3.1 Transfection efficiency of siRNA into rat insulin producing β cells. 
 
INS-1E cells were transfected with fluorescein-labeled siRNA, after complex formation 
with Lipofectamine 2000 at siRNA concentration of 50,100,150 nM. At 12 h after 
transfection, cells were visualized under fluorescence microcopy and analyzed with flow 
cytometry. (A) Fluorescent images showing fluorescein-labeled siRNA incorporation into 
INS-1E cells. Left panels show cells under visible light, and right panel under visible 
light. Upper panel is low magnification (100 X) and lower panel is high magnification 
(400 X). (B) Percentage of green fluorescence positive cells. Results are the mean ± SD, 
n = 3. The p value of < 0.05 was considered statistically significant. 
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cellular uptake and nuclear translocation. To quantitatively determine the transfection 
efficiency, cells were analyzed by flow cytometry. As shown in Figure 3.1B, the 
transfection efficiency increased from 75.9% to 95.9% with increase in siRNA 
concentration from 50 nM to 150 nM. The average fluorescence intensity also increased 
accordingly from 2.48 x 104 to 6.72 x 104 (Data not shown). 
 
 
3.3.2. Effect of siRNA sequence on iNOS gene silencing and NO production on rat β 
cells 
 
Figure 3.2A demonstrates the effect of siRNA sequences on iNOS gene silencing. All 
four siRNA sequences were able to silence iNOS expression and siRNA-iNOS-898 
showed silencing around 50% of iNOS expression. Figure 3.2B shows the effect of 
siRNA sequence on the NO production by rat β cells. Compared with control siRNA, all 
four siRNAs targeting different regions of rat iNOS mRNA showed inhibition of NO 
production by rat β cells. Among them siRNA-iNOS-898 was the most potent one, which 
reduced the NO production by 60%. Therefore, siRNA 898 was used for further studies 
on rat β cells. We also noticed that there was almost no change in the NO production in 
the control siRNA treated group (Figure 3.2B), which indicates the inhibition of NO 
production was due to the specific silencing of iNOS mRNA, and not due to the non-
specific effects.  
 
 
3.3.3. Effect of iNOS gene silencing on rat β-cell death 
 
To determine whether iNOS gene silencing inhibit apoptosis of rat β-cells induced by 
inflammatory cytokines, INS-1E cells (106/well in a 12 well plate) were transfected with 
siRNA against rat iNOS as well as the control siRNA. Then the cells were incubated with 
cytokine cocktail (IL-1β 50 pg/mL, TNF-α 5 ng/mL, and IFN-γ 50ng/mL) for 48 h. As 
visualized under microscopy, almost all the cells transfected with the control siRNA were 
aggregated and round up, indicating cell death, probably due to apoptosis (Figure 3.3A). 
In contrast, only a small part of the cell treated with siRNA-iNOS were aggregated, 
indicating only a small fraction of the cells were undergoing apoptosis. 
 
One of the later steps in apoptosis is DNA fragmentation, which results from the 
activation of endonucleases during the apoptotic process. Therefore, the analysis of DNA 
fragmentation with TUNEL assay is a useful approach to get information regarding cell 
apoptosis. As shown in Figure 3.3B, cells with no cytokine treatment showed 0.8% 
apoptotic cells, cells transfected with control siRNA treated with cytokines showed 
42.3% apoptotic cells. The cells transfected with siRNA against iNOS and treated with 
cytokines showed 12.3% apoptotic cells; clearly demonstrating that iNOS gene silencing 
can help protect  cell from proinflammatory cytokines. 
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Figure 3.2 Effect of siRNA sequences on iNOS gene expression and NO 
production in rat β cells. 
 
Effect of siRNA sequences on iNOS gene expression, (A) and NO production (B) in rat β 
cells. Following transfection of INS-1E cells with 150 nM siRNA-iNOS complexed with 
5 μg/mL Lipofectamine 2000, cells were treated for additional 12 h with the cytokine 
cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL). Cells not treated 
with the cytokines were used as negative control. iNOS expression is expressed as the 
amount of iNOS mRNA measured by real time RT-PCR. Nitrite concentration is 
expressed as percentage of positive control. Results are the mean ± SD (n = 3) and were 
normalized with live cells. The p value of < 0.05 was considered statistically significant. 
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Figure 3.3 Effect of iNOS gene silencing on rat β cell death. 
 
Following transfection of INS-1E cells with siRNA-iNOS-898 as well as the control 
siRNA, the cells were incubated with a cytokine cocktail of IL-β (50 pg/mL),TNF-α (5 
ng/mL), and IFN-γ (50 ng/mL) for 48 h, then visualized under microscopy (A) and 
analyzed by TUNEL assay (B). A), left panel, most cells treated with the control siRNA 
were aggregated and round up, indicating cell death; right panel, only a part of the cell 
treated with siRNA-iNOS were aggregated and indicating only a small fraction of the 
cells were undergoing apoptosis. B), TUNEL assay of INS-1E cells treated with siRNA-
iNOS-898 as well as control siRNA. Negative control, cells with no cytokine treatment; 
siRNA-iNOS, cells treated with siRNA-iNOS-898 and cytokine; control siRNA, cells 
treated with control siRNA and cytokine. The values show the percentage of positive 
cells. 
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3.3.4. Transfection efficiency of lipid/siRNA complexes into human islets 
 
After confirming the beneficial effect of iNOS gene silencing on rat β-cells from 
proinflammatory cytokines, we used fluorescein-labeled siRNA at doses of 100 and 400 
nM to determine the transfection efficiency in human islets under fluorescence 
microscopy. Figure 3.4A demonstrates that human islets were transfected with 
fluorescein-labeled siRNA. While the untreated control human islets showed only weak 
background fluorescence, human islets transfected with fluorescein-labeled siRNA 
showed distinct spots speckled throughout their surface with some concentrations noted 
at the edges and over their interior surface. These images clearly demonstrated that 
siRNA was introduced into human islets in culture, but we could not determine whether 
siRNA has penetrated into the interiors of human islets. Thus, transfected human islets 
were analyzed by flow cytometry upon dispersion into single cells after treating with 
trypsin-EDTA for 10 min at 37 C followed vigorous pipeting. Both the fluorescent 
images for siRNA dose titration and the more quantitative FACS date help document 
how much siRNA was incorporated into islet cells. Almost 21.5% and 28.3% islet cells 
incorporated fluorescein-labeled siRNA when transfected with siRNA at a concentration 
of 100 nM and 400 nM, respectively (Figure 3.4B). 
 
 
3.3.5. Effect of siRNA sequences on iNOS gene silencing in human islets 
 
Following screening of the siRNA sequences using INS-1E cells and demonstrating the 
beneficial effect of iNOS gene silencing on the protection of -cells from inflammatory 
cytokines, we determined the effect of iNOS gene silencing in human islets. Since there 
is not 100% homogeneity in rat iNOS mRNA (Gene Bank Accession# NM_012611) and 
human iNOS mRNA (Gene Bank Accession# NM_000625), we re-designed three siRNA 
sequences targeting different regions of human iNOS and used for transfection into 
human islets. Quantitative real-time RT-PCR was used to measure the human iNOS gene 
expression level using SYBR green chemistry with human iNOS specific primer and 
human S19 as a reference gene. Figure 3.5A shows that all three siRNAs tested were able 
to reduce iNOS gene expression levels in human islets. Among all the siRNAs tested, 
siRNA-iNOS-691 was the most potent one, which reduced iNOS expression level by 
50%. Therefore, siRNA-iNOS-691 was used for further evaluation. Compared to the 
control siRNA group, there was significant decrease in NO production when human islets 
were transfected with lipid/siRNA-iNOS-691 complexes (Figure 3.5B). This result 
indicates that the inhibition of NO production was due to the specific silencing of iNOS 
mRNA and not due to the off-target effects. 
 
 
3.3.6. Effect of iNOS gene silencing on human islet cell death 
 
We have shown that siRNA against iNOS mRNA could reduce the apoptosis of rat β-
cells. In addition, siRNA can be delivered into human islets and reduce iNOS mRNA 
level. Therefore, we continued to test whether iNOS gene silencing can also prevent the 
cytokine-induced apoptosis of human islets. TUNEL assay was used to detect DNA  
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Figure 3.4 Transfection efficiency of siRNA into intact human islets. 
 
Fluorescein-labeled siRNA were transfected into human islets and visualized under 
fluorescence microscope at 12 h post transfection. (A) Fluorescent images showing 
fluorescein-labeled siRNA incorporation into intact human islets, Left panels show 
human islets under visible light, and right panel under fluorescence. (B) flow cytometry 
analysis showing percentage of green fluorescence positive cells.  
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Figure 3.5 Effect of siRNA sequence on iNOS expression on human islets. 
 
Human islets (2000 IE) were transfected for 12 h with 400 nM iNOS-siRNA complexed 
with 13.3 μg/mL Lipofectamine 2000. Then human islets were treated for additional 12 h 
with a cytokine cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL). 
The iNOS mRNA were measured by real time RT-PCR and expressed as the percentage 
of control. B) Nitrite concentration of the culture supernatants was determined by Griess 
assay. Human islets treated with control siRNA were used as control. Results are 
represented as the mean ± SD , n = 3. Significance established at P < 0.05 (), P < 0.01 
(), and P < 0.001 (). 
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fragmentation. As shown in Figure 3.6A, siRNA against human iNOS reduced the 
percentage of apoptotic cells to 28.5% compared to the control siRNA group (36.2%). 
Although the prevention of apoptosis in human islets was not as high as shown in rat β 
cells (Figure 3.3B and Figure 3.6A), this is not a surprise to get different results from 
INS-1E cell and human islets, which is a cluster of 200-1000 cells. Increased caspase 3 
activity is often used as a marker for apoptotic signaling cascade [276]. Therefore, we 
tested the effects of iNOS gene silencing on caspase 3 activities of human islets (Figure 
3.6B). Compared with the control siRNA treated group, siRNA-iNOS reduced human 
islets caspase 3 activity by around 25%.  
 
 
3.3.7. Human islet function after iNOS gene silencing 
 
The effect of transfection process on in vitro islet function was determined by static 
incubation of islets with different concentration of glucose. There was increase in insulin 
secretion as a function of glucose concentration for islets transfected with lipid/siRNA-
iNOS complexes, with stimulation index of 1.40. In contrast, there was little increase in 
insulin secretion with increase in glucose concentration for islets transfected with 
lipid/siRNA-control (Figure 3.7). The results suggest that iNOS gene silencing partly 
protected human islet from inflammatory cytokine mediated destruction.  
 
 
3.4. Discussion 
 
Human islet transplantation has great potential for treating insulin dependent diabetes, 
allowing stable glucose homeostasis without exogenous insulin regimens and thus 
avoiding several diabetic glucose complications. Despite some recent improvements in 
transplantation technology, a large number of transplanted islets do not function properly, 
which results in the need for multiple islet infusions for each patient. Moreover, the 
success of islet transplantation is currently dependent on chronic treatment of the patient 
with strong immunosuppressant drugs, which are often associated with serious side 
effects. Due to the limited supply of cadaver donor, it is essential to improve the survival 
of transplanted islets. Therefore, we and others have been working on genetic 
modification of islets to improve the outcome of islet transplantation [12, 17, 64, 246, 
247, 277].The over-expression of therapeutics genes has been demonstrated to improve 
the survival and function of islets post-transplantation [246, 278]. Our previous work 
showed improved islet transplantation by genetic modification of human islets  with 
human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor 
antagonist (hIL-1Ra) [246]. The expression of hVEGF and hIL-1Ra synergistically 
suppress islet dysfunction and NO production in human islets. After transplantation of 
these transfected human islets into diabetic mice, reduced blood glucose levels and 
increased blood insulin and c-peptide level was observed [246].  
 
In contrast to the over-expression of therapeutic genes, ex vivo silencing of harmful 
genes, offers an alternative approach to induce human islets to modify their internal 
signal transduction pathways to prevent the damage inflicted upon them by  
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Figure 3.6 Effect of iNOS gene silencing on human islets cell death. 
 
Following transfection with 400nM siRNA-iNOS-691 as well as the control siRNA, 
human islets (2000 IE) were incubated with the cytokine cocktail of IL-1β (50 pg/mL), 
TNF-α (5 ng/mL), and IFN-γ (50 ng/mL) for 48 h. (A) The TUNEL assay was used to 
analyze cell apoptosis. (B) Human islets were collected and lysed with 50 μL lysis buffer. 
Ten microliters of cell lysate from each group sample were used for caspase 3 activity 
assay using Ac-DEVD-pNA substrate. Results are expressed as the percentage of control 
and represented as the mean ± SD, n = 3. Significance established at P < 0.05 () and P < 
0.01 (). 
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Figure 3.7 Human islet function after iNOS gene silencing. 
 
At 12 h post- transfection  with Lipofectamine 2000/ siRNA-iNOS or Lipofectamine 
2000/siRNA-control complexes, islets were incubated with inflammatory cytokines 
cocktail of IL-1β (50 pg/mL), TNF-α (5 ng/mL), and IFN-γ (50 ng/mL) for 48 h. Then, 
islets were challenged with two different concentration of glucose(60 and 360 mg/dL). 
Insulin stimulation index (SI) was determined. Results are the average of three replicates. 
(A) insulin secretion as a function of glucose concentration, (B) stimulation index. P < 
0.05 was considered statistically significant. 
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proinflammatory responses. Therefore, we recently determined the effect of chemically 
synthesized siRNAs against iNOS and NF-κB on iNOS gene expression, NO production 
and apoptosis in insulin producing β-cell line, INS-1E, and demonstrated that silencing of 
iNOS is more effective than that of NF-κB [116]. Since human islets are clusters of 100-
2000 cells, it is difficult to achieve high transfection efficiency. Therefore, in present 
study, we compared the transfection efficiency of lipid/siRNA complexed in rat β cells 
and intact human islets. We first determined the transfection efficiency on INS-1E cells, 
which showed 95.9% cells were incorporated with fluorescein-labeled siRNA (Figure 
3.1B). This result is consistent with a previously report by Hagerkvist et al [271], who 
demonstrated a transfection efficiency of 96.2% in another murine β cells line, ß-TC-6 
cells.  
 
For human islets, as shown in Figure 3.4B, the transfection efficiency was 21.5% and 
28.3% at siRNA concentrations of 100 nM and 400 nM in human islets, which are lower 
than that reported by Bradly et al,[270] (46.3% at siRNA concentration of 400 nM), but 
higher than that reported by Hagerkvist et al [271], (10.9% at siRNA concentration of 
100 nM). This discrepancy may be due to the fact that these authors used mouse islets, 
while we used human islets. In addition, the difference in transfection protocol may also 
contribute to the varied transfection efficiency achieved. Nevertheless, this is an 
interesting finding suggesting that siRNA may penetrate beyond the periphery into a 
larger percentage of an intact islet cell mass than previously thought. Unlike intact islets, 
transfection efficiency was > 90% in dispersed islets, which is close to that observed in 
cultured -cells. However, we prefer to use intact islets, which are a cluster of 200-1000 
cells and represent the real situation [271]. Nevertheless, these results shed light on the 
reasons that cause the different transfection efficiency between intact human islets and β-
cell lines.   
 
It is widely believed that the treatment of proinflammatory cytokine results in β-cell 
death possibly due to apoptosis and necrosis [52, 279]. This cytotoxic effect of cytokines 
may be mediated by inducing iNOS and subsequently producing radical NO as well as of 
other free radicals, such as peroxynitrite (OONO-) and superoxide (O2-)[59, 280, 281]. 
As reported previously [59], nearly 50% of the gene related to cytokine-induced β cell 
death are NO-dependent, which shows the essential role of iNOS pathway in cytokine-
mediated cell toxicity. Necrosis and apoptosis are found shortly after rat islet 
transplantation. Non-specific inflammation at the graft site may contribute to the initial 
islet damage which results in massive loss of transplanted tissues, and primary non-graft 
function [282]. iNOS gene expression on islets increased significantly after 
transplantation. The maximal iNOS gene expression was observed day 1 after 
transplantation and then declined progressively [48]. Increased iNOS gene expression led 
to an early inflammatory process in islet transplantation, suggesting iNOS is an important 
mediator of graft inflammation and islet damage in early islet transplantation [48]. 
Therefore, we hypothesized that the silencing of iNOS gene might reduce iNOS mediated 
inflammatory response, and prevent islet cell death. 
 
To determine iNOS gene silencing in human islets, we redesigned three siRNA 
sequences targeting different regions of human iNOS and used for transfection in human 
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islets. As shown in Figure 3.5A, there was around 50% iNOS gene expression has been 
silenced by siRNA complexed with Lipofectamine 2000, which is similar to that reported 
by Bradley et al., [270] who demonstrated 55% reduction of Ins-2 gene expression by 
isolated rodent islets. This finding is attractive which demonstrates the possibility to 
specifically reduce the target mRNA in human islets with siRNA. Various extent of iNOS 
gene silencing was achieved in present study with different siRNA duplexes targeting 
different regions of iNOS mRNA, with the highest gene silencing for the siRNA-iNOS-
691 group compared to the control siRNA group (Figure 3.5A). There was also 
significant decrease in NO production when islets were transfected with lipid/siRNA-
iNOS-691 complexes (Figure 3.5B). As reported previously, the gene silencing effect of 
siRNA varied considerably  depends on target sequences [283], and the secondary 
structure of target region that is essential for siRNA binding [284]. Therefore, a more 
potent siRNA could be found by designing and screening more siRNA sequences target 
different regions of mRNA. 
 
Caspases play a key role in apoptosis. In mammals, there are 14 caspases, among them 
caspase3 is the major effector caspase involved in apoptosis. It is activated by upstream 
proteases including caspase 6, caspase 8, and cytotoxic T cell-derived granzyme B [65]. 
The critical role of caspase 3 in cytokine-induced β cell apoptosis has been reported [285-
287]. Both caspase 3 inhibitor (Z-DEVD-FMK) [288] and X-linked inhibitor of apoptosis 
protein (XIAP) [64] have been shown to prevent apoptosis of transplanted human islets. 
We observed that siRNA targeting iNOS decreased proinflammatory cytokine-induced 
caspase 3 activity in human islets (Figure 3.6B). The reduced caspase 3 activity probably 
contributes to the prevention of human islets from apoptosis. 
 
One of the later steps in apoptosis is DNA fragmentation, which results from the 
activation of endonucleases during the apoptotic process. The free 3′-OH strand breaks 
resulting from DNA degradation can be measured by a TUNEL assay using the APO-
DIRECTTM, which is a single-step staining method for labeling DNA breaks to detect 
apoptotic cells by flow cytometry analysis. Consistent with the results of caspase 3 
activity, TUNEL assay demonstrated the prevention of β cell apoptosis on human islet as 
well as INS-1E cells. As shown in Figure 3.3B, siRNA-iNOS treatment significantly 
reduced cytokine-induced INS-1E cell apoptosis to 12.3%, compared to the control 
siRNA treated cells with 42.3% apoptotic cells. In human islets the protective effect is 
less than that observed in INS-1E cells. The treatment of siRNA-iNOS decreased the 
percentage of cell apoptosis from 36.2% to 28.5% (Figure 3.6B). The difference in the 
protective effects can be explained by much lower transfection efficiency achieved in 
intact human islets compared to that achieved in INS-1E cells (21-28% VS 95%; Figure 
3.1B and 3.4B). Besides, due to the heterogeneous feature of human islets, we cannot 
exclude the existence of other mechanisms involved in the apoptosis of human islets [52]. 
 
To determine the effect of transfection process on the in vitro islet function, islets were 
transfected with lipid/siRNA-iNOS and lipid/siRNA-control complexes and then 
incubated with a cocktail of inflammatory cytokines. The islet function was determined 
by static incubation of islets with different concentration of glucose. There was increase 
in insulin release as a function of glucose concentration for the islets transfected with 
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lipid/siRNA-iNOS complexes. In contrast, there was little increase in insulin secretion 
with increase in glucose concentration for the islets transfected with lipid/siRNA-control 
(Figure 3.7). The results suggest that iNOS gene silencing partly protected human islets 
from proinflammatory cytokine-mediated destruction. The stimulation index is somewhat 
lower than what we usually achieve, possibly due to the poor quality of human islets.  
 
Our results demonstrate that silencing of iNOS gene expression results in reduction of 
NO production and reduced cell death in rodent β cell line as well as in human islets. Due 
to the pivotal role of iNOS in cytokine signal cascade, it is not unexpected that we could 
prevent proinflammatory cytokine-induced β cell death by silencing iNOS gene 
expression. iNOS gene silencing also partly protected human islets from inflammatory 
cytokine mediated destruction of glucose stimulated insulin secretion. The present study 
is the first to demonstrate the prevention of proinflammatory cytokine-induced cell death 
in human islets with siRNA target iNOS gene. 
 
  
 56 
 
CHAPTER 4. BIPARTITE VECTORS FOR CO-EXPRESSION OF A GROWTH 
FACTOR CDNA AND SHRNA AGAINST AN APOPTOTIC GENE* 
 
 
4.1. Introduction 
 
RNA interference (RNAi) is an evolutionarily conserved biologic process that regulates 
gene expression by small interfering double stranded RNA (siRNA) mediated sequence-
specific, post-transcriptional gene silencing [21, 22, 269]. Several steps are involved in 
RNAi: 1) long double-stranded RNA (dsRNA) is processed by DICER into 19-23 base 
pair siRNA duplex; 2) siRNA duplex is incorporated into a complex named RNA-
induced silencing complex (RISC); 3) RISC is activated by eliminating passenger strand 
of siRNA duplex, and results in mRNA degradation or translational repression [120].  
 
RNAi has been extensively used as a tool for gene knockout in cell lines and animal 
models [289, 290]. In addition, it is also a promising therapeutic approach for disease 
therapy [26, 291]. Recently, we have tested the effects of siRNAs against inducible nitric 
oxide synthase (iNOS) genes on insulin producing β-cell line (INS-1E) and on human 
islets [25, 115]. iNOS gene silencing with chemically synthesized siRNA decreased NO 
production in INS-1E rat β-cells and human islets, reduced proinflammatory cytokine-
induced β-cell death, and partially protected the human islet function [115]. We also 
observed in another study that adenovirus-based shRNA against caspase 3 gene (Adv-
caspase 3-shRNA) efficiently silenced caspase 3 gene and its gene silencing effect lasted 
beyond five days, which resulted in the protection of islets from cytokine-induced 
apoptosis[107].  
 
As an alternative cure for type I diabetes, human islet transplantation has made a great 
progress, especially after the success of Edmonton protocol [7, 292]. However, a large 
number of the patient returned to insulin dependent within a year after islet 
transplantation [293]. The main reason for the failure of islet transplantation is that less 
than 30% of the transplanted islets are survived in the early days post-transplantation due 
to several reasons, including (1) poor revascularization, which results in insufficient 
supply of oxygen and nutrition; and (2) proinflammatory cytokines-induced islet β-cell 
death including apoptosis and necrosis [12]. In our previous study, we investigated the 
use of bipartite plasmid or Adenoviral vectors which co-express one gene for reducing 
inflammatory response (e.g. hIL-1Ra) and another for facilitating revascularization (e.g. 
HGF, VEGF) [18, 294]. This combinatorial approach showed synergistic effect by 
working on two independent therapeutic targets. Therefore, it is possible to observe 
improved therapeutic efficacy with bipartite vectors that co-express a vascular endothelial 
growth factor (VEGF) cDNA and shRNA targeting an apoptotic gene such as iNOS or 
caspase 3. 
 
 
* Adapted with permission. F. Li, R.I. Mahato, Bipartite vectors for co-expression of a 
growth factor cDNA and short hairpin RNA against an apoptotic gene, J Gene Med, 11 
(2009) 764-771. 
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In order to co-express two genes in a single vector, we can use two separate expression 
cassettes driven by two promoters or using internal ribosome entry site (IRES) sequence 
[295, 296]. The use of IRES is usually not preferred, since the gene after IRES usually 
showed lower expression level [297]. Co-expression of a shRNA and a gene with two 
separate promoters is similar to that of two different genes, but it might be different for 
co-expression of a shRNA and a gene with a single promoter. Unlike gene expression 
plasmid which utilizes a Pol-II promoter, shRNA expression can utilize both Pol-II 
promoters (such as CMV promoter) and Pol-III promoters (such as H1, U6 promoters). 
IRES sequence is not necessary for co-expressing multiple shRNA or combination of a 
shRNA and a cDNA within a single promoter [158, 298, 299]. It is has also been reported 
that co-expression of shRNA and cDNA can be realized by inserting a promoterless 
shRNA within the intron of a gene [197]. 
 
A bipartite vector, which can effectively silence a target gene and expresses a therapeutic 
gene properly, is in great need for treating various diseases including diabetes, cancer and 
viral infection. siRNA targeting sequence and promoters used will greatly influence gene 
silencing efficiency. A shRNA and cDNA could be expressed by two different promoters 
or by a single promoter. It was also reported that the miRNA-based shRNA showed 
improved gene silencing than conventional shRNA [152, 153]. In this study, we have 
systemically investigated these factors to find a most optimal bipartite vector and 
indentify parameters defining a potent shRNA and gene co-expression vector. 
 
 
4.2. Materials and Methods 
 
 
4.2.1. Materials 
 
Fetal bovine serum (FBS) was purchased from Mediatech, Inc (Herndon, VA). 
Penicillin/streptomycin, phosphate-buffered saline (PBS), 0.25% (w/v) trypsin-EDTA 
and DMEM medium were purchased from GIBCO-BRL (Gaithersburg, MD). All 
oliginucleotides used for shRNA cloning were obtained from Integrated DNA 
Technology (Coralville, IA). All the enzymes used in cloning were purchased from New 
England Biolabs (Ipswich, MA). 
 
 
4.2.2. Plasmids 
 
Negative control shRNA plasmid and Human iNOS cDNA plasmid (p-iNOS) were 
purchased from OriGene (Rockville, MD). Plasmids encoding shRNA targeting five 
different regions of iNOS gene were purchased from Open Bioystems (Huntsville, AL). 
To generate p-H1-shiNOS-CMV-GFP, p-U6-shiNOS, and p-CMV-shiNOS, two shRNA 
oligos ( synthesized by IDT DNA) were annealed and cloned into pRNAT-H1.1/shuttle 
(BamHI, HindIII), pSIREN-Shuttle (BamHI, EcoRI) and p-shuttle2 (XbaI+AflII), 
respectively. p-H1-shiNOS-CMV-VEGF was generated by replacing GFP gene with 
VEGF PCR fragment from p-CMV-VEGF165. Briefly, p-H1-shiNOS-CMV-GFP was 
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digested with PflmI, followed by treating with Klenow enzyme. After purification, it was 
digested with NheI and then purified.  VEGF gene was amplified with PCR using 
following primer: Forward (Nhe I) –
GCCTAGCTAGCTAGATGAACTTTCTGCTGTCTTG; Reverse (DraI) 
CGCTATTTAAATCACCGCCTCGGCTTGTCACATC.  To make p-U6-shiNOS-CMV-
VEGF, pSIREN-shuttle was digested with I-ceu and Bam HI, and the fragment with U6 
promoter was sub-cloned into I-Ceu and Bam HI site in p-H1-shiNOS-CMV-VEGF.P-
U6-mir375-shiNOS was generated by cloning annealed mir375 oligos into pSIREN-
shuttle (BamHI,EcoRI). To make p-U6-mir30-shiNOS, mir30-shiNOS sequence was 
synthesized and sub-cloned into pSIREN-Shuttle (BamHI, EcoRI). mir30-shiNOS 
sequence:GGATCCGTGCTCGCTTCGGCAGCACATATACTAGTCGACTAGGGATA
ACAGGGTAATTGTTTGAATAGGCTTCAGTACTTTACAGAATCGTTGCCTGCAC
ATCTTGGAAACACTTGCTGGGATTACTTCTTCAGGTTAACCCAACAGAAGGG
CGGCCGCAAGGTATATTGCTGTTGACAGTGAGCGCGTGTATTTAACTGCCTTG
TGTAGTGAAGCCACAGATGTACACAAGGCAGTTAAATACACATGCCTACTGC
CTCGTCTAGAAAGGGGCTACTTTAGGAGCAATTATCTTGTTTACTAAAACTGA
ATACCTTGCTATCTCTTTGATACATTTTTTGaattc. To make p-CMV-mir30-
shiNOS, mir30-shiNOS sequence was amplified with PCR using following primer: 
forward (Dra I) GTATTTAAAGGATCCGTGCTCGCTTCGGC; reverse (Afl II) 
CGCCTTAAGAATGTATCAAAGAGATAGCA and PCR product was cloned into p-
shuttle2 (DraI, AflII) after restriction enzyme digestion. p-CMV-VEGF-mir30-shiNOS 
was made by inserting VEGF PCR fragment between CMV promoter and mir30 shiNOS 
sequence in p-CMV-mir30-shiNOS using NheI and DraI sites. shRNA sequences are 
listed in supplementary information. All the plasmids were purified by Promega mini-
prep kit and confirmed by DNA sequencing. 
 
 
4.2.3. Cell culture and transfection 
 
AD-293 cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL 
penicillin, and 100 mg/ml streptomycin. In transfection experiments, cells were seeded in 
a 48-well plate at a density of 20,000 cells per well 24 h before transfection. Then, 0.05 
µg iNOS cDNA plasmid and 0.3 µg shRNA plasmid were co-transfected into cells with 
Fugene HD transfection reagent (Roche applied science, Indianapolis, IN).  
 
 
4.2.4. Real time RT-PCR  
 
Human iNOS and VEGF expression were determined at mRNA level by real time RT-
PCR. Following treatment, total RNA was extracted with RNeasy Mini KIT and treated 
with DNase by on-column digestion (RNase-Free DNase Set). RNA concentration was 
determined by spectrophotometer (NanoDrop). One hundred and seventy nanograms total 
RNA was converted into cDNA using multiscribe reverse transcriptase reagents and 
random hexamers at a 10 µl reaction system. Two microliters of cDNA were used as a 
template and analyzed by SYBR Green-I dye universal PCR master mix on LightCycler 
480 Instrument. The primers used for real-time PCR were as follows: human iNOS: 
 59 
 
Forward  5’-ACGTGCGTTACTCCACCAACA-3’; Reverse  5’-
CATAGCGGATGAGCTGAGCA-3’(amplicon size 102 bp); human ribosomal protein 
S19 (human S19); Forward  5’ GCTTGCTCCCTACCGATGAGA-3; Reverse 5’-
ACCCCGGAGGTACAGGTG-3’(amplicon size 73 bp) [115]. The primer for VEGF 
gene was the same as previously described [18].To assess the specificity of the amplified 
PCR product, the Melting Curve Analysis was performed on the LightCycler 480 
Instrument. The results iNOS mRNA level were compared by calculating the CP value 
and normalized by the reference genes (rat 18S or human S19).  
 
 
4.2.5. Determination of nitric oxide production 
 
Nitric oxide (NO) is rapidly oxidized in culture medium into nitrite, which accumulates 
in the sample and can be easily correlated with NO production. Therefore, nitrite 
concentration was determined using the Griess assay (Promega, Madison, MI). Fifty 
microliters of cell culture supernatant was added to a 96 well-plate and mixed with 50 μL 
of 1% sulfanilamide in 5% phosphoric acid solution and incubated for 5 min at room 
temperature in the dark. Then, 50 μL of 0.1% N-1-naphthylethylenediamine 
dihydrochloride (NED) aqueous solution was added to each well. The plate was 
incubated for an additional 10 min, and absorbance was measured at 560 nm using a 
microplate reader. To determine the nitrite concentration in each sample, a standard curve 
was prepared using nitrite standard solution and culture medium as matrix. 
 
 
4.2.6. Determination of VEGF expression from bipartite plasmids with ELISA 
 
At 36 h after transfection of AD-293 cells with 0.3µg per well plasmids, culture medium 
of AD-293 cells were collected. The VEGF concentration in the culture medium was 
measured by ELISA according to the manufacture’s protocol (R& D systems, 
Minneapolis, MN). 
 
 
4.3. Results 
 
 
4.3.1. Effect of targeting sequence on iNOS gene silencing 
 
Targeting sequence is one of the most important elements for effective gene silencing. 
Therefore, we first screened five plasmids encoding shRNA targeting different regions of 
human iNOS gene. The targeting sequences of different plasmids are listed in Figure 
4.1A. To find the most potent targeting sequence, plasmids expressing shRNA against 
five different iNOS mRNA regions were co-transfected with p-iNOS into AD-293 cells. 
Plasmid with scrambled sequence was used as a control. At 24 hours after transfection, 
NO production from iNOS gene expression was measured as nitrite by Griess Assay. As 
demonstrated in Figure 4.1B, all five shRNA expression plasmids were able to silence 
iNOS expression and among them the 4060 showed 66% reduction of NO production. 
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Figure 4.1 Effect of targeting sequence on iNOS gene silencing. 
 
(A) Sequences of shRNA against different regions of human iNOS gene (NM_000625). 
(B) Plasmids with different shRNA sequences as well as control plasmid were co-
transfected with piNOS into AD293 cells. At 24 h after transfection, NO production was 
measured by Griess Assay. Nitrite concentration is expressed as the percentage of 
control. Results are the mean ± SE (n = 4). ** indicates P < 0.01 compared with control 
plasmid group. 
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Therefore, the targeting sequence 4060 was used in the following experiments for 
shRNA-based or miRNA-based shRNA construction. 
 
 
4.3.2. Effect of promoters on iNOS gene silencing 
 
Promoter is an important regulatory element in gene expression. Among several 
promoters, H1, U6 and CMV promoters are most widely used for shRNA mediated gene 
silencing. Since some discrepancies have been reported for the efficiency of these 
promoters [125, 153], we compared the efficiency of these three promoters for shRNA 
mediated iNOS gene silencing by constructing iNOS shRNA expression plasmids with 
H1, U6 and CMV promoters (Figure 4.2A). After co-transfection with p-iNOS plasmid 
into AD-293 cells, we found that iNOS shRNA expression plasmids could effectively (p 
< 0.01) reduce the NO production by 69, 62, and 60% for H1, U6 and CMV, respectively 
(Figure 4.2B). This suggests that there is no significant difference among these three 
promoters in iNOS gene silencing.  
 
 
4.3.3. Effect of VEGF co-expression on iNOS gene silencing 
 
Co-expression of shRNA and therapeutic proteins is a promising combinatorial RNAi 
strategy [185], which will have synergistic effect by acting on different targets. However, 
it is not sure whether the over-expression of VEGF gene under a strong CMV promoter 
will interfere with the expression and processing of shRNA. As illustrated in Figure 4.3A, 
a plasmid has been constructed to co-express VEGF cDNA and iNOS-shRNA. VEGF 
cDNA was under the control of CMV promoter, while iNOS-shRNA was driven by U6 
promoter. As shown in Figure 4.3B, p-U6-shiNOS-CMV-VEGF and p-U6-shiNOS 
reduced the NO production by 59% and 62%, respectively (p < 0.01). In contrast, the 
plasmid expressing VEGF did not shown significant reduction of NO production. It was 
also noticed that there was no significant difference between p-U6-shiNOS and p-U6-
shiNOS-CMV-VEGF. Therefore, the co-expression of VEGF cDNA and iNOS-shRNA 
will not have much interference with the shRNA-mediated gene silencing.  
 
 
4.3.4. Effect of mir375 and mir30 backbones on iNOS gene silencing  
 
Efficient gene silencing has been reported when shRNA was embedded in miRNA 
backbone [153, 154].  To find out the possibility of increasing iNOS gene silencing effect 
by shRNA with miRNA backbone, two shRNA were designed based on mir375 and 
mir30 structures (Figure 4.4A). As shown in Figure 4.4C, significant reduction of NO 
production were observed in all of three vectors tested, p-U6-shiNOS (reduced by 62%, p 
< 0.01), p-U6-mir375-shiNOS (reduced by 39%, p < 0.01) and p-U6-miR30-shiNOS 
(reduced by 30%, p < 0.01). In addition, p-U6-shiNOS is significantly more efficiently 
than p-U6-mir375-shiNOS or p-U6-mir30-shiNOS (p < 0.01). Gene silencing efficiency 
of these three shRNA vectors was further investigated at mRNA levels by real-time PCR 
(Figure 4.4B). All of these three vectors reduced NO mRNA expression significantly
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Figure 4.2 Effect of different promoters on iNOS gene silencing. 
 
(A) Structure of pH1-shiNOS-CMV-GFP, pU6-shiNOS and pCMV-shiNOS. (B) 
Plasmids with different promoters (H1, U6 and CMV) as well as control plasmid were 
co-transfected with piNOS into AD293 cells. At 24 hours after transfection, NO 
production was measured by Griess Assay. NO concentration is expressed as the 
percentage of control. Results are the mean ± SE (n = 4). ** indicates P < 0.01 compared 
with control plasmid group. 
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Figure 4.3 Effect of VEGF gene co-expression on iNOS gene silencing. 
 
(A) Structure of pU6-shiNOS, and pU6-shiNOS-CMV-VEGF. (B) Plasmids co-
expressing shRNA and VEGF, plasmid expressing VEGF alone, as well as control 
plasmid were co-transfected with piNOS into AD293 cells. At 24 h after transfection, NO 
production was measured by Griess Assay. Nitrite concentration is expressed as the 
percentage of control. Results are the mean ± SE (n = 4). ** indicates p < 0.01 compared 
with control plasmid group. 
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Figure 4.4 Effect of mir375 and mir30 backbone on iNOS gene silencing. 
 
(A) Structure of pU6-shiNOS, pU6-mir375-shiNOS and pU6-mir30-shiNOS. Plasmids 
with different backbones as well as control plasmid were co-transfected with piNOS into 
AD-293 cells. At 24 hours after transfection, (B) iNOS mRNA levels was measured by 
Real-time PCR, (C) NO production was measured by Griess Assay. NO concentration is 
expressed as the % of control. Results are the mean ± SE (n = 4). **, p < 0.01 compared 
with control plasmid group; ++ , p < 0.01, +, p < 0.05, respectively, compared with pU6-
shiNOS group. 
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(p < 0.01, compared with control). In addition, p-U6-shiNOS（reduced by 56%） is 
significantly more efficiently than p-U6-miR375-shiNOS (reduced by 30%) or p-U6-
miR30-shiNOS (reduced by 28%) (p < 0.05, compared with p-U6-shiNOS). 
 
 
4.3.5. Inserting VEGF gene between CMV promoter and mir30-shRNA enhanced 
iNOS gene silencing  
 
We have shown the successful co-expression of iNOS shRNA and VEGF cDNA under 
two expression cassettes. To further investigate the possibility of co-expressing VEGF 
cDNA and iNOS shRNA under a single promoter, a plasmid with mir30-shiNOS under 
the control of CMV promoter was constructed and a VEGF cDNA was inserted between 
CMV promoter and mir30-shiNOS (Figure 4.5A). As shown in Figure 4.5B, a 39% 
reduction in NO production was achieved with p-CMV-mir30-shiNOS (p < 0.01, 
compared with control plasmid), which is close to that of p-U6-mir30-shiNOS (30%). 
However, the gene silencing effect was significantly enhanced by inserting a VEGF 
cDNA between CMV promoter and mir30-shRNA. In contrast, 61% reduction in NO 
production was achieved with p-CMV-VEGF-mir30-shiNOS (p < 0.01, with p-mir30-
shiNOS). 
 
 
4.3.6. Expression of VEGF from bipartite plasmids 
 
Not only potent silencing of proapoptotic gene, but also sufficient expression of VEGF is 
essential. Therefore, we measured VEGF gene expression from two bipartite plasmids, p-
U6-shiNOS-CMV-VEGF and p-CMV-VEGF-mir30-shiNOS.  We measured VEGF gene 
expression by ELISA of the cell culture medium. VEGF concentration was around 65 
ng/mL for all above plasmids and there is no significant difference among these two 
plasmids (Figure 4.6B). The VEGF gene expression from these two bipartite plasmids 
was also measured at mRNA levels with real-time PCR by using VEGF gene specific 
primers (Figure 4.6A). The results indicated VEGF mRNA levels in these two plasmids 
treated groups were 914 ± 18 and 922 ± 35 folds high than that in control group, 
respectively. 
 
 
4.4. Discussion 
 
Co-transfection approach for evaluating gene silencing effect has been extensively 
reported [125, 152, 155, 300], which allowed researchers to measure the gene silencing 
effect with good convenience and reliability. Therefore, a co-transfection of p-iNOS 
plasmid was used in this study to investigate gene silencing effect of shRNA iNOS 
vectors with different gene target sequence, promoters, backbones we have constructed. 
The use of a stably transfected cell line has also been reported [136]. A C6 cell stably 
expressing firefly luciferase gene was used to study the gene silencing effect shRNAs 
vectors against firefly luciferase gene. However, this is not appropriate for iNOS gene 
silencing. iNOS is up-regulated only after stimulation with cytokines or other reagents. 
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Figure 4.5 Insertion of VEGF gene between CMV promoter and mir30-shRNA 
enhanced iNOS gene silencing. 
 
(A) Structure of pCMV-mir30-shiNOS and pCMV-VEGF-mir30-shiNOS. (B) pCMV-
mir30-shiNOS, pCMV-VEGF-mir30-shiNOS as well as control plasmid were co-
transfected with piNOS into AD-293 cells. At 24 h after transfection, NO production was 
measured by Griess Assay. Nitrite concentration is expressed as the % of control.  Results 
are the mean ± SE (n = 4).** indicates p < 0.01 compared with control plasmid group; ++ 
indicates p < 0.01 compared with pCMV-VEGF-mir30 group. 
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Figure 4.6 Expression of VEGF from pU6-shiNOS-CMV-VEGF and pCMV-
VEGF-mir30-shiNOS. 
 
pU6-shiNOS-CMV-VEGF and pCMV-VEGF-mir30-shiNOS was transfected into AD-
293 cells. (A) At 24 hours after transfection, VEGF gene expression levels were 
measured by Real-time PCR, (B) At 36 h after transfection, VEGF expression was 
measured with ELISA. Results are the mean ± SE (n = 4). 
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By using co-transfection approach, the iNOS mRNA was expressed from p-iNOS 
plasmid after transfection. This could mimic the scenario of cytokine-induced iNOS gene 
much better than iNOS stable expressing cell lines, in which iNOS gene was constantly 
over-expressed. In addition, there are several limitations for the using of stable cell lines: 
1) the establishment of a stable cell line usually takes a long time (at least several weeks); 
2) a cDNA expressing vector with an antibiotics resistance gene (eg. Neomycin, 
puromycin); 3) Only a gene that is not toxic or will not interfere with the vital cellular 
process could be used to make a stable cell line. Because of above mentioned reasons, a 
co-transfection method would be a good approach for evaluation gene silencing effect 
during the development of gene silencing vectors. 
 
The selection of potent targeting sequence that leads to effective gene silencing still 
remains the key issue for practical application of RNAi technique for disease therapy. 
Web-based computer programs with different algorithms for designing siRNA and 
shRNA are available. To increase the chance of finding a potent sequence, empirical 
rules usually incorporated in these algorithms. These empirical rules includes: 
thermodynamic property; length of siRNA target; GC content; and RNA secondary 
structure [121, 126, 301-303]. However, the selection of targeting sequence is still an 
empiric process and depends on experimental screening of potential targets. This is 
because our understanding of RNAi mechanism is still insufficient.  In addition, most of 
the algorithms for shRNA sequence design are actually that of siRNA design and convert 
the siRNA into shRNA sequence. In our study, we have converted potent siRNA 
targeting sequence into shRNA sequence with success [184, 304]. However, we also 
observed loss of silencing effect after converting potent siRNA sequence into shRNA 
(data not show). A better understanding of RNAi mechanism is required for improved 
design of shRNA. In this study, five shRNA expression plasmids were purchased and 
screened to find the potent shRNA targeting sequence. In practical, this might be an 
efficient way to find a potent shRNA for certain application. 
 
Promoter is another important element that determines the duration, intensity and 
specificity of gene expression [305-307]. The activity of several promoters including 
tRNA, H1, U6, CMV, LTR, CMV enhancer/H1 has been investigated [136, 153, 299].  In 
this study, we did not observe significant difference in the levels of iNOS gene silencing 
when CMV, U6, and H1 promoters were used for driving shRNA-iNOS. Similar results 
have been reported by other research groups, where they found that when a less efficient 
luciferase shRNA sequence was used, there were some differences in luciferase gene 
silencing among different promoters; with H1 promoter being less efficient than CMV 
and U6 promoters. However, when a potent luciferase shRNA sequence was used, the 
difference in gene silencing effect among different promoters became minimal [153]. 
 
The use of miRNA-shRNA in siRNA expression vector is an attractive strategy, which 
mimics the structure of natural occurring miRNA and thus can be processed by cellular 
miRNA machinery more efficiently compared with conventional shRNA [153]. Almost 
80% more effective in reducing HIV p24 antigen production was achieved with TAT 
shRNA using mir-30 backbone compared with conventional shRNA [152]. shRNA is 
expressed in high level and yields an abundance of precursor, while miRNA-based 
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shRNA is expressed at low levels but processed more efficiently [300]. In order to further 
improve the silencing effect, we designed two shRNAs-based the mir375 and mir30 
sequences. The gene silencing potency of mir375-shRNA and mir30-shRNA was 
compared with that of conventional shRNA. However, the shRNA showed best gene 
silencing effect (62% reduction of NO production), while mir375 or mir30 shRNA are 
less potent with 39% and 30% reduction of NO production, respectively. Similar findings 
have been reported by other groups [125, 155]. Li et al., have compared conventional 
shRNA and mir30-based shRNAs against luciferase gene or mouse tyrosinase. Among 14 
different targeting sequences against luciferase tested, in 11 sequences the conventional 
shRNA showed better silencing effect than mir30-based shRNA.  All the conventional 
shRNA with 10 different targeting sequences against mouse tyrosinase showed 
significantly better silencing effect than mir30-based shRNA counterpart. They explained 
that the shRNA structure used previously for comparison [153] which has a 29-nt stem 
and a 4-nt loop is not a optimal design for shRNA. When a 4-nt loop sequence was used 
in shRNA, an insufficient processing of shRNA by Dicer was observed which resulted in 
poor gene silencing [125]. However, when a 9-nt loop (UUCAAGAGA) and 19-nt stem 
structure was used in shRNA design, a better gene silencing was observed in 
conventional shRNA compared with mir30-based shRNA. Therefore, it is reasonable 
observe better gene silencing effect in shRNA used in our study which has a 21-nt stem 
and 6-nt loop (CTCGAG). Boudreau et al. also demonstrated in their work that optimized 
shRNAs are more potent than mir30-based shRNAs for silecing of three genes including 
GFP,SCA 1 and HD, when the variables were minimized in the comparision [155]. For 
our study, the ultimate goal is to develop a vector for therapeutic purpose, thus the 
conventional shRNA which showed better iNOS gene silencing effect will be used in our 
future study. 
 
Another important feature of miRNA-based shRNA is that they are more amendable to 
pol II transcription and polycistronic strategies, allowing delivery of multiple siRNA 
sequences (or a siRNA sequences and a cDNA) with a single promoter [158, 198, 298].  
We first designed a miRNA30-based shRNA plasmid p-CMV-mir30-shiNOS, but it was 
not as potent as we expected. However, when we inserted a VEGF cDNA between CMV 
promoter and mir30-shiNOS sequence (p-CMV-VEGF-mir30-shiNOS), the gene 
silencing effect was significantly increased. This result is consistent with the work of 
Stegmeier et al.,[154] who reported that the insert of GFP, dsRED and Neo genes 
between CMV promoter and mir30-shRNA cassette increased the knock down of Rb 
gene. The exact reason for this is still unknown. Probably certain space between CMV 
promoter and mir30-shRNA is necessary for efficient gene silencing. The p-CMV-
VEGF-mir30-shiNOS could be another bipartite vector for therapeutic application, which 
co-expresses shRNA and a cDNA with a single promoter. 
 
The purpose of this study was to construct bipartite plasmids that could co-express VEGF 
gene for promoting revascularization and shRNA against iNOS gene to reduce human 
islet β-cell death. This combinatorial strategy will help to improve the survival and 
function of islet graft by promoting revascularization and inhibiting apoptosis [12]. The 
reason for using bipartite plasmids is that it will reduce the use of total plasmid backbone, 
thus minimizing the immunogenic effect caused by bacterial plasmids [294]. In addition, 
 70 
 
the bipartite plasmids were specially designed as a shuttle plasmid for construction of 
adenoviral vectors. Moreover, two restriction enzyme sites have been preserved flanking 
shRNA sequence in our bipartite vector. This feature will allow us to replace the shRNA 
sequence with a new one through directional cloning. We could conveniently construct p-
U6-shCas3-CMV-VEGF by replacing shRNA sequence in p-U6-shiNOS-CMV-VEGF 
and caspase 3 gene silencing was observed (data not shown.). 
 
In conclusion, we have constructed bipartite plasmids which co-express VEGF cDNA 
and shRNA against proapoptotic genes, e.g. iNOS gene. VEGF cDNA and shRNA were 
driven by two different promoters or by one single promoter. These plasmids are properly 
designed, which allows us to conveniently change shRNA sequence. In addition, all of 
these plasmids could be used as a shuttle plasmid for producing adenoviral vectors. 
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CHAPTER 5. SYNTHESIS, FORMULATION AND IN VITRO EVALUATION OF 
A NOVEL MICROTUBULE DESTABILIZER, SMART-100* 
 
 
5.1. Introduction 
 
Several microtubule-targeting drugs, including paclitaxel and docetaxel, have been 
developed for treating breast, prostate and non-small-cell lung cancers with great success 
[308-312]. However, their anticancer effects are diminished because of their intrinsic or 
acquired drug resistance, which involves the over-expression of P-glycoprotein (P-gp), 
multidrug resistance protein 7 (MRP 7) and the βIII-tubulin isotype [313-316]. Therefore, 
the development of novel anticancer drugs that can circumvent MDR will contribute 
significantly to the progress of cancer chemotherapy. Ixabepilone (IXEMPRA), an 
epothiline analog, has recently been approved the FDA to be used as a monotherapy or in 
combination with capecitabine for treating patients with metastatic or locally advanced 
breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is 
taxane resistant and for whom further anthracycline therapy is contraindicated [317].  
 
Recently, we have also we have synthesized a series of substituted methoxybenzoyl-ary-
thiazole (SMART) with good anticancer activity on different cancer cell types, including 
leukemia, non-small cell lung cancer, colon cancer, CNS cancer, renal cancer, melanoma, 
ovarian cancer, prostate cancer, and breast cancer [318]. The SMART compounds work 
as microtubule destabilizers by inhibiting tubulin polymerization. Compared with other 
microtubule–targeting drugs [316], SMART drugs are much easier to synthesize, which 
will reduce the manufacturing cost and thus make them more affordable to patients. 
 
Although SMART compounds demonstrated excellent anticancer bioactivities, their use 
was limited due to their poor intrinsic aqueous solubility. Two possible approaches could 
be used to address this problem. One is chemical modification, which may involve an 
extensive structure activity relationship (SAR) study. Another way is to improve the 
solubility of SMART drugs through formulation approaches. Conventionally, dimethyl 
sulfoxide (DMSO), Cremophor EL, polysorbate 80 (Tween 80) or other surfactants are 
commonly used to solubilize hydrophobic drugs such as taxane. However, the use of 
these solubilizing agents is usually associated with liver and kidney toxicity, hemolysis, 
acute hypersensitivity reaction and peripheral neuropathies [319]. 
 
Biodegradable polymeric micelles have recently been developed as  vehicles for 
hydrophobic drugs, since these micelles significantly increase the aqueous solubility of 
hydrophobic drugs and reduce their toxicity by avoiding the use of toxic co-solvents or 
solubilizing agents [320]. The improved safety profile makes it possible to administer 
drugs at a higher dose which may enhance their therapeutic efficacy while minimizing  
 
 
* Adapted with permission. F. Li, Y. Lu, W. Li, D.D. Miller, R.I. Mahato, Synthesis, 
formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100, J 
Control Release, 143 (2010) 151-158. 
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their side effects. Previously, we used a poly(ethylene)-b-poly(D,L-lactide) (PEG-PLA) 
polymeric micelles to solubilize two hydrophobic drugs such as bicalutamide and 
embelin, and at least 60-fold increase in drug aqueous solubility was observed [321]. 
Micelles prepared using PEG-PLA copolymer has PLA as a hydrophobic core, which is 
responsible for drug loading, and PEG as a hydrophilic shell to confer stealth properties 
and thus prevents recognition by the reticuloendothelial system (RES) [322]. Due to its 
small size of 20-60 nm and stealth properties, a passive tumor targeting using these 
micelles through enhanced permeability and retention (EPR) could be achieved [323]. 
 
In this study, the anticancer effect of SMART-100 on cancer cells and its ability to 
circumvent P-gp mediated drug resistance were determined. PEG-PLA micelles were 
used to improve the aqueous solubility of SMART-100. In addition, the in vitro 
anticancer activity of SMART-100 loaded micelles and its mechanism of action were 
determined. 
 
 
5.2. Materials and Methods 
 
 
5.2.1. Materials 
 
Materials Formyl terminated PEG-PLA of 4500-5100 Da was purchased from Polymer 
Source (Montreal, Canada). HepG2 and C4-2 cells were purchased from American Type 
Culture Collection (ATCC, Manassas, VA). Parent DU145 and paclitaxel resistant 
DU145-TXR cells were provided by Professor Evan T. Keller of the University of 
Michigan. Caspase-Glo™ 3 assay kit was purchased from Promega (Madison, WI). All 
other reagents were obtained from Sigma–Aldrich (St. Louis, MO).  
 
 
5.2.2. Synthesis of SMART-100 
 
SMART-100, (2-Phenyl-thiazol-4-yl)-(3,4,5-trimethoxy-phenyl)-methanone, was 
synthesized as described [318]. Briefly, benzonitrile (40 mmol) was mixed with L- 
cysteine (45 mmol) in 100 mL of 1:1 MeOH/pH 6.4 phosphate buffer solution (PBS). 
The reaction was stirred at 40 C for 3 days. The precipitate was removed by filtration, 
and methanol was removed using a rotary evaporator. 1 M hydrochloric acid was added 
to the remaining solution to adjust pH to 2 at 0 C. The resulting precipitate was filtered 
to yield a white solid 2-phenyl-4, 5-dihydrothiazole-4-carboxylic acid, which was used 
directly for the next step. 
 
A mixture of 2-phenyl-4, 5-dihydrothiazole-4-carboxylic acid (5 mmol), 1-ethyl-3-(3'-
dimethylaminopropyl) carbodiimide (EDCI, 6 mmol) and hydroxybenzotriazole (HOBt, 5 
mmol) in CH2Cl2 (50 mL) was stirred for 10 min. To this solution, N-methylmorpholine 
(NMM, 11 mmol) and HNCH3OCH3 HCl salt (5 mmol) were added and stirring 
continued at room temperature for 6-8 h. The reaction mixture was diluted with CH2Cl2 
(100 mL) and sequentially washed with water, satd. NaHCO3, brine and dried over 
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MgSO4. The solvent was removed under reduced pressure to yield a crude product, which 
was purified by column chromatography to get 2-phenyl-4, 5-dihydrothiazole-4-
carboxylic acid methoxymethylamide (Yield 92.0%). A solution of 2-phenyl-4, 5-
dihydrothiazole-4-carboxylic acid methoxymethylamide (1 equiv) in CH2Cl2 was cooled 
to 0 C and distilled DBU (2 equiv) was added. Bromotrichloromethane (1.7 equiv) was 
then introduced dropwise via syringe over 10 min. The reaction mixtures were allowed to 
warm to room temperature and stirred overnight. Upon washing with satd. aqueous 
NH4Cl (2 × 50 mL), the aqueous phase was extracted with ethyl acetate (3 × 50 mL). The 
combined organic layers were dried on MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography as needed providing 2-phenyl-thiazole-4-
carboxylic acid methoxymethylamide (87.1%). 
 
To a solution of 3, 4, 5-trimethoxyphenylmagnesium bromide (0.5 M, 3 mL) in 2 mL 
tetrahydrofuran (THF) was charged a solution of 2-phenyl-thiazole-4-carboxylic acid 
methoxymethylamide (1 mmol) in 3 ml THF at 0 C. The mixtures were stirred for 30 
min until amides disappeared on TLC plates. The reaction mixture was quenched with 
satd. NH4Cl, extracted with ethyl ether, dried with MgSO4. The solvent was removed 
under reduced pressure to yield a crude product, which was purified by column 
chromatography to obtain pure compound SMART-100. 
 
 
5.2.3. Preparation and characterization micelles 
 
5.2.3.1. Preparation of micelles 
 
Drug loaded micelles were prepared by a film-dispersion method. Briefly, various 
amounts of SMART-100 and PEG-PLA were dissolved in acetonitrile and a thin film was 
formed after removing solvent under reduced pressure. The resulting film was hydrated 
and sonicated. The resultant formulation was then centrifuged to remove residual free 
drug. The supernatant was then filtered using a 0.22 µm filter and used within 48 h. 
 
5.2.3.2. Determination of drug solubility and loading efficiency 
 
To determine water solubility of free drug, 1 mg of SMART-100 was suspended in 1 mL 
water and shake for 48 h at room temperature. The suspension was centrifuged at 10,000 
rpm for 10 min and filtered on 0.22 µm filter. To determine the solubility of SMART-100 
in micelles, 50 µL of SMART-100 loaded micelles solution was diluted with acetonitrile, 
and the drug concentration was measured by UV-spectrometer or reverse phase high 
performance liquid chromatography (RP-HPLC, Waters, Milford, MA) with UV detector 
at 292 nm using a reverse phase C18 column (250 mm x 4.6 mm, Alltech, Deerfield, IL). 
The mobile phase was composed of 40:60 V/V water and acetonitrile. SMART-100 
concentration was calculated by peak area according to the following calibration equation: 
C = 188.24A-593.64 (R2 = 1, detection limit: 2 ng/mL). The drug encapsulation 
efficiency of SMART-100 in polymeric micelles was calculated with the following 
equation: drug encapsulation efficiency % = ((weight of drug in micelles) / (weight of 
drug origally fed)) × 100%.  
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Fold of drug solubility increase were calculated with following equation: fold of drug 
solubility increse = drug solubility in micelles / drug solubility in water. 
 
 
5.2.3.3. Measurement of particle size 
 
The particle size distribution of micelles was determined by dynamic light scattering with 
Malvern Nano ZS. The intensity of scattered light was detected at 90°.  
 
 
5.2.4. Propidium iodide staining and cell cycle analysis 
 
Cells were cultured in a 24-well plate to 90% confluence and treated with SMART-100 
(2.8 µM) for 24 h. Cells were trypsinized and fixed in 70% ice-cold ethanol. After 
washing with PBS, cell pellet was re-suspended in 5 µg/mL propidium iodide staining 
solution for 15 min at room temperature. Cell cycle distribution was measured by flow 
cytometry (Becton, Dickinson, NJ). Results from 10,000 fluorescent events were 
obtained for analysis.  
 
 
5.2.5. MTT assay 
 
Cells were seeded in 96-well plates at a density of 5,000 cells per well. At the end of 
treatment, cell culture media was replaced by 100 μl medium with 0.5 mg/mL MTT (3-
(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide and incubated for 1 h at 
37°C. After removing the media, 200 μL of DMSO was added into each well to dissolve 
the formazan crystals. The absorbance was measured in a microplate reader at a 
wavelength of 560 nm. Cell viability was expressed as the percentage of control group.  
 
 
5.2.6. Calcein acetoxymethylester (calcein AM) assay 
 
Cells were seeded into a black wall clear bottom 96-well plate at a density of 20,000 cells 
per well one day before the experiment. After treating cells with various concentration of 
SMART-100 in 50 μL DPBS for 20 min at 37 ?, 50 μL Calceim AM (10 μM) in DPBS 
were added to each well and the plate was incubated at 37 C for additional 20 min. 
Fluorescence intensity in each well were determined using a SpectraMax M2/M2e 
spectrofluorometer (Sunnyvale, CA) at the excitation wavelength of 494 nm and emission 
wavelength of 517 nm. 
 
 
5.2.7. Determination of caspase 3 activity 
 
Cells were seeded in a 48-well plate to reach 80% confluence before experiment. After 
treating the cells for 16 h, culture media was removed and 100 µL Caspase Glo 3 reagent 
was added to each well. After gently mixing the content in each well, the plate was 
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incubated at room temperature for 60 min protected from light. Finally, 70 µL of the 
reaction solution was measured using a luminometer.  
 
 
5.2.8. Establishing a luciferase expression cell line for IVIS imaging 
 
For stable luciferase expression, C4-2 cells were seeded in a 6-well plate 24h before 
being transfected with pRc/CMV2-Luc plasmid (from Dr. Shu Wang, National 
University of Singapore) for 18 h. Two days after transfection, cells were transferred into 
a T-25 cell culture flask and selected with 600 µg/mL G418. The resulting 
bioluminescent cells were maintained in media containing 300 µg/mL G418. These cells 
were then seeded from 120,000 to 100 cells into a black wall clear bottom 96-well plates. 
D-luciferin (150 µg/mL) in DPBS was added to each well at 2 min prior to imaging using 
an IVIS imaging system (Xenogen, Alameda, CA). 
 
 
5.3. Results 
 
 
5.3.1. Synthesis and characterization of SMART-100 
 
SMART-100 was synthesized as described by Lu et al.[318], and illustrated in Figure 
5.1A. SMART-100 was characterized by 1H NMR (Figure 5.1B), 13C NMR and ESI-MS. 
1H NMR (300 MHz, CDCl3): δ 8.29 (s, 1 H), 8.03 (q, 2 H), 7.80 (s, 2 H), 7.49-7.47 (m, 3 
H), 3.96 (s, 6 H), 3.97 (s, 3 H). 13C NMR (75 MHz, CDCl3): 185.1, 168.1, 167.0, 155.4, 
152.7, 133.1, 131.9, 130.6, 129.1, 127.7, 126.6, 108.6, 60.9, 56.2. MS (ESI) m/z 378.1 
[M + Na]+. 
 
 
5.3.2. Anti-cancer activity of SMART-100 on HepG2 cells 
 
The anticancer activity of SMART-100 was determined in HepG2 cells with MTT assay. 
SMART-100 effectively inhibited HepG2 cell growth (Figure 5.2), with an IC50 of 
around 0.56 µM. The effect was observed as early as 24 h post treatment and became 
more significant after 48 h post treatment. There is no significant difference between “0” 
group, which is the cells treated with 0.5% DMSO and “DMEM” group, which is the 
cells treated with DMEM cell culture medium. Dose response curve was of typical 
sigmoid shape, with steep linear response at the mid-range dose groups. While there was 
no measurable effect at low doses ( 0.06 nM), the dose response curve became less 
steep and finally reaches plateau at high dose groups. 
 
 
5.3.3. Anti-cancer activity of SMART-100 in resistant prostate cancer cells 
 
We also tested the anticancer effect of SMART-100 on DU145-TXR cell, a paclitaxel 
resistant prostate cancer cell line with high P-gp activity and the parent DU145 cell, a
 76 
 
 
 
 
Figure 5.1 Synthesis and characterization of SMART-100. 
 
(A) Synthesis scheme of SMART-100. (B) 1H NMR spectrum of SMART-100. 
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Figure 5.2 Anti-cancer effect of SMART-100 on HepG2 cells. 
 
HepG2 cells were treated with increasing concentration of SMART-100 for 24, 48 and 72 
h. Cell viability was determined by MTT Assay and expressed as % of control. 
  
0
20
40
60
80
100
120
DMEM 0 0.06 0.56 5.63 56.34 
SMART-100 concentration (µM)
Vi
ab
le
 C
el
ls
 (%
)
24 h
48 h
72 h
i-ca
 78 
 
paclitaxel sensitive cell with low P-gp activity. Even though paclitaxel showed good 
activity on DU145 cells (IC50 < 50 nM), its efficacy was greatly reduced on DU145-TXR 
cells and killing only 20% of cells at a concentration of 1 µM (Figure 5.3A). In contrast, 
SMART-100 showed equally good anticancer activity on both DU145 and DU145-TXR 
cells with IC50 around 70 nM (Figure 5.3B). From Figure 5.3B, we could see that 
SMART-100 at 1 µM inhibited 63.7% and 67.6% cancer cell growth for DU145 and 
DU145-TXR, respectively. 74.2% (DU145) and 74.9% (DU145-TXR) cancer cell growth 
inhibition was achieved by SMART-100 at concentration of 5.63 µM. 82.1% (DU145) 
and 83.8 % (DU145-TXR) cancer cell growth inhibition was achieved by SMART-100 at 
concentration of 11.26 µM. 
 
Intracellular calcein levels in DU145 cells were much higher than those in DU145-TXR 
cells (Figure 5.4A), indicating higher P-gp activities in DU145-TXR cells but not in 
DU145 cells. The treatment of verapamil, a P-gp inhibitor, significantly increased 
intracellular calcein levels in DU145-TXR cells in a dose dependent manner, while no 
changes in intracellular calcein levels were observed in DU145 cells. Treatment of 
DU145-TXR cells with SMART-100 also increased intracellular calcein levels, while 
treatment of paclitaxel showed no effect (Figure 5.4B). This indicated that SMART-100 
might also act as a P-gp inhibitor in addition to its anti-mitotic activity and thus overcome 
the drug resistance in DU145-TXR cells due to P-gp over-expression. 
 
 
5.3.4. Micellar solubility of SMART-100  
 
Although SMART-100 showed good anticancer activity, its application was limited due 
to its poor water solubility, which is less than 2 ng/mL. Therefore, PEG-PLA micelles 
were used to improve its solubility. A film dispersion method was used to prepare 
micelles [321]. The mean particle size of micelles was around 50 nm and no significant 
difference in particle size was observed in micelles with and without drug. These micelles 
were stable for at least 12 days without significant change in particle size. 
 
When we increased the theoretical loading from 0.5% to 5% w/w, the drug solubility 
increased from 26.8 ± 0.1 µg/ml to 48.0 ± 0.3 µg/ml until theoretical loading reached 1% 
(Figure 5.5A). The drug loading efficiency decreased significantly after the theoretical 
loading became larger than 1% (Figure 5.5B).To further increase the drug solubility, the 
effect of polymer concentration on drug solubility was determined. The solubility of 
SMART-100 increased linearly from 48.0 ± 0.3 to 213.9 ± 8.1 µg/mL (2.4 x 104 to 1.1 x 
105 folds as that of free SMART-100 in water), when the polymer concentration was 
increased from 5 mg/mL to 20 mg/mL (Figure 5.5C).The drug loading efficiency was 
around 100% for all tested polymer concentration (Figure 5.5D). 
 
 
5.3.5. Anticancer effect of SMART-100 loaded PEG-PLA micelles 
 
No obvious cytotoxicity was observed in blank PEG-PLA micelles group with a polymer 
concentration of as high as 1 mg/mL (Figure 5.6). Significant anticancer effect was 
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Figure 5.3 Anti-cancer effect of SMART-100 on MDR cancer cells. 
 
Inhibition of DU145 and DU145-TXR cells growth by SMART-100 (A) and paclitaxel 
(B) Cell viability was determined by MTT Assay 48 h after drug treatment and expressed 
as the % of control. 
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Figure 5.4 Effect of SMART-100 on P-gp activity. 
 
(A) Intracellular calcein accumulation in DU145 and DU145-TXR cells. (B) Effect of 
SMART-100 on intracellular calcein accumulation in DU145-TXR cells. Results are 
expressed as the mean ± SE (n = 3). 
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Figure 5.5 Solubilization of SMART-100 with PEG-PLA. 
 
Effect of theoretical loading on SMART-100 solubility (A) and loading efficiency (B); 
Effect of polymer concentration on SMART-100 solubility (C) and loading efficiency 
(D). Results are expressed as the mean ± SE (n = 3). 
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Figure 5.6 Anti-cancer effect of PEG-PLA micelles formulated SMART-100. 
 
HepG2 cells were treated with different SMART-100 formulations for 48 h. Cell viability 
was determined by MTT Assay and expressed as the percentage of control. *, p < 0.001, 
compared with blank PEG-PLA control. 
 
 
 
  
0
20
40
60
80
100
120
0.06 0.56 5.63
Vi
ab
le
 C
el
ls
 (%
)
SMART-100 concentration (µM)
PEG-PLA
DMSO-SMART100
PEG-PLA-SMART100*
* *
 83 
 
observed in both SMART-100 loaded PEG-PLA micelles and SMART-100 dissolved in 
DMSO and the anticancer activity increased with the dose. Even though the final DMSO 
concentration used was 0.5%, which did not show any obvious toxicity on our 
experiment, no direct comparison can be made with the results of SMART-100 dissolved 
in DMSO, as DMSO is known to kill tumor and may not be suitable for in vivo 
applications. 
 
 
5.3.6. Cell cycle perturbation 
 
The treatment of SMART-100 formulated in both DMSO and PEG-PLA micelles caused 
cell cycle arrest in HepG2 cells, while no effect was observed after treating cells with 
blank PEG-PLA micelles or DMSO (Figure 5.7). The treatment of SMART-100 
formulations caused the cells in G0/G1 phase decreased from 49.18 ± 1.59% in the 
control group to 21.03 ± 0.54% in DMSO dissolved SMART-100 group and 19.24 ± 
0.89% in PEG-PLA micelles formulated SMART-100 group, respectively. While the 
cells in G2/M phase were increased from 29.59 ± 1.55% in control group to 73.06 ± 
1.68% in DMSO dissolved SMART-100 group and 74.91 ± 1.10% in PEG-PLA micelles 
formulated SMART-100 group, respectively. In addition, we also determined the effect 
of treatment time on cell cycle distribution (Figure 5.7B). Cells were treated with 
SMART-100 loaded PEG-PLA micelles for 24, 48, and 72 h. There was no change in the 
percentage of cells in G0/G1 phase after treating the cells for prolonged time at 48 or 72 
h. The percentage of the cells in G2/M phase was decreased from 74.91 ± 1.1% at 24 h to 
68.71 ± 1.95% at 48 h and to 65.5 ± 1.65% at 72 h. In addition, the cells in sub G1 phase 
were also increased from 0.29 ± 0.21% at 24 h to 2.96 ± 1.34% at 48 h and to 8.94 ± 
1.15% at 72 h. The increase of cell population in subG1 phase indicated that apoptotic 
cells were increased after SMART-100 treatment for prolonged time. 
 
 
5.3.7. Caspase 3 activity  
 
In the cell cycle analysis, we found that the treatment of SMART-100 resulted in 
increased cell population in subG1 phase, which is an indication of apoptosis. To confirm 
whether cell death induced by SMART-100 was associated with apoptosis, caspase 3 
activity was measured after treating HepG2 cells with SMART-100. As shown in Figure 
5.8, no significant difference was observed between untreated cell and cells treated with 
DMSO or empty PEG-PLA micelles. The treatment of SMART-100 with both DMSO 
and PEG-PLA micelles at a concentration of 2.8 µM resulted in increased caspase 3 
activity (p < 0.05), which is comparable to those caused by paclitaxel with the same 
molar concentration (p > 0.05). This result indicated that SMART-100 may cause cell 
apoptosis by the activation of caspase 3 activity. However, increase of caspase 3 activity 
in SMART-100 treated groups was relatively low compared with cells treated with 
staurosporine, a well-known caspase 3 activator (p < 0.01). 
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Figure 5.7 Effect of SMART-100 on cell cycle and apoptosis. 
 
(A) HepG2 cells were treated with different SMART-100 formulations (drug 
concentration 1µg/ml) for 24 h and cell cycles were analyzed by flow cytometry. Upper 
panel, Cell cycle distribution; Lower panel, quantitative analysis. (B) Time course of cell 
cycle perturbation in HepG2 cells treated with SMART-100 loaded PEG-PLA micelles. 
Upper left panel, cell cycle distribution; Upper right panel, graphical representation of 
apoptotic index (percent sub-G1 cells) over time; and Lower panel, quantitative analysis. 
Results are expressed as the mean ± SE (n = 3). * P < 0.001, ** P < 0.01, compared with 
control.  
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Figure 5.8 Effect of SMART-100 on caspase 3 activity. 
 
After treatment with 1µg/ml SMART-100 or same molar concentration of paclitaxel or 
saturosporeine for 16 h, caspase 3 activity was determined. Caspase 3 activities were 
expressed as relative light unit (RLU) and normalized by cell viability. Drugs were 
dissolved in DMSO, unless otherwise stated. Results are the mean ± SE (n = 3). *, p < 
0.001, **, p < 0.01, ***, p < 0.05 compared with DMSO control. ++, p < 0.01 compared 
with blank PEG-PLA micelles. #, p < 0.001, compared with saturosporeine. 
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5.3.8. IVIS imaging for assessing antitumor activity 
 
We established a luciferase expressing C4-2 prostate cancer cell line for IVIS imaging 
(Figure 5.9A). There was a good correlation between the cells number and 
bioluminescence signals captured by IVIS imaging (R2 = 0.9769, Figure 5.9B), thus live 
cell number could be quantitatively determined by IVIS imaging. Treatment with 
SMART-100 resulted in significant reduction in the bioluminescence signal (Figure 
5.9C). However, the treatment with empty PEG-PLA micelles did not cause any change 
in bioluminescence signal. The viable cell number was also been quantitatively 
determined by measuring bioluminescence signal (Figure 5.9D). 
 
 
5.4. Discussion  
 
The discovery of paclitaxel has resulted in significant progress for the treatment of 
several cancers including breast, ovarian, and non-small cell lung cancers. Paclitaxel 
works through stabilizing microtubules, and thus causing mitotic arrest and apoptosis. 
Despite the potent anticancer activity of paclitaxel, its clinical application is often 
undermined due to the occurrence of MDR. Cancer cells become resistant to anticancer 
drugs due to the change in cell membrane ATP-binding cassette (ABC) super family 
transporters such as P-gp, multiple drug resistance protein (MRP) and breast cancer 
resistance protein (ABCG2). Particularly, the over-expression of P-gp encoded by MDR1 
gene is widely investigated and known to be responsible for the resistance to several 
anticancer agents such as paclitaxel and docetaxel.  
 
Several strategies have been studied to overcome MDR mechanism including the use of 
novel drug delivery systems, co-administration of P-gp inhibitors, and the search of new 
compounds that could overcome MDR. Drug delivery systems such as HPMA copolymer 
drug conjugates [324], polymeric micelles [325], liposomes [326], and nanoparticles [327] 
have been successfully used to reduce the drug resistance by enhanced intracellular drug 
delivery and/or inhibition of P-gp activities. In addition to formulation approaches, 
scientists have also successfully discovered several new compounds to overcome MDR. 
Ixabepilone, for example, has been approved by the FDA as a drug for MDR breast 
cancer [328]. 
 
To test whether SMART-100 could overcome MDR, a paclitaxel-resistant cell line, 
DU145-TXR, was used in this study. DU145-TXR is resistant to paclitaxel as well as 
several other anticancer agents including estramustine phosphate, docetaxel, doxorubicin 
and vinblastine [329]. SMART-100 showed potent anticancer activities in both 
paclitaxel-sensitive (DU145) and paclitaxel-resistant (DU145-TXR) cancer cells (Figure 
5.3B). These results suggest that SMART-100 has the potential to be used for treating 
MDR cancers. 
 
To further understand why SMART-100 could keep its anticancer activity in paclitaxel-
resistant cells capable of overexpressing P-gp, Calcein acetoxymethylester (Calcein AM) 
assay was carried out to determine the effect of SMART-100 on P-gp functions. Calcein
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Figure 5.9 Determination of anti-cancer activity by IVIS imaging. 
 
(A) In vitro bioluminescence of C4-2 human prostate tumor cell lines expressing 
luciferase. C4-2-luc cells were seeded from 120,000 to 100 cells per well and imaged 
after the addition of luciferin. Wells containing cells but no luciferin were served as 
negative controls. (B) Correlation between cell number and mean bioluminescence 
signal. (C) Effect of SMART-100 loaded PEG-PLA micelles on the Inhibition of C4-2-
Luc cell growth. Cells were treated with blank PEG-PLA micelles and SMART-100 
loaded micelles for 4 days at the dose of 1µM and the in vitro bioluminescence was 
determined by IVIS imaging. (D) The cell viability was quantitatively determined by 
bioluminescence reading and expressed as percentage of control group. *, p < 0.001, 
compared with blank PEG-PLA control. 
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AM is a substrate for efflux activity of P-gp. In cells with high P-gp activity, Calcein AM 
is constantly pumped out, preventing intracellular accumulation of fluorescent calcein. 
The inhibition of P-gp function by inhibitors such as verapamil results in reduced efflux 
of fluorescent calcein and thus increases intracellular fluorescence intensity. The change 
of fluorescence intensity could be quantitatively determined by fluorometer and used as 
an indicator for P-gp activities. The treatment of SMART-100 significantly increased the 
intracellular accumulation of calcein, which indicated that it might be an inhibitor of P-gp 
and prevented the efflux of drug out of P-gp over-expressing cells (Figure 5.4). Therefore, 
inhibition of P-gp activity might be a mechanism of SMART-100 to overcome multiple 
drug resistance. 
 
Our previous study showed that SMART-100 works by targeting and destabilizing 
microtubules. As a microtubule destabilizer, its anti-proliferative effect is involved in the 
inhibition of tubulin polymerization [318]. The cell cycle analysis indicated that after 
treatment with SMART-100 the cells were arrested in G2/M phase (Figure 5.7). Since the 
destabilization of microtubule dynamics will result in the cell cycle arrest at mitotic phase, 
cell cycle analysis experiment further confirmed that the anticancer mechanism of 
SMART-100 is through destabilizing microtubule. We also found that after SMART-100 
treatment cells in sub-G1 phase were significantly increased (Figure 5.7). The increase in 
cell population in sub-G1 phase indicated the induction of cell apoptosis by SMART-100 
[330, 331]. The increase in caspase 3 activity is an important marker for cell apoptosis. 
Treatment with SMART-100 increased caspase 3 activities in this study (Figure 5.8), 
which indicated the occurrence of apoptosis. From the binding of microtubule 
destabilizer with the tubulin to apoptosis is a complicated intracellular process, which 
involves multiple signal pathways, including the checkpoint of mitotic spindle assembly, 
the activation of cyclin-dependent kinases, and the JNK/SAPK [332]. However, these 
signal pathways are beyond the scope of this study. 
 
PEG-PLA micelles have been successfully used as a Cremophor EL free formulation for 
paclitaxel (Genexol-PM), which is under multicenter phase II clinical trial [333]. Because 
of its superior performance as a delivery system for paclitaxel, we used PEG-PLA 
micelles to improve the solubility of SMART-100. Due to the high logP value (4.08) of 
SMART-100, its aqueous solubility is very low (below the detection limit, 2 ng/mL). 
However, the use of PEG-PLA micelles significantly increased its aqueous solubility. 
The maximum solubility reached to 213.9 ± 8.1 µg/mL, where SMART-100 solubility 
was increased by at least 1.1x105 folds (Figure 5.5). Polymeric micelles are known to 
enhance the solubilization of hydrophobic compounds by accommodating them in the 
hydrophobic core of polymers. A critical parameters involves in the solubilization 
process is polymer-drug compatibility, which could be evaluated by solubility difference 
(Δ) and Flory-Huggins interaction parameter (Xsp) [334]. We have calculated the 
solubility parameters of SMART-100 and PLA hydrophobic core by Molecular Modeling 
Pro Software (ChemSW Inc., Fairfield, CA). The calculated parameters for PLA is 19.7 
(δd), 2.48 (δp) and 20.9(δh), while those of SMART-100 is 20.3 (δd), 6.5 (δp) and 9.2 
(δh). Thus, the solubility difference (Δ) between PLA and SMART-100 is 12.4. Typically, 
a solubility difference value less than 5 is needed to observed good solubility [335]. 
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Therefore, we plan to design and modify the hydrophobic core of the polymer to make it 
more compatible with SMART-100 and further increase the solubility of SMART-100. 
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CHAPTER 6. SYNTHESIS AND CHARACTERIZATION OF AMPHIPHILIC 
LIPOPOLYMERS FOR MICELLAR DRUG DELIVERY* 
 
 
6.1. Introduction 
 
Many anticancer agents are poorly soluble in water, which can cause serious problems for 
their clinical application. Dimethyl sulfoxide (DMSO), Ctenophore EL, Tween 80 or 
other surfactants are commonly used to solubilize these drugs. However, these 
solubilizing agents are harmful to the liver and kidney and cause dose-dependent 
hemolysis and acute hypersensitivity reactions [319, 336]. In addition, because of high 
critical micelle concentration (CMC) values associated with low molecular weight 
surfactant micelles, they are not stable after systemic administration and thus result in the 
precipitation of solubilized drugs. 
 
Poly(ethylene glycol)(PEG)-lipid conjugates, such as PEG-phosphatidylethanolamie 
(PEG-PE) have been used for micellar drug delivery [337, 338]. The use of PEG-lipid 
conjugates for drug delivery are superior to conventional small molecular weight 
surfactants, since PEG-lipid conjugates have lower critical micelle concentration (CMC: 
around 10-5 M) than conventional surfactants (CMC: around 10-3 M), suggesting PEG-
lipid conjugate micelles are more stable than those formed by conventional surfactants. A 
typical PEG-lipid conjugate structure includes a hydrophilic PEG corona and a 
hydrophobic lipid core, which, in turn, is composed of two lipid chains varying from C12 
to C18 in chain length. Although we could conjugate PEG with different lipids to make 
different PEG-lipid conjugates, the flexibility in the design of hydrophobic core is still 
limited. 
 
Alternatively, amphiphilic copolymers have become promising materials for micellar 
drug delivery. Pluronic is a triblock copolymer composed of a central hydrophobic chain 
of poly (propylene oxide) (PPO) flanked by two hydrophilic chains of poly (ethylene 
glycol) (PEG), and has been widely used for drug delivery [339]. It not only increases 
drug solubility, but also overcomes drug resistance in cancer [340, 341]. The CMC of 
Pluronic copolymers ranges from 5.3 x 10-3 M to 2.8 x 10-6 M depending on the 
molecular weight and composition of copolymers [339]. However, the use of Pluronic for 
drug delivery is somewhat problematic because they are non-biodegradable. Therefore, 
biodegradable copolymers such as PEG-PLLA-PEG were designed to facilitate the 
elimination of polymers from the body [342]. In addition, the structure and size of 
hydrophobic core block could be properly designed to improve the micelle stability and 
drug loading. A significantly reduced CMC (10-6 to 10-7 M) is observed in a diblock 
copolymer, which is 10 to 100 folds lower than PEG-lipid conjugates [343]. For 
examples, the CMC of PEG5100-PLA4500 was around 3 x 10-6 M as determined by  
 
 
* Adapted with permission. F. Li, M. Danquah, R.I. Mahato, Synthesis and 
characterization of amphiphilic lipopolymers for micellar drug delivery, 
Biomacromolecules, 11 (2010) 2610-2620. 
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Danquah et al.[321] Similar results were also reported by Yasugi et al.,[339] who showed 
that the CMC of PEG5700-PLA5400 was around 3 x 10-7 M. The low CMC of micelles 
formed by amphiphilic copolymers indicates that they are more stable than PEG-lipid 
conjugate micelles and can maintain the integrity of micelles upon dilution. In addition, 
we and others have showed that the drug solubility has been significantly improved by 
properly designing the hydrophobic core structure to improve the compatibility between 
the hydrophobic core and drugs [344]. For an example, PEG-b-poly(N-alkyl stearate L-
aspartamide), a lipid conjugated polymer, has been used to improve the solubility of a 
hydrophobic drug, amphotericin B, and demonstrated the possibility of using 
lipopolymers for solubilization of lipid-like drugs [345, 346]. 
 
In this study, we synthesized a novel amphiphilic lipopolymer, poly(ethylene glycol)-
block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD). The 
polymer synthesis procedures were optimized and the properties of polymers were 
characterized. PEG-PCD lipopolymers could form micelles and effectively incorporate 
embelin and improve its water solubility. PEG-PCD lipopolymers were compared with 
similar polymers with different core structures to investigate the effect of core structure 
on micelle properties, such as stability, drug loading, particle size and morphology, and 
in vitro drug release. In addition, we also investigated the effect of hydrophobic core size 
on the properties of PEG-PCD lipopolymer micelles. Finally, the anti-cancer activities of 
embelin loaded micelles were determined in vitro with prostate cancer cells. 
 
 
6.2. Materials and Methods 
 
 
6.2.1. Materials 
 
Hydroxybenzotriazole (HOBT), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
dodecanol, triethylamine (TEA), stannous 2-ethylhexanoate (Sn(Oct)2), diethyl zinc 
(Et2Zn), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 2,2-bis(hydroxymethyl) propionic 
acid, methoxy poly(ethylene glycol) (mPEG, Mn = 5000, PDI = 1.03) and all other 
reagents were purchased from Sigma Aldrich (St. Louis, MO) and used as received. 
 
 
6.2.2. Synthesis of poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene 
carbonate-graft-dodecanol) (PEG-PCD) 
 
PEG-PCD lipopolymer was synthesized using the following two methods (Figure 6.1): 
 
6.2.2.1. Method I 
 
Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) 
(PEG-PBC) was synthesized with the following procedures. Monomer 2-methyl-2-
benzyloxycarbonyl-propylene carbonate (MBC) was synthesized as described by  
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Figure 6.1 Synthesis of PEG-PCD lipopolymer. 
 
Reaction conditions: (IA) DBU, CH2Cl2, RT, 3 h. (IB) Pd/C (10%), H2 , 
THF/Methanol(1:1), RT, 18 h.(IC) EDC, HOBT,TEA, DMF, RT, 18 h. (IIA) Pd/C 
(10%), H2, EtOAc, RT, 3 h. (IIB) EDC, HOBT,TEA, DMF, RT, 18 h. (IIC) 
DBU,CH2Cl2, RT, 3h. 
  
MBC
MCC MDC
PEG-PCD
PEG-PCC
PEG-PBC
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Danquah et al. [344]. Briefly, a mixture of 0.168 mol 2,2-bis(hydroxymethyl)propionic 
acid and 0.169 mol potassiumhydroxide was dissolved in 125 mL dimethylformamide 
(DMF) by heating to 100 ? for 1 h with stirring. Then, 0.202 mol benzyl bromide was 
added drop-wise to the warm solution, and stirred at 100 ? for 16 h. At the end of 
reaction, the solvent was removed under reduced pressure. The residue was dissolved in 
150 mL ethyl acetate, washed with water, and dried over MgSO4. The solvent was 
removed to yield a crude product, which was re-crystallized from toluene to give pure 
benzyl 2,2-bis(methylol)propionate. Then, 0.05 mol of benzyl 2,2-
bis(methylol)propionate  was dissolved in 150 mL CH2Cl2 containing  25 mL pyridine, 
and the solution was chilled to 78 ?. A solution of CH2Cl2 containing 25mmol 
triphosgene was dripped into the solution over 1 h. The reaction mixture was stirred for 
additional 2 h at the room temperature before quenched with 75 mL saturated aqueous 
NH4Cl. Subsequently, the organic layer was sequentially washed with aqueous HCl (1M, 
300 mL), saturated aqueous NaHCO3 (300 mL), dried with Na2SO4, evaporated to give 2-
methyl-2-benzyloxycarbonyl-propylene carbonate (MBC) as a crude product, which was 
further recrystallized from ethyl acetate to give white crystals. 
 
Three methods with different catalysts were investigated in this study to synthesize PEG-
PBC from copolymerization of mPEG with monomer MBC. (1) Sn(Oct)2 (10 mol% 
relative to mPEG) was added to the mixture of given amount of mPEG and MBC 
dissolved in anhydrous toluene in a dried polymerization flask under the protection of 
nitrogen atmosphere. To optimize the reaction condition, the reaction mixture was heated 
to 80 ? for 3 h and 16 h under stirring, respectively. (2) DBU (40 µL) was added to the 
mixture of given amount of mPEG and MBC dissolved in 10 ml anhydrous CH2Cl2 and 
reacted at RT for 3 h under stirring. (3) Et2Zn (10 mol% relative to mPEG) was added to 
the mixture of given amount of mPEG and MBC dissolved in anhydrous toluene in a 
dried polymerization flask under the protection of nitrogen atmosphere and reacted at 80 
? for 16 h under stirring. At the end of reaction, the reaction mixture was dissolved in 
CHCl3 and the product was precipitated with a large amount of ice-cold diethyl ether and 
dried under vacuum at room temperature. 
 
To remove protective benzyl groups, PEG-PBC was subjected to hydrogenation. Briefly, 
one gram of PEG-PBC was dissolved in 12 mL of tetrahydrofuran (THF) and methanol 
mixture (1:1) containing 200 mg of palladium on charcoal (Pd/C). The reaction flask was 
purged with N2 thrice and charged with H2 using a balloon. The reaction was carried out 
for 18 h with stirring. At the end of reaction, Pd/C was removed by centrifugation. The 
solvent was removed under reduced pressure to get poly(ethylene glycol)-block-poly(2-
methyl-2-carboxyl-propylene carbonate)(PEG-PCC). 
 
Lipid was conjugated to PEG-PCC as described in the following. For lipid conjugation to 
PEG-PCC, 300 mg PEG-PCC, 260 mg dodecanol, 223 mg hydroxybenzotriazole 
(HOBT), and 317 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) were 
dissolved in 10 mL DMF and 340 µL of triethylamine (TEA) was then added to the 
mixture with stirring. After reaction for 18 h, products were precipitated with a large 
amount of cold isopropyl alcohol twice and diethyl ether once, and then dried under 
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vacuum at the room temperature to afford poly(ethylene glycol)-block-poly(2-methyl-2-
carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD). 
 
6.2.2.2. Method II 
 
Firstly, 2-methyl-2-carboxyl-propylene carbonate (MCC) was synthesized by 
hydrogenation of MBC as described previously [344]. Briefly, one gram of monomer 
MBC was dissolved in 10ml ethyl acetate containing 100 mg of Pd/C. The reaction flask 
was purged with N2 three times and charged with H2 to 45 psi. The reaction was carried 
out for 3 h. Then, Pd/C was removed by centrifugation. The solvent was removed under 
reduced pressure to give MTC-OH as white crystal. 
 
Then, 2-methyl-2-dodecanoxycarbonyl-propylene carbonate (MDC) was synthesized. To 
synthesize MDC, 480 mg MTC-OH, 465 mg dodecanol, 506 mg HOBT, and 720 mg 
EDC were dissolved in 20 ml DMF and 490 µL of TEA was then added to the mixture 
with stirring for 18 h. The reaction mixture was diluted with ethyl acetate (20 mL) and 
washed with water and dried over MgSO4. The solvent was removed under reduced 
pressure to yield a crude product, which was further purified by column chromatography 
to get MDC as white powder. 
 
Finally, PEG-PCD was prepared from copolymerization of mPEG with MDC. DBU (40 
µL) was added to the mixture of a given amount of mPEG and MDC was dissolved in 
anhydrous CH2Cl2 and reacted under stirring for 3 h. The reaction mixture was dissolved 
in CHCl3 and the product was precipitated with a large amount of cold isopropyl alcohol, 
diethyl ether, and dried under vacuum at room temperature to get PEG-PCD lipopolymer. 
 
 
6.2.3. Polymer characterization 
 
6.2.3.1. Nuclear magnetic resonance (NMR) 
 
1H NMR spectra were recorded on Varian (500 MHz) using deuterated chloroform 
(CDCl3) as a solvent unless otherwise noted. The chemical shifts were calibrated using 
tetramethylsilane as an internal reference and given in parts per million. 
 
6.2.3.2. Infrared (IR) spectra 
 
The composition of synthesized polymers was also confirmed with Infra red (IR) spectra 
using a Perkin-Elmer IR spectrometer. 
 
6.2.3.3. Gel permeation chromatography (GPC) 
 
The weight (Mw) and number (Mn) average molecular weight and polydispersity index 
(PDI) of synthesized polymers were determined by a Waters GPC system equipped with 
a GPC column (AM Gel 103/5) and a differential refractive index detector. THF was used 
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as an eluent at a flow rate of 1 ml/min. A series of narrow polystyrene standards (700–
40,000 g/mol) were used for calibration. 
 
6.2.3.4. Differential scanning calorimetry 
 
The thermal properties, including glass transition temperature (Tg), melting temperature 
(Tm), crystalline temperature (Tc) of the synthesized polymers were determined by 
differential scanning calorimetry (DSC) (TA Instrument DSC Q2000 module). Samples 
were placed in aluminum pans under nitrogen heated from 25 ? to 100 ?, cooled to -70 
? to remove thermal history and heated from -70 ? to 100 ? at a rate of 5 ? / min.  
 
 
6.2.4. Critical micelle concentration 
 
Critical micelle concentration (CMC) was determined with fluorescent spectroscopy 
using pyrene as a hydrophobic fluorescent probe, as previously described [347]. Briefly, 
forty microliters of pyrene stock solution (2.4 x 10-3 M) in acetone was added to 40 mL 
water to prepare a saturated pyrene aqueous solution. Polymer samples were dispersed in 
water with concentration ranges from 0.5 to 4.8 x 10-7 mg/mL and mixed thoroughly with 
above pyrene solution at a volume ratio of 1:1. The fluorescent intensity was recorded 
with a Molecular Devices SpectraMax M2/M2e spectrofluorometer (Sunnyvale, CA) 
with a EX = 338 nm (I3) and 333 (I1), Em = 390 nm. The intensity ratio (I338/I333) was 
plotted against the logarithm of polymer concentration. The CMC value was obtained as 
the point of intersection of two tangents drawn to the curve at high and low 
concentrations, respectively. 
 
 
6.2.5. Preparation of polymeric micelles 
 
Polymeric micelles were prepared with a film dispersion method as previously reported 
with some modifications [348]. Briefly, 15 mg of polymer and given amount of embelin 
were dissolved in 0.5 mL CH2Cl2, and then the solvent was removed under reduced 
pressure. The resulting film was hydrated in 3 mL PBS (pH 7.4) and sonicated for 1 min. 
Then, the residue free drug was removed by centrifugation at 12,000 rpm for 5 min. The 
supernatant was filtered using a 0.22 µM filter. 
 
 
6.2.6. Drug loading and encapsulation efficiency 
 
To determine drug loading, 10 µL of embelin loaded micelle solution was diluted with 
methanol. Then drug concentration was determined using a UV spectrometer at 310 nm 
(Thermo Spectronic). Embelin concentration was calculated based the UV absorbance 
using a standard curve. Drug loading and encapsulation efficiency were then determined 
using the following equations, respectively. Drug loading (%) = ((amount of loaded drug) 
⁄ (amount of polymer)) × 100%. Drug encapsulation efficiency (%) = ((amount of loaded 
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drug) ⁄ (amount of drug added)) × 100%. Theoretical loading (%) = ((amount of drug 
added) ⁄ (amount of polymer)) × 100%. 
 
 
6.2.7. Morphology and particle size 
 
The particle size of polymeric micelles was determined by dynamic light scattering 
(Malvern Nano ZS). The intensity of scattered light was detected at 90°. The particle size 
measurement was repeated three times and the data were reported as the mean ± SD. The 
morphology of polymeric micelles were observed using a transmission electron 
microscope (TEM, JEM-100S) using an acceleration voltage of 60 kV. Micelles was 
loaded on a copper grid and stained with 1% uranyl acetate. The grid was visualized 
under the electron microscope with magnifications of 75,000. 
 
 
6.2.8. In vitro drug release 
 
The dialysis technique was employed to determine the release of embelin from polymeric 
micelles in PBS (pH 7.4) with 0.1% Tween 80. The micelles used for in vitro release 
study have a polymer concentration of 5 mg/mL. Eight hundred microliters of micelles 
with 5% drug loading were used to compare the release profiles of PEG-PCD with 
different PCD length. In addition, 2 mL micelles with 2% drug loading were also used to 
compare the release profiles of PEG114-PCD29 and PEG114-PBC30. Embelin-loaded 
micelles were placed into a dialysis tube with a molecular weight cut-off of 3500 Da and 
dialyzed against 50 mL release medium in a thermo-controlled shaker with a stirring 
speed of 180 rpm at 37 ?. At specified time, 1 mL release medium was withdrawn and 
embelin concentration was determined with a UV spectrophotometer based on UV 
absorbance at 310 nm. All experiments were performed in triplicate and the data reported 
as the mean of the three individual experiments. The release profiles were assessed as 
described previously [349] using similarity factor (f2). The percentage of cumulative 
drug release was calculated with the following equation: cumulative drug release (%) = 
((cumulative amount of released drug) / (total amount of drug added)) × 100%. 
 
 
6.2.9. In vitro cytotoxicity of embelin loaded micelles 
 
C4-2 prostate cancer cell line was used to determine the cell growth inhibition ability of 
embelin-loaded micelles. Cells were cultured in RPMI 1640 media supplemented with 
10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37 ? in humidified 
environment of 5% CO2. Cells were seeded in 96-well plates at a density of 5,000 cells 
per well 18 h before treatment. Then, cells were treated with drug-loaded micelles or 
equivalent amount of blank micelles for additional 72 h. At the end of treatment, cell 
culture medium was replaced by 100 μL medium with 0.5 mg/mL 3-(4,5-dimethyl-
thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) and incubated for 1 h at 37 °C. 
Then the medium was carefully removed and 200 μL of DMSO was added into each well 
to dissolve the formazan crystals. The absorbance was measured in a microplate reader at 
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a wavelength of 560 nm. Cell viability was expressed as the percentage of control group. 
Cell viability (%) = (Atest / Acontrol) × 100%. 
 
 
6.3. Results 
 
 
6.3.1. Synthesis and characterization of polymers 
 
As summarized in Figure 6.1, the target lipopolymer PEG-PCD was synthesized by two 
approaches. In the first approach, PEG was copolymerized with MBC to afford 
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) 
(PEG-PBC). Then, the pendant benzyl group was removed by hydrogenation to expose 
carboxyl groups to get poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene 
carbonate)(PEG-PCC). Finally, poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-
propylene carbonate-graft-dodecanol) (PEG-PCD) lipopolymer was synthesized by 
conjugating dodecanol to the carboxyl groups.  In the second approach, PEG was 
copolymerized with a lipid modified monomer 2-methyl-2-dodecanoxycarbonyl-
propylene carbonate (MDC).  MCC and MDC were characterized with 1H NMR and ESI-
MS: MCC,1H NMR (500 MHz, DMSO): δ13.35 (s, 1 H), 4.57 (d, 2 H), 4.32 (d, 2 H), 
1.18(s, 3 H). MS (ESI) m/z 159 [M-H]-. MCC,1H NMR (500 MHz, CDCl3): δ4.50 (d, 2 
H), 4.2 (d, 4 H), 1.65 (m, 2 H), 1.4-1.2(m, 21 H), 0.85 (t, 3 H). MS (ESI) m/z 351 [M + 
Na]+. Although we could synthesize the lipopolymers with both approaches, the second 
approach involves column purification of MDC which is a time consuming process. 
Therefore, the first approach was selected to generate lipopolymer PEG-PCD. 
 
To achieve the optimal polymerization efficiency, three different catalysts were tested for 
copolymerization of PEG and MBC as summarized in Table 6.1. Among three catalysts 
tested, DBU was the best, as the conversion rate was 80-88% at the molar ratio of 
monomer and PEG ranging from 10 to 34. Both Sn(oct)2 and Et2Zn were used at 80 ? 
and the degree of polymerization (DP) was increased with prolonged reaction time from 
3h to 16 h for Sn(oct)2. However, both of these two catalysts gave less DP under the 
reaction conditions described in Table 6.1. Therefore, DBU was selected in the current 
study. 
 
The structures of PEG-PBC, PEG-PCC, and PEG-PCD were confirmed by 1H NMR 
(Figure 6.2). From Figure 6.2A, the following peaks were observed for PEG-PBC 
polymer at δ 1.2 (CH3 in BC unit), δ 3.6 (CH2 in PEG), δ 4.3(CH2 in BC main chain), δ 
5.2 (CH2 in BC side group), and δ 7.3 (phenyl ring). All signals are assigned as methoxy 
poly(ethylene glycol) (mPEG) and polymerized BC units. In addition, the success of 
polymerization was confirmed by the disappearance of signal at δ 4.2 and δ 4.6 in the 
MBC monomer and appearance of a new peak at δ 4.3. The degree of polymerization and 
molecular weight of the polymers was estimated based on the peak areas of PEG CH2 
groups at δ 3.6 and those of CH2 in BC main chain at δ 4.3. 
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Table 6.1 Effect of different catalyst on the polymerization of PEG-PBC copolymer. 
 
Catalysta [MBC]/ 
[PEG-OH]e 
Mn, Targetf DPMBCg Mnh Conversion 
(%)i 
DBUb 10 7500 8 7000 80 
DBUb 20 10000 17 9250 85 
DBUb 34 13500 30 12500 88 
Sn(oct)2c 34 13500 17 9250 50 
Sn(oct)2d 34 13500 22 10500 65 
Et2Znd 20 10000 6 6500 30 
 
a. DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene; Sn(oct)2: stannous 2-ethylhexanoate; Et2Zn: diethy zinc. 
b. Reaction condition: RT, 3 h. 
c. Reaction condition: 80 ?, 3 h. 
d. Reaction condition: 80 ?, 16 h. 
e. Molar ratio of monomer (MBC) to PEG in the feed. 
f. Mn, target = [MBC] / [PEG-OH] x Mmonomer unit (250) + MPEG-OH (5000). 
g. DP: Degree of Polymerization, determined by 1H NMR. 
h. Mn = DP x Mmonomer unit (250) + MPEG-OH (5000). 
i. Determine by 1H NMR, Conversion (%) = DP / ([MBC] / [PEG-OH]) x 100%. 
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Figure 6.2 1H NMR of polymers. 
 
(A) PEG114-PBC30 in CDCl3, (B) PEG114-PCC30 in DMSO, (C) PEG114-PCD29 in CDCl3. 
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The benzyl groups were removed via Pd/C catalyzed hydrogenation. The peaks at δ 5.2 
(CH2 in BC side group) and δ 7.3 (phenyl ring) disappeared after hydrogenation (Figure 
6.2B), which indicates the complete removal of pendant benzyl group. In addition, a peak 
at δ 13 was observed, which belongs to the exposed carboxyl group after removing 
protective benzyl group. Dodecanol was conjugated onto the polymer backbone using 
EDC/HOBT chemistry. The success of dodecanol conjugation to PEG-PCC carboxyl 
group was confirmed by the appearance of new peaks at δ 4.1, δ 1.6, δ 1.2-1.4, and δ 0.9, 
which could be assigned to different groups in the lipid as shown in Figure 6.2C. 
 
The FTIR of PEG-PBC, PEG-PCC, and PEG-PCD also confirmed the success of the 
reaction (Figure 6.3). In FTIR spectra of PEG-PBC, there were peaks at 736 and 696  
cm-1, which were due to the CH vibrations of benzyl groups. These two peaks were 
absent in the FTIR spectra of PEG-PCC and PEG-PCD, indicating the removal of the 
pendant benzyl groups during hydrogenation. In addition, we also observed a broad OH 
stretch band, which was centered at 3450 cm-1 and partially overlapped with C-H stretch. 
This further confirmed the presence of pendant COOH groups.  Besides, we also 
observed absorbance bands due to the C = O stretching vibration at 1749 cm-1 (PEG-
PBC), 1748 cm-1 (PEG-PCC), and 1755 cm-1 (PEG-PCD), respectively. The C-H stretch 
band was observed at 2886 cm-1 for PEG-PBC, 2874 cm-1 for PEG-PCC. In addition, 3 
bands at 2923, 2889, and 2855 cm-1 were observed for PEG-PCD, indicating the presence 
of pendant long alkanes. 
 
The characteristics of PEG-PBC, PEG-PCC, and PEG-PCD polymers are summarized in 
Table 6.2. The molecular weight of PEG-PBC and PEG-PCC were calculated based on 
the peak areas of PEG CH2 groups at δ 3.6 and those of CH2 in BC main chain at δ 4.3 in 
the 1H NMR spectrum. In addition, the percentage of conjugation and molecular weight 
of the lipopolymer was calculated by the peak areas at δ 4.3 (belongs to polymer 
backbone) and at δ 4.1 (belongs to the conjugated pendant lipid) in the 1H NMR 
spectrum. The Mn determine by 1H NMR were 12,500 g/mol for PEG114-PBC30, 9,800 
g/mol for PEG114-PCC30, 13,561 g/mol for PEG114-PCD29, 10,248 g/mol for PEG114-
PCD16, and 6,968 g/mol for PEG114-PCD6, respectively. GPC was also used to determine 
the apparent weight (Mw) and number (Mn) average molecular weight of polymers and 
their polydispersity index. A good correlation was observed between the molecular 
weight estimated from NMR and Mw or Mn determined by GPC. All of the polymers 
showed narrow distribution as revealed by the small polydispersity index (1.06 to 1.23). 
A representative plot comparing the GPC chromatograms for PEG114-PCC30, PEG114-
PBC30, and PEG114-PCD29 was shown in Figure 6.4. 
 
DSC was used to determine the thermal properties of the synthesized block copolymers. 
The thermograms of diblock copolymers with different core structures are shown in 
Figure 6.5. PEG114-PBC30 has a Tg = -35.7 ?, Tc = 6.3 ?, and Tm = 49.5 ?, respectively. 
PEG114-PCC30, which is a transparent viscous liquid, showed a Tg of -30.7?, but no 
obvious Tc or Tm. PEG114-PCD29 showed a Tm of -35.7 ?, but no obvious Tg or Tc.  The 
different thermal properties observed with DSC suggesting different properties of the 
copolymers. Only Tg was observed in PEG114-PCC30, indicating it is an amorphous 
polymer. PEG114-PCD29 has a high degree of crystallinity, since there was no Tg. 
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Figure 6.3 FTIR spectra of polymers. 
 
(A) PEG114-PBC30, (B) PEG114-PCC30, and (C) PEG114-PCD29. 
 
 
cm-1
%
T
A
B
C
736 6961749
1748
1755
2866
2874
2923, 2889, 2855
3450
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Table 6.2 Characteristics of PEG copolymers with different core structure. 
 
Polymera Mn 
(NMR) 
Mw 
(GPC)b 
Mn 
(GPC)b 
PDIb CMC 
(g/L) 
CMC 
(M)c 
Crystallinity 
PEG114-PBC30 12500 11140 9703 1.15 4.0x10-4 3.2x10-8 semicrystalline 
PEG114-PCC30 9800 7447 6563 1.13 2.2x10-2 2.3x10-6 amorphous 
PEG114-PCD29 13561 13342 11636 1.15 3.6x10-4 2.6x10-8 crystalline 
PEG114-PCD16 10248 11794 9590 1.23 9.0x10-4 8.7x10-8 crystalline 
PEG114-PCD6 6968 6580 6203 1.06 1.4x10-3 2.0x10-7 crystalline 
 
 
a. PEG-PBC: poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate); PEG-PCD: poly(ethylene glycol)-
block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-dodecanol); PEG-PCC: poly(ethylene glycol)-block-poly(2-methyl-2-
carboxyl-propylene carbonate). 
b. Mw and Mn was apparent molecular weight determined by GPC; PDI = (Mw / Mn) x 100%. 
c. CMC (g/L) normalized with Mn from 1H NMR. 
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Figure 6.4 Gel permeation chromatography (GPC) of polymers. 
 
(1) PEG114-PCC30 [Mn = 6563 g/mol, Mw/Mn = 1.13]; (2) PEG114-PBC30 [Mn = 9703 
g/mol, Mw/Mn = 1.15]; (3) PEG114-PCD29 [Mn = 11636 g/mol, Mw/Mn = 1.15]. 
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Figure 6.5 Thermal analysis of polymers by DSC. 
 
(A) Polymers of different core structures: PEG114-PBC30, PEG114-PCC30, and PEG114-
PCD29. (B) PEG-PCD polymers with different PCD core length: n = 6, 16, and 29. 
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The observed Tg, Tc, and Tm in PEG-PBC indicate the existence of both amorphous 
domain and crystalline domains in PEG114-PBC30, which is a semi-crystalline polymer. 
We also calculated the degree of crystallinity based on the DSC peak areas, which was 
57.1%. Different degrees of crystallinity of PEG114-PCC30, PEG114-PBC30, and PEG114-
PCD29, might be due to the different intermolecular forces among these three polymers 
with different hydrophobic core structures. We also determined the effect of hydrophobic 
core size on the Tm of PEG-PCD. As shown in Figure 6.5B, the Tm for PEG114-PCD29, 
PEG114-PCD16, and PEG114-PCD6 were 51.7 ?, 53.6 ?, 55.3 ?, respectively. 
 
The polymers were further characterized by fluorescence spectroscopy to determine the 
CMC (Figure 6.6). PEG114-PBC30 and PEG114-PCD29 had low CMC values of 4.0 x 10-4 
g/L and 3.6 x 10-4 g/L, respectively. In contrast, the CMC of PEG114-PCC30 was 2.2 x 10-
2 g/L, which was around 50 folds higher than those of PEG114-PBC30 or PEG114-PCD29. 
The low CMC indicates the good stability of micelles prepared from PEG114-PBC30 and 
PEG114-PCD29. The effect of hydrophobic core size on PEG-PCD micelle stability was 
also determined. The CMC of PEG-PCD micelles decreased significantly from 1.4 x 10-3 
g/L to 3.6 x 10-4 g/L, when the DP(n) increased from 6 to 29 (Figure 6.6B). 
 
 
6.3.2. Preparation and characterization of micelles 
 
6.3.2.1. Drug loading efficiency 
 
The amount of embelin loaded into polymeric micelles and loading efficiency were 
calculated using the equations described in the experimental methods. As demonstrated in 
Figure 6.7, PEG-PBC showed 2% drug loading at 5% theoretical loading, which 
corresponds to 40% loading efficiency, in contrast, 5% drug loading was achieved by 
PEG-PCD with different hydrophobic core lengths, which corresponds to 100% loading 
efficiency. Increase in theoretical loading from 5% to 10% showed little effect on the 
drug loading of PEG-PBC micelles and the loading efficiency decreased correspondingly. 
However, the drug loading increased from 5% to 6% and 7% for PEG-PCD micelles, 
when theoretical loading increased from 5% to 10% and 15%, with decrease in loading 
efficiency from 100% to 60% and 50%, respectively. There was no significant difference 
among three PEG-PCD lipopolymers with different hydrophobic core lengths. 
 
6.3.2.2. Core-shell structure formation 
 
1H NMR spectroscopy was used to demonstrate the formation of core-shell of PEG-PCD 
lipopolymer micelles (Figure 6.8). In CDCl3, peaks from both the hydrophilic PEG block 
(3.6 ppm) and the hydrophobic core block (4.3, 4.1, 1.6, 1.2-1.4, and 0.9 ppm) was 
observed. In D2O, all the peaks corresponding to the hydrophobic core block were 
significantly diminished in contrast to the strong peaks for hydrophilic PEG block (Figure 
6.8A). This is consistent with a core-shell structure with a collapsed hydrophobic core. In 
addition, we also compared 1H NMR spectra of embelin loaded PEG-PCD lipopolymer in 
CDCl3 and D2O. Although the specific peaks for embelin at 6 and 2.4 ppm was observed 
when dissolved in CDCl3, they disappeared when they formed micelles in D2O.  
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Figure 6.6 Determination of CMC values. 
 
Plots of the intensity ratio I338/I333 from pyrene excitation spectra at λem = 390 nm versus 
log C for (A) Polymer with different core structures: PEG114-PBC30, PEG114-PCD29, and 
PEG114-PCC30. (B) PEG-PCD polymers with different PCD core length: n = 6, 16, and 
29.  
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Figure 6.7 Optimization of embelin loaded micelle formulations. 
 
(A) Effect of hydrophobic core structure and length on drug loading and (B) loading 
efficiency. Embelin loaded PEG-PBC and PEG-PCD micelles were prepared at 5, 10 and 
15% of theoretical drug loading. (C) Encapsulation of embelin by PEG-PCD micelles as 
a function of polymer concentration. 
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Figure 6.8 Core-shell structure formed by PEG-PCD lipopolymer. 
 
(A) 1H NMR of blank PEG114-PCD29 in CDCl3 and D2O. (B) 1H NMR of PEG114-PCD29 
and emblin. (1) Free embelin dissolved in CDCl3. (2) embelin and PEG114-PCD29 
dissolved in CDCl3 at embelin to polymer ratio of 3%. (3) embelin loaded PEG114-PCD29 
micelles in D2O at embelin to polymer ratio of 3%. 
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These results indicate that PEG-PCD lipopolymer will form micelles in water with a PEG 
hydrophilic shell and a hydrophobic core, and embelin is incorporated into the 
hydrophobic core. 
 
6.3.2.3. Physical appearance and particle size distribution 
 
The physical appearance of blank and drug loaded micelles were shown in Figure 6.9A. 
Both PEG-PCD and PEG114-PBC30 formed a translucent micelle solution, which was 
stable at the room temperature and showed no precipitation on storage at the room 
temperature for one week. In contrast, there was a milk-like suspension formation of 
PEG114-PCC30 copolymer micelles and precipitation was observed after overnight storage 
of these micelles. Also, the drug loaded micelles showed a pink color due to the 
solubilized embelin (EM). The color observed in PEG114-PCD29 micelles was darker than 
those of PEG114-PBC30 micelles prepared at same theoretical loading (5%). And this was 
consistent with the high drug loading in PEG114-PCD29 micelles. We also determined the 
particle size and size distribution of blank and embelin loaded micelles by dynamic light 
scattering (Figure 6.9B). The blank and embelin loaded PEG114-PCB30 micelles had the 
mean particle size of 74 nm and 64 nm, respectively. The particle size of blank and 
embelin loaded PEG114-PCD29 micelles was 129 nm and 110 nm, respectively. There was 
no increase in the mean particle size after embelin loading. In contrast, micelles formed 
by PEG114-PCC30 showed a particle size of 204 nm. We also determined the particle size 
of PEG-PCD with different PCD core length, the mean particle size were 129 nm for 
PEG114-PCD29, 42.6 nm for PEG114-PCD16, and 25 nm for PEG114-PCD6, respectively. 
 
6.3.2.4. Morphology of micelles 
 
The morphology of micelles formed by PEG-PBC and PEG-PCD was determined by 
transmission electron micrography (TEM) (Figure 6.10). PEG-PCD formed micelles with 
different morphologies and sizes, depending on the ratio of hydrophobic core (Figure 
6.10A-C). PEG114-PBC30 formed spherical micelles (Figure 6.10D). PEG114-PCD29 
formed both spherical and cylindrical micelles with a diameter less than 50 nm, and the 
cylindrical micelle was the dominant form. The contour length of the cylindrical micelles 
ranged from several hundred nanometers to several micrometers. However, PEG114-
PCD16 and PEG114-PCD6, formed only spherical micelles. We also determined the 
morphology of embelin loaded micelles prepared from PEG114-PCD6, PEG114-PCD16, 
PEG114-PCD29, and PEG114-PBC30. In addition, the loading of embelin at 5% in PEG-
PCD and 2% at PEG114-PBC30, had no effect on the morphology of micelles (data not 
shown). 
 
6.3.2.5. In vitro drug release 
 
The cumulative percentage of embelin released from PEG-PCD micelles with different 
PCD block length was shown in Figure 6.11A. Similarity factors (f2) were calculated to 
compare the drug release profiles of micelles with various hydrophobic core lengths. The 
similarity factors were 63 (n = 6 Vs 16), 78 (n = 6 Vs 29), and 74 (n = 16 Vs 29), 
respectively. Therefore, these micelles showed similar release profiles, since the release
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Figure 6.9 Physical appearance and particle size of micelles. 
 
(A) Appearance of blank or embelin loaded micelles prepared from polymers with 
different core structure and length (polymer concentration 5 mg/mL). (B) Mean particle 
size of blank or embelin loaded micelles prepared from PEG114-PCD29, PEG114-PBC30, 
and PEG114-PCC30. (C) Mean particle size of micelles prepared from PEG-PCD polymers 
with different PCD core length: n = 6, 16, and 29. 
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Figure 6.10 Transmission electron microscopy (TEM) of micelles. 
 
Micelles were prepared from (A) PEG114-PCD6; (B) PEG114-PCD16; (C) PEG114-PCD29, 
and (D) PEG114-PBC30. 
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profiles are considered as the same, when the similarity factors are greater than 50. The 
release of embelin from PEG-PCD micelles was fit to a first-order process for the first 24 
h .The release half-life was around 12 h. The effect of hydrophobic core on embelin 
release was also investigated (Figure 6.11B). The release of embelin from PEG114-PCD30 
was significantly slower compared to PEG114-PBC30 with a similarity factor of 38. In 
addition, the embelin release half-life from PEG114-PBC30 micelles was 4 h, which was 
much shorter than that of PEG114-PCD30. 
 
6.3.2.6. Bio-evaluation of drug loaded micelles 
 
The anticancer activity of embelin loaded PEG-PCD micelles was determined in C4-2 
prostate cancer cells. As shown in Figure 6.12, while blank PEG114-PCD29 polymer 
showed negligible effect on cell proliferation at polymer concentration up to 0.3 mg/ml, 
embelin loaded PEG114-PCD29 micelles showed significant inhibition of C4-2 cell 
proliferation in a dose dependent manner, with the IC50 of 10 µM. The free drug 
dissolved in DMSO showed similar anticancer effects to micelle formulated embelin 
(data not shown). No direct comparison can be made with the results of embelin 
formulated in micelles and dissolved in DMSO, as DMSO is known to kill tumor cells 
and may not be suitable for in vivo applications. However, this finding is significant, 
since the application of polymeric micelles could avoid the use of toxic solubilzing 
agents such as DMSO, Cremophore EL and Tween 80. 
 
 
6.4. Discussion 
 
Polymeric micelles can serve as a vehicle, which self-assemble into a core-shell structure 
with a hydrophobic core capable of loading hydrophobic drugs [350, 351]. The stealth 
properties associated with hydrophilic PEG corona of micelles prevent their aggregation, 
restrict plasma protein adsorption, prevent recognition by the reticuloendothelial system 
(RES), and minimize their rapid elimination from the bloodstream. The small size of 
micelles ensures their accumulation preferentially in the tumor via EPR effects [323, 
352]. However, successful micellar drug delivery into tumor requires the micelles remain 
stable during blood circulation upon systemic administration. The stability of micelles 
could be enhanced by crosslinking of the shell, core-shell interface, or the core of the 
micelles [353-355]. However, the application of chemical crosslinked micelles is limited 
due to the complexity of crosslinking process, possible effects on the structure and 
properties of loaded drugs, and problems associated with drug release. Alternatively, the 
stability of micelles could also be improved by engineering the structure of hydrophobic 
block by introducing aromatic moieties [356, 357]. 
 
We have successfully synthesized PEG-PCD lipopolymer with two different approaches 
(Figure 6.1). However, the first approach was selected due to the relative simplicity in the 
synthesis process, which is critical for its application. In this synthesis approach, PEG-
PBC was synthesized by ring-opening polymerization of MBC in the presence of PEG 
carrying a hydroxyl end group with one of the following catalysts: DBU, Sn(oct)2, and 
Et2Zn (Table 6.1). Relatively lower reaction efficiency was observed with Sn(oct)2, and
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Figure 6.11 In vitro release of embelin from polymeric micelles. 
 
(A) Release profiles of PEG-PCD micelles with different PCD core lengths at drug 
loading of 5%. (B) Release profiles of PEG114-PCD29, and PEG114-PBC30 micelles at drug 
loading of 2%. *, P < 0.05 , +, P < 0.01, compared with PEG114-PBC30 micelles using 
Student’s unpaired t test. Results were expressed as Mean ± SD (n = 3). 
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Figure 6.12 Inhibition of C4-2 cell proliferation by PEG-PCD blank micelle and 
micelle formulated embelin. 
 
Lipopolymer micelles were prepared with PEG114-PCD29.The weight ratio of embelin and 
polymer was 4% (embelin/polymer). Blank micelles with same polymer concentration 
were served as control. Cell viability was determined by MTT assay at 72 h post 
treatment. Results were expressed as Mean ± SD (n = 4). 
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Et2Zn, this is due to the high reaction temperature and long reaction time required for 
these two catalysts, which is usually associated with the potential polymer degradation 
due to transesterification or backbiting side reaction [356, 358]. In addition, the use of 
these metallic catalysts is also associated with safety issues due to the presence of trace 
metal residue in the polymer. Therefore, DBU was used in the current study, which is 
purely organic and suitable for the synthesis of biomaterials. Besides, the reaction was 
carried out in solution and at room temperature, which is superior to bulk reaction that 
usually results in broad polydispersity due to the inefficient mixing of reactants. To 
optimize the reaction time, molecular weight of the polymer was monitored during the 
reaction. We found that the reaction was almost completed after 3 h and the DP of 
polymerization decreased after reaction for 24 h. This may be due to the occurring of 
transesterification of polymer which becomes dominant when monomer is consumed 
[358]. Therefore, the reaction time was set to 3 h to achieve optimal polymerization 
efficiency and polydispersity. Subsequently, the benzyl groups in the PEG-PBC were 
removed via hydrogenation to expose COOH function group. This reaction was also 
carried out under at the room temperature to avoid the potential degradation of polymer 
backbone, while still maintaining the high reaction efficiency to completely remove 
benzyl groups. The dodecanol was conjugated to the COOH groups in the polymer 
backbone through EDC/HOBT coupling chemistry with conjugation efficiency of around 
95%. This is much higher than the previous report, where less than 70% of conjugation 
efficiency was achieved in conjugating fatty acids to poly(ethylene glycol)-block-poly(β-
benzyl-L-aspartate) through a link molecule [359]. Because of the commercial 
availability of starting materials, simple synthesis procedure, and high reaction 
efficiency, this synthesis procedure will have a broad application in the drug delivery and 
bioengineering. 
 
PEG-PCD lipopolymer synthesized in the current study has the polycarbonate backbone 
and dodecanol was conjugated to this backbone with an ester bond. Therefore, this is a 
biodegradable polymer, which is expected to degrade in vivo through hydrolysis of the 
ester linkages. The hydrolysis of polycarbonate backbone was facilitated at the presence 
of esterase such as lipase or cholesterol esterase [360, 361]. In addition, the final 
degradation product was CO2, dual alcohol, dodecanol, and PEG5000, which have less 
effect on pH change in vivo compared to poly(D,L-lactide) and thus are less likely to 
cause inflammation [362]. These degradation products are non-toxic and could be 
eliminated from the body. 
 
PEG-PCD lipopolymer has multiple dodecanol lipid chains attached to the polycarbonate 
backbone, which mimics the structure of interface crosslinked PEG-lipids (Figure 6.13) 
and could enhance the hydrophobic interaction among the hydrophobic cores. Because 
the crosslinking of micelles are known to improve stability, it is not surprising to observe 
significantly reduced CMC values for PEG-PCD lipopolymer compared to conventional 
PEG-lipid conjugates. Due to its low CMC value (~10-8 M), the concentration of PEG-
PCD in the bloodstream is expected to be much higher than the CMC value of PEG-PCD 
after systemic administration, which indicates its good in vivo stability. Therefore, PEG-
PCD lipopolymer micelles can serve as an alternative to cross-linked PEG-lipid micelles 
for in vivo drug delivery.  
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Figure 6.13 Structure of PEG-lipid and lipopolymer PEG-PCD. 
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Among PEG-PCD series, we found that the CMC decreased with increasing the number 
of lipid in the hydrophobic core (Figure 6.6B). This is due to the increased length of 
hydrophobic block, which is known to enhance the hydrophobic interaction among the 
core block [363]. The effects of core structure were also investigated and the results 
showed that the CMC of PEG-PCD or PEG-PBC was around 50 folds lower than 
corresponding PEG-PCC (Figure 6.6A). This is because of the presence of hydrophobic 
aromatic rings in PEG-PBC and lipid chains in PEG-PCD, which will all facilitate the 
hydrophobic interaction within the core of micelles and promote the self-assembly of 
polymeric micelles. However, PEG-PCC has a higher CMC due to the presence of 
COOH group which significantly reduced the hydrophobicity of the core block. 
Comparable CMC values were observed for PEG-PBC and PEG-PCD, though the 
structure of PBC and PCD are significantly different (Figure 6.6A). Since the backbone is 
the same for PEG-PBC and PEG-PCD, the close similarity in CMC values are due to 
comparable contributions by the pedant phenyl rings in the PBC and the pedant 
dodecanol carbon chain in PCD to the core block hydrophobicity. 
 
Spherical, cylindrical, and vesicular assemblies are three commonly observed 
morphologies of micelles prepared from amphiphilic block copolymers. Recently, 
interest has shifted from spherical to cylindrical micelles, due to their longer systemic 
circulation time compared to spherical micelles [364-366]. The cylindrical micelles 
prepared from poly(ethylene glycol)-b-poly(caprolactone) (PEG-PCL) showed 
significantly longer circulation time than that of spherical micelles prepared from the 
same polymer and was persistent up to several days after intravenous injection [364]. In 
addition, paclitaxel loaded cylindrical micelles were more effective to induce apoptosis 
and reduce the tumor size in tumor bearing mice [365, 366]. Several approaches have 
been investigated to control the morphology of micelles, including kinetic control [367], 
the use of interfacial instability [368], aromatic oxidation [369], and the use of nanopore 
extruder [370]. The most important parameter that determines the morphology and 
architecture of micelles is the copolymer composition and volume ratio between 
insoluble and soluble blocks. Sumeet et al. have studied the effect of molecular size and 
composition using poly(ethylene glycol)-b-poly(1,2-butadiene)(PEG-PB) as a model 
diblock copolymer. These authors found that PEG-PB form spheres, cylinders, and 
bilayers in water, sequentially, with decreased ratio of PEG block [371]. This could 
explain the transition from spherical to cylindrical micelles with the increased 
hydrophobic length of PEG-PCD. In the current study, the use of PEG-PCD29 with a PEG 
ratio of 0.37 produced cylindrical micelles, while PEG-PCD6 (PEG ratio: 0.49) and PEG-
PCD16 (PEG ratio: 0.72) produced only spherical micelles. Although PEG-PCD29 formed 
cylindrical micelles, PEG-PBC30, a polymer with similar hydrophobic core length did not 
form cylindrical micelles but spherical micelles (Figure 6.10). This indicates that not only 
the PEG ratio but also the structure of hydrophobic core determines the morphology of 
micelles.  Thus the morphology of micelles can be controlled by changing the length and 
structure of hydrophobic core of polymer. The preparation of micelles of different 
morphologies will help us to understand the effect of micelles morphology and their in 
vivo biodistribution and bioactivities. 
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The compatibility of core-forming block and the drug to be loaded is critical for drug 
loading capacity [344]. One objective of this study was to design an engineered 
polymeric micelle for improved solubilization and delivery of embelin based on the 
polymer-drug compatibility. PEG-PCD showed significantly high embelin loading 
capacity compared with PEG-PBC (Figure 6.7), although these two polymers have 
similar CMC value and comparable thermodynamic stability. The compatibility is highly 
dependent on the three-dimensional arrangement and conformation of different groups in 
the structure of drug and polymer core [357]. Figure 6.14 illustrates the structure of 
embelin and the repeating units of PEG-PBC and PEG-PCD hydrophobic core block. In 
contrast to PEG-PBC, the structure of the repeating unit of PEG-PCD is similar to that of 
embelin. A similar finding was reported previously, where the attachment of cholesterol 
to the poly(caprolactone) block of a poly(ethylene glycol)-b-poly(caprolactone) 
copolymer significantly improved the loading of cucurbitacin I, which is similar to 
cholesterol in the structure [357]. Our previous data also showed that the introduction of 
carbonate moiety into a PEG-PLA copolymer significantly increased the micellar 
solubility and loading of bicalutamide into micelles [344]. In this study, we also found 
that PEG-PCD lipopolymers with different core block length (repeating unit number 
ranges from 6 to 29) did not show significant difference in the drug loading (Figure 6.7). 
Although an increased drug loading efficiency was observed with increased length of 
PCL blocks in PEG-PCL polymer [372], this may not be applicable for PEG-PCD, which 
has a highly branched structure in contrast to the linear structure of PEG-PCL. In fact, a 
good drug loading was observed in PEG-lipid conjugates with much shorter hydrophobic 
core length [337], indicating that the further increase in hydrophobic length might not be 
able to improve the drug loading of lipopolymers with similar structure as PEG-PCD. 
Similarly, we also observed there was no significant difference in the in vitro drug release 
profiles among these PEG-PCD polymers with different block lengths (Figure 6.11A). 
The drug release profiles of polymeric micelles are influenced by several factors 
including strength of the interaction between drug and hydrophobic core, physical state of 
the core, the amount of drug loaded, the length of hydrophobic core, and the location of 
drug inside the micelle core [363]. In addition, the highly branched structure in the 
hydrophobic core of PEG-PCD may have contributed to the observation in this study. We 
also found that the release of embelin from PEG-PCD was much slower than that from 
PEG-PBC (Figure 6.11B). This might due to the fact that the interaction between PEG-
PCD and embelin was stronger than those of PEG-PBC and embelin. 
 
 
6.5. Conclusion 
 
We have successfully synthesized a novel lipopolymer poly(ethylene glycol)-block-
poly(2-methyl-2-carboxyl-propylene carbonate–graft-dodecanol) (PEG-PCD) for 
delivery of a hydrophobic anticancer drug, embelin. PEG-PCD lipopolymer could form 
micelles in water through self-assembly and significantly improved embelin solubility by 
loading drugs inside its hydrophobic core. The drug loading and encapsulation efficiency 
were dependent on the length and structure of polymer hydrophobic core block. The 
CMC of PEG-PCD micelles was around 10-8 M and decreased with increasing the length 
of hydrophobic block, indicating good thermodynamic stability of PEG-PCD micelles.
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Figure 6.14 Structure of embelin and repeating unit of hydrophobic core. 
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The particle size and morphology of micelles were also dependent on the structure and 
length of hydrophobic core. Embelin loaded PEG-PCD micelles showed significant 
inhibition of C4-2 prostate cancer cell proliferation in a dose dependent manner, while no 
obvious cellular toxicity was observed with blank micelles themselves. Thus, these 
lipopolymer have the potential to be used as vehicles for anticancer hydrophobic drug 
delivery. 
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CHAPTER 7. PACLITAXEL AND LAPATINIB LOADED LIPOPOLYMER 
MICELLES OVERCOME MULTIPLE DRUG RESISTANCE IN PROSTATE 
CANCER 
 
 
7.1. Introduction 
 
Prostate cancer is the second common male cancer in the United States. More than 
186,000 American men learn are diagnosed to have prostate cancer each year 
(http://www.cancer.gov/cancertopics/wyntk/prostate). Although the majority of patients 
respond well to androgen ablation therapy, chemotherapy, and radiotherapy at the 
beginning, many patients relapse over time and become resistant to chemotherapy [373, 
374]. This is mainly due to the over-expression of multiple drug resistant (MDR) 
transporters in prostate cancer cells (Figure 7.1). These transporters, such as P-gp, breast 
cancer resistance protein (BCRP), and multiple drug resistance protein (MRP), increase 
drug efflux and reduce drug accumulation in tumor cells [375, 376].The prognosis of 
patients with MDR cancer is poor, due to the lack of effective clinical interventions. 
Thus, there is an urgent need for effective therapies for MDR prostate cancers. Several 
strategies have been used to overcome MDR, including developing of novel anticancer 
agents [348], using novel delivery systems, such as liposomes [377], solid lipid 
nanoparticles [327], polymer-drug conjugates [324], and the use of MDR transporter 
inhibitor [378]. 
 
Lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (Her-2) tyrosine kinases, was approved by the FDA 
for the treatment of advanced breast cancers [379]. Studies indicate that lapatinib can 
inhibit the function of ATP-binding cassette (ABC) transporters, and thus sensitize MDR 
cancer cells to chemotherapeutic agents (Figure 7.1) [380-382]. Lapatinib has also been 
reported to decrease the percentage of cancer stem cells and improved the long term 
survival of patients [383]. Therefore, the combination of lapatinib and paclitaxel provides 
a new regimen for treating MDR cancers [380]. 
 
Polymeric micelle is a recently developed drug delivery system and prepared from 
amphiphilic diblock copolymers. It forms a core-shell structure by self-assembly. The 
hydrophobic core of micelles is capable of loading hydrophobic drugs, and thus avoids 
the use of toxic solubilizing agents in the delivery of poorly soluble anticancer drugs 
[350, 351]. The stealth properties associated with hydrophilic PEG corona of micelles 
prevent their aggregation, restrict plasma protein adsorption, prevent recognition by the 
reticuloendothelial system (RES), and minimize rapid elimination from the bloodstream. 
The small size of micelles ensures their accumulation preferentially in the tumor via EPR 
effects [323, 352]. In order to targeted deliver drugs into tumors, the micelles need to be 
stable in the blood circulation. The stability of micelles can be improved through the 
engineering of the hydrophobic core. In our previous study, we designed a lipopolymer 
poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate-graft-
dodecanol) for micelle drug delivery. This lipopolymer showed significantly improved 
stability and good drug loading for many poorly soluble drugs [384] .  
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Figure 7.1 Paclitaxel and lapatinib combination for treating MDR cancer. 
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In the current study, we used lipopolymer PEG-PCD micelles to formulate lapatinib and 
paclitaxel. Firstly, we optimized the micelle formulation and characterized the 
formulation with analytical and biophysical methods. Then, the anticancer effects of 
lapatinib and paclitaxel micelle formulations were determined with in vitro cell-based 
assays, focusing on their effects on overcoming MDR in prostate cancers. We also tested 
their abilities to inhibit of MDR growth in vivo with athymic mice xenograft tumor 
models established with the MDR prostate cancer cells. 
 
 
7.2. Materials and Methods 
 
 
7.2.1. Materials 
 
Hydroxybenzotriazole (HOBT), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 
dodecanol, triethylamine (TEA), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 2,2-
bis(hydroxymethyl) propionic acid, methoxy poly(ethylene glycol) (mPEG, Mn = 5000, 
PDI = 1.03) and all other reagents were purchased from Sigma Aldrich (St. Louis, MO) 
and used as received. DU145-TXR cells were provided by Professor Evan T. Keller of 
the University of Michigan. 
 
 
7.2.2. Synthesis of lipopolymer poly(ethylene glycol)-block-poly(2-methyl-2-
carboxyl-propylene carbonate-graft-dodecanol) (PEG-PCD) 
 
Lipopolymer PEG-PCD was synthesized as described by Li et al. [384]. Firstly, 
poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) 
(PEG-PBC) was synthesized through a ring-opening polymerization from monomer 
MBC, using mPEG as macro imitator and DBU as a catalyst. Then, protective benzyl 
groups in PEG-PBC was removed by hydrogenation to get poly(ethylene glycol)-block-
poly(2-methyl-2-carboxyl-propylene carbonate) (PEG-PCC). Finally, lipopolymer PEG-
PCD was obtained after conjugation of dodecanol lipid pendant groups to PEG-PCC. 
 
Lipopolymers and intermediate polymers were characterized with following methods. (1) 
Nuclear magnetic resonance (NMR). 1H NMR spectra were recorded on Varian (500 
MHz) using deuterated chloroform (CDCl3) as a solvent unless otherwise noted. The 
chemical shifts were calibrated using tetramethylsilane as an internal reference and given 
in parts per million. (2) Gel permeation chromatography (GPC). The weight (Mw) and 
number (Mn) average molecular weight and polydispersity index (PDI) of synthesized 
polymers were determined by a Waters GPC system equipped with a GPC column (AM 
Gel 103/5) and a differential refractive index detector. THF was used as an eluent at a 
flow rate of 1 mL/min. A series of narrow polystyrene standards (700 – 40,000 g/mol) 
were used for calibration. 
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7.2.3. Preparation and characterization of lipopolymer micelles 
 
7.2.3.1. Preparation of lipopolymeric micelles 
 
Lipopolymer micelles were prepared with a film dispersion method as previously 
reported with some modifications [348]. Briefly, 30 mg of polymers and given amount of 
drugs were dissolved in 0.5 mL CH2Cl2, and then the solvent was removed under reduced 
pressure. The resulting film was hydrated in 3 ml saline (0.9%) and sonicated for 1 min. 
Then, the residue free drug was removed by centrifugation at 12,000 rpm for 5 min. The 
supernatant was filtered using a 0.22 µM filter. 
 
7.2.3.2. Drug loading and encapsulation efficiency 
 
To determine drug loading, 10 µL of drug loaded micelle solution was diluted with 
acetonitrile. Then drug concentration was determined using a reverse phase high 
performance liquid chromatography (RP-HPLC, Waters, Milford, MA) with UV detector 
at 227 nm. A C18 column (250 mm 4.6 mm, Alltech, Deerfield, IL) was used. The 
mobile phase was composed of 50:50 V/V water and acetonitrile at 1 mL/min. Lapatinib 
and Paclitaxel concentration was calculated based on peak area.  
 
7.2.3.3. Measurement of particle size 
 
The particle size distribution of micelles was determined by dynamic light scattering with 
Malvern Nano ZS. The intensity of scattered light was detected at 90 °.  
 
 
7.2.4. MTT assay 
 
Drug resistant prostate cancer cell DU145-TXR was used to determine the cell growth 
inhibition ability of drug-loaded micelles. Cells were cultured in DMEM media 
supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at 37 ℃ 
in humidified environment of 5% CO2. Cells were seeded in 96-well plates at a density of 
5,000 cells per well. At the end of treatment, cell culture medium was replaced by 100 μL 
medium with 0.5 mg/mL MTT (3-(4,5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide and incubated for 1 h at 37 °C. Then medium was removed and 200 μL of 
DMSO was added into each well to dissolve the formazan crystals. The absorbance was 
measured in a microplate reader at a wavelength of 560 nm. Cell viability was expressed 
as the percentage of control group. Cell viability (%) = (Atest ⁄ Acontrol) × 100%. 
 
 
7.2.5. Calcein AM assay 
 
Cells were seeded into a black wall clear bottom 96-well plate at a density of 20,000 cells 
per well one day before experiment. After treating cells with various concentration of test 
compounds in 50 μL DPBS for 20 min at 37 ℃, 50 μL Calceim AM (10 μM) in DPBS 
were added to each well and incubated at 37 ℃ for additional 20 min. Fluorescence 
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intensity in each well were determined using a SpectraMax M2/M2e spectrofluorometer 
(Sunnyvale, CA) at the excitation wavelength of 494nm and emission wavelength of 517 
nm. 
 
 
7.2.6. Propidium iodide staining and cell cycle analysis 
 
Cells were cultured in a 24-well plate to 90% confluence and then treated for 24 h. Cells 
were trypsinized and fixed in 70% ice-cold ethanol. After washing with PBS, cell pellet 
was re-suspended in 5 µg/mL propidium iodide staining solution for 15 min at room 
temperature. Cell cycle distribution was measured by flow cytometry (Becton, Dickinson, 
NJ). Results from 10,000 fluorescent events were obtained for analysis. 
 
 
7.2.7. TUNEL assay 
 
TdT-mediated dUTP Nick End Labeling (TUNEL) assay was performed using DeadEnd 
Fluorometric TUNEL System (Promega, Madison, WI). Briefly, DU145-TXR cells were 
grown on Lab-tek chamber slide and treated with lapatinib, paclitaxel, and their 
combination for 24 h. At the end of treatment, cells were fixed with -20 °C acetone for 10 
min, washed with PBS, and equilibrated with buffer at RT for 10 min. Then, it was 
incubated with staining agent composed of nucleotide and rTdT, in a humidified chamber 
at 37 °C for 1 h and protected from light. The reaction was terminated with 2 X SSC 
buffer and washed with PBS to remove unincorporated fluorescein-12-dUTP. The 
washed specimens were then counterstained with DAPI and visualized with Zeiss 
AxioVision fluorescent microscope. 
 
 
7.2.8. In vivo anticancer efficacy study 
 
All animal experiments were performed in accordance with NIH animal use guidelines 
and the protocol approved by the Animal Care and Use Committee at the University of 
Tennessee Health Science Center. Xenograft flank tumors were established in 8 week old 
male athymic nude mice (Charles River) by subcutaneously injection of five million 
DU145-TXR prostate cancer cells suspended in 1:1 media and matrigel. When tumors 
reached approximately 100 mm3, mice were randomized assigned to different treatments. 
Drugs were administrated through tail vain injection. Tumors were measured with a 
caliper prior to each injection, and their volumes were calculated using the formula: 
(width2 × length) / 2. At the end of study, tumor tissue was excised from the mice and 
weighted. 
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7.3. Results and Discussion 
 
 
7.3.1. Effect of lapatinib and paclitaxel on MDR prostate cancer cells 
 
We determined whether lapatinib could reverse MDR in prostate cancer cells. Paclitaxel 
resistant prostate cells DU145-TXR were treated with the combination of paclitaxel and 
lapatinib. As shown in Figure 7.2, the IC50 of paclitaxel was 2069 ± 597 nM in the 
absence of lapatinib, indicating DU145-TXR cells were resistant to paclitaxel. However, 
the IC50 of paclitaxel decreased to 79 ± 29 nM, at lapatinib concentration of 1 µM, and to 
15 ± 8 nM at lapatinib concentration of 5 µM. Fold of reversal was 26.2 and 138 at the 
lapatinib concentration of 1 µM and 5 µM, respectively. The results showed that lapatinib 
can reverse the sensitivity of DU145-TXR to paclitaxel. This study proved the feasibility 
of using lapatinib and paclitaxel combination to overcome MDR in prostate cancers.  
 
 
7.3.2. Preparation of paclitaxel and lapatinib loaded PEG-PCD lipopolymer micelle 
formulations 
 
7.3.2.1. Synthesis and characterization of PEG-PCD lipopolymer 
 
PEG-PCD lipopolymer were synthesized according our previous developed methods. The 
synthesized PEG-PCD lipopolymer were characterized with 1H NMR, GPC. The Mn 
calculated based on 1H NMR is 11560. We also used GPC to determine the apparent Mn 
and Mw of lipopolymer PEG-PCD, which was 10800 and 14986, respectively. 
 
7.3.2.2. Preparation and characterization of drug loaded lipopolymer formulations 
 
A film dispersion method was used to prepare lipopolymer micelles. The paclitaxel and 
lapatinib drug concentration in the formulations were determined with a HPLC method. 
Due to the different retention time for paclitaxel (4.7 min) and lapatinib (7.1 min), we can 
simultaneously determine the concentration of these two drugs (Figure 7.3A). We first 
tested the ability of lipopolymer PEG-PCD micelles to load a single drug of paclitaxel or 
lapatinib. As shown in Figure 7.3B and C, both paclitaxel and lapatinib can be effectively 
loaded into lipopolymer micelles. For both of these two drugs, the final drug 
concentrations in the formulation increase from around 0.5 to 2 mg/mL with increased 
theoretical loading (weight ratio of initial drug/polymer) from 5% to 20%. The drug 
loading efficiency were around 100%, indicating all the drugs can be effectively loaded 
into micelles at this range. Based on above findings, we developed several lipopolymer 
micelle formulations to simultaneously load paclitaxel and lapatinib. As shown in Figure 
7.3D, we could simultaneously load both paclitaxel and lapatinib into lipopolymer 
micelles and reach final drug concentration to at least 1 mg for each drug. The drug 
loading efficiencies were also around 100% for both drugs in all of these three 
formulations. We also determined the particle size of lipopolymer micelles with or 
without drug. The particle size was around 60 nm for all the tested formulations and the 
incorporation of drugs had almost no effect on particle size.  
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Figure 7.2 Effect of lapatinib on reversing MDR in DU145-TXR cells. 
 
Percentage of viable cells was determined by MTT assay at 48 h post treatment. Data are 
the means ± SD (n = 4). Fold of reversal = IC50, with lapabinib / IC 50, no lapatinib. PTX, 
paclitaxel; LAPA, lapatinib. 
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Figure 7.3 Determine drug concentrations in paclitaxel and/or lapatinib loaded 
lipopolymer micelles. 
 
(A) HPLC chromatography of paclitaxel and lapatinib; (B) Effect of theoretical loading 
on paclitaxel solubility; (C) Effect of theoretical loading on lapatinib solubility; (D) drug 
concentration in paclitaxel and lapatinib co-loaded lipopolymer micelles. 
  
0
0.5
1
1.5
2
2.5
D
ru
g 
C
on
ce
nt
ra
tio
n 
(m
g/
m
L)
Paclitaxel
Lapatinib
Polymer (mg)       10                 20               10
Paclitaxel (mg)    0.5                 1                  1
Lapatinib (mg)     0.5                 1                  1 
AU
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
Paclitaxel
Lapatinib
Retention time (Min)
1        2        3        4        5        6        7        8       9      
0
0.5
1
1.5
2
5 10 20
C
on
ce
nt
ra
tio
n 
(m
g/
m
L)
Theoretical Loading (%)
Paclitaxel
0
0.5
1
1.5
2
2.5
5 10 20
C
on
ce
nt
ra
tio
n
( m
g/
m
L)
Theoretical Loading (%)
Lapatinib
A B
C
D
 129 
 
7.3.3. Inhibition of MDR prostate cancer cell proliferation by paclitaxel and lapatinib 
loaded lipopolymer micelles 
 
The anticancer effect of paclitaxel and lapatinib loaded lipopolymer micelles were first 
tested in vitro with MDR prostate cancer cells DU145-TXR (Figure 7.4). No obvious 
toxicity was observed in cells treated with blank micelles, lapatinib (2 µM), or paclitaxel 
(0.5 µM) alone for 48 h, while the combination of lapatinib (2 µM) and paclitaxel (0.5 
µM) significantly reduced cell viability to around 23% of the control group. In addition, 
the combination of lapatinib (1 µM) and paclitaxel (0.25 µM) also showed significant 
inhibition of DU145-TXR cell proliferation. (Cell viability was around 35% of the 
control group). This study further confirmed the lapatinib and paclitaxel loaded 
lipopolymer micelles formulation can overcome MDR in prostate cells and effectively 
inhibit the proliferation of resistant prostate cancer cells in vitro. 
 
 
7.3.4. Inhibition of P-gp activity in MDR cancer cells by lapatinib 
 
To understand the mechanism that lapatinib overcomes MDR in cancer cells, we 
performed a calcein AM assay. Calcein AM assay was used to determine the effect of 
lapatinib on P-gp activity [348]. The intracellular accumulation of calcein, which is a P-
gp substrate with fluorescence, was observed with a fluorescence microscope and also 
quantitatively determined by a spectrofluorometer. As shown in Figure 7.5A, lapatinib 
treatment led to dose-dependent increase in intracellular calcein fluorescence. The 
fluorescence intensity increased with increased lapatinib concentration from 0 to 20 µM. 
We also quantitatively determined the fluorescent intensity with a spectrofluorometer 
(Figure 7.5B). In the absence of lapatinib the fluorescence intensity was very low (around 
50 RFU), however, it increased to around 800 RFU at a lapatinib concentration of 20 µM. 
In contrast, treatment with blank PEG-PCD lipopolymer micelles showed neglectable 
effect on intracellular accumulation of calcein fluorescence. Since calcein AM is a P-gp 
substrate, the observed results indicate that lapatinib works as an inhibitor of P-gp, 
reduces the P-gp substances efflux, and thus increases the intracellular accumulation of 
P-gp substances (Such as paclitaxel). 
 
 
7.3.5. Effect of paclitaxel and lapatinib loaded micelles on cell cycle and apoptosis of 
MDR prostate cancer cells 
 
We also determined the effect of lapatinib and paclitaxel loaded lipopolymer micelles on 
DU145-TXR cells by analyzing cell cycle distribution and cell apoptosis with a flow 
cytometry. Cells were treated with different formulations for 24 h before analysis. As 
shown in Figure 7.6, the treatment of lapatinib (2 µM) or paclitaxel (0.5 µM) alone had 
no effects on the cycle distribution, in contrast, their combination showed significant 
effects on cycle distribution and cell apoptosis. The treatment of lapatinib (2 µM) + 
paclitaxel (0.5 µM) caused cells in G0/G1 phase decreased from 29.0 ± 2.1 % in control 
group to group to 4.7 ± 0.2 % in the combination group. Meanwhile, cells in G2/M phase 
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Figure 7.4 Anticancer effect of paclitaxel and lapatinib combination on MDR 
DU145-TXR cells. 
 
DU145-TXR cells were treated for 48 h, and then cell viability was determined by MTT 
assay and expressed as the percentage of control. *, p < 0.01, compare with non-treated 
control (NT). 
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Figure 7.5 Inhibition of P-gp activity by lapatinib. 
 
The effects of lapatinib on intracelluar accumulation of calcein (P-gp substrate) in 
DU145-TXR cells were determined with (A) Fluorescence microscope, and (B). 
spectrofluorometer. 
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Figure 7.6 Effect of paclitaxel and lapatinib combination on cell cycle and 
apoptosis of MDR prostate cancers. 
 
DU145-TXR cells were treated with PEG-PCD micelles formulated Lapatinib (2 µM), 
Paclitaxel (0.5 µM), and Lapatinib (2 µM) + Paclitaxel (0.5 µM). After 24 h treatment, 
cell cycles were analyzed by flow cytometry after PI staining. (A) Cell cycle distribution; 
(B) Quantitative analysis. *, p < 0.01, **, p < 0.05, compare with control. 
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were increased from 50.7 ± 4.0 % in control group to 61.1 ± 1.2 % in the combination 
group. In addition, the apoptotic subG1 phase cells increased from 0.4 ± 0.2 % in the 
control group to 25.1 ± 2.5 % in the combination group. These results indicated that the 
cells treated with above combination therapy were failed to undergo mitosis. This is 
consistent with the anticancer mechanism of paclitaxel, which is a microtubule inhibitor 
and can cause the arrest of the cell cycle at mitotic phase. The increased cell population 
in subG1 phase indicated that apoptotic cells were increased after treating with 
combination therapy [332332]. We also used TUNEL assay to further confirm that the 
combination of paclitaxel and lapatinib induced apoptosis in DU145-TXR cells. TUNEL 
is a method for detecting DNA fragmentation by labeling the terminal end of nucleic 
acids. As shown in Figure 7.7, neither paclitaxel (0.5 µM) nor lapatinib (2 µM) alone 
caused apoptotic cell death in DU145-TXR cells, while the combination of paclitaxel (0.5 
µM) and lapatinib (2 µM) induced significant cell apoptosis. 
 
 
7.3.6. Lapatinib and paclitaxel loaded lipopolymer micelles overcome MDR in vivo 
 
Encouraged by the in vitro anticancer effect of lapatinib and paclitaxel loaded 
lipopolymer micelles in MDR prostate cancer cells. We decided to test their ability to 
overcome MDR in vivo using athymic nude mice xenograft model established with 
DU145-TXT MDR prostate cancer cells. When tumors reached approximately 100 mm3, 
mice were randomized assigned to two groups of four mice. Mice were treated with tail 
vain injection of lipopolymer micelle formulations at a dose of paclitaxel (10 mg/kg) in 
monotherapy group or paclitaxel (5 mg/kg) + lapatinib (5 mg/kg) in combination therapy 
group, respectively. In contrast to paclitaxel monothearpy, the lapatinib and paclitaxel 
combination therapy significantly inhibited in vivo tumor growth (Figure 7.8A). We also 
determined the weight of tumor at the end of the study, which also showed that the 
weight of tumors in combination group were significantly less than those in the paclitaxel 
monotherapy group (P < 0.05, Figure 7.8B). In addition, we did not observe any mortality 
and significant decrease body weight in mice after drug administration, indicating the 
neglectable toxicity of lipopolymer micelle formulations used in this study (Figure 7.8C). 
 
 
7.4. Summary and Conclusion 
 
Paclitaxel and lapatinib loaded lipopolymer micelle formulations were developed, which 
showed high drug loading efficiency. These lipopolymer micelle formulations have a 
particle size of around 60 nm and narrow size distribution. In vitro cell-based studies 
showed that paclitaxel and lapatinib loaded lipopolymer micelles can overcome MDR in 
prostate cancers. The paclitaxel (0.5 µM) and lapatinib (2 µM) combination effectively 
inhibited DU145-TXR cell proliferation in vitro, induced cell cycle perturbation and cell 
apoptosis. In contrast, monotherapy with paclitaxel (0.5 µM) or lapatinib (2 µM) alone 
showed almost no effect on DU145-TXR cells. Effect of combination therapy was further 
investigated in vivo with athymic nude mice xenograft tumor model established with 
MDR prostate cancer cells. Similar to in vitro study, paclitaxel (5 mg/kg) + lapatinib (5 
mg/Kg) combination therapy significantly inhibited tumor growth in vivo compared with 
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Figure 7.7 Detection of paclitaxel and lapatinib combination induced cell 
apoptosis with TUNEL staining. 
 
Paclitaxel and Lapatinib combination induced cell apoptosis in DU145-TXR Cells. 
DU145 Cells were treated with (A) paclitaxel 0.5 µM, (B) Lapatinib 2 µM, and (C) 
paclitaxel 0.5 µM + lapatinib 2 µM. After 24 h treatment, cells were subject to TUNEL 
Staining and counterstained with DAPI. Images are overlay of green fluorescence from 
the TUNEL stain with blue fluorescence from DAPI.  
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Figure 7.8 In vivo anticancer effect of paclitaxel and lapatinib loaded 
lipopolymer micelles on xenograft MDR prostate tumors. 
 
MDR xenograft athymic tumor models were established with DU145-TXR prostate 
cancer cells. When the tumor size reaches 100 mm3, mice were given intravenously 
injection of lipopolymer formulations on day 0, 3, and 4, respectively. The dose was 10 
mg/Kg paclitaxel for paclitaxel monotherarpy group, 5 mg/kg each of lapatinib and 
paclitaxel in combination therapy group. Tumor growth was measured with a caliper and 
tumor size was calculated using the formula: (width2 × length)/2 (A). At the end of study, 
tumor tissue was excised from the mice and weighted (B). Meanwhile, the body weight 
of mice were also determined (C). Points are mean tumor size (n = 4); bars, SE. *, p < 
0.01, **, p < 0.05. 
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high dose paclitaxel (10 mg/kg) monothearpy. These studies indicate that the paclitaxel 
and lapatinib loaded PEG-PCD lipopolymer micelle formulations could be used to treat 
MDR prostate cancers. 
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